
<html lang="en"     class="pb-page"  data-request-id="9fbe7839-7fad-487e-8529-c98abbfa6d15"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.6b01559;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2017.60.issue-4;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode" /></meta><meta name="dc.Creator" content="Elizabeth A.  Jurica" /></meta><meta name="dc.Creator" content="Ximao  Wu" /></meta><meta name="dc.Creator" content="Kristin N.  Williams" /></meta><meta name="dc.Creator" content="Andres S.  Hernandez" /></meta><meta name="dc.Creator" content="David S.  Nirschl" /></meta><meta name="dc.Creator" content="Richard A.  Rampulla" /></meta><meta name="dc.Creator" content="Arvind  Mathur" /></meta><meta name="dc.Creator" content="Min  Zhou" /></meta><meta name="dc.Creator" content="Gary  Cao" /></meta><meta name="dc.Creator" content="Chunshan  Xie" /></meta><meta name="dc.Creator" content="Biji  Jacob" /></meta><meta name="dc.Creator" content="Hong  Cai" /></meta><meta name="dc.Creator" content="Tao  Wang" /></meta><meta name="dc.Creator" content="Brian J.  Murphy" /></meta><meta name="dc.Creator" content="Heng  Liu" /></meta><meta name="dc.Creator" content="Carrie  Xu" /></meta><meta name="dc.Creator" content="Lori K.  Kunselman" /></meta><meta name="dc.Creator" content="Michael B.  Hicks" /></meta><meta name="dc.Creator" content="Qin  Sun" /></meta><meta name="dc.Creator" content="Dora M.  Schnur" /></meta><meta name="dc.Creator" content="Doree F.  Sitkoff" /></meta><meta name="dc.Creator" content="Elizabeth A.  Dierks" /></meta><meta name="dc.Creator" content="Atsu  Apedo" /></meta><meta name="dc.Creator" content="Douglas B.  Moore" /></meta><meta name="dc.Creator" content="Kimberly A.  Foster" /></meta><meta name="dc.Creator" content="Mary Ellen  Cvijic" /></meta><meta name="dc.Creator" content="Reshma  Panemangalore" /></meta><meta name="dc.Creator" content="Neil A.  Flynn" /></meta><meta name="dc.Creator" content="Brad D.  Maxwell" /></meta><meta name="dc.Creator" content="Yang  Hong" /></meta><meta name="dc.Creator" content="Yuan  Tian" /></meta><meta name="dc.Creator" content="Jason J.  Wilkes" /></meta><meta name="dc.Creator" content="Bradley A.  Zinker" /></meta><meta name="dc.Creator" content="Jean M.  Whaley" /></meta><meta name="dc.Creator" content="Joel C.  Barrish" /></meta><meta name="dc.Creator" content="Jeffrey A.  Robl" /></meta><meta name="dc.Creator" content="William R.  Ewing" /></meta><meta name="dc.Creator" content="Bruce A.  Ellsworth" /></meta><meta name="dc.Description" content="A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic ..." /></meta><meta name="Description" content="A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="February 9, 2017" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.6b01559" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Â© 2017 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01559" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.6b01559" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.6b01559" /></link>
        
    
    

<title>Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.6b01559" /></meta><meta property="og:title" content="Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0023.jpeg" /></meta><meta property="og:description" content="A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding Ki and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both Gq-coupled intracellular Ca2+ flux and Gs-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.6b01559"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.6b01559">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=âtrueâ></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=âtrueâ></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.6b01559&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.6b01559&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.6b01559&amp;href=/doi/10.1021/acs.jmedchem.6b01559" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2017</span><span class="cit-fg-volume">, 60</span><span class="cit-fg-issue">, 4</span><span class="cit-fg-pageRange">, 1417-1431</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/60/4" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.6b01521" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.6b01641" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth+A.++Jurica">Elizabeth A. Jurica</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0003-3689-5451" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Ximao++Wu">Ximao Wu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kristin+N.++Williams">Kristin N. Williams</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Andres+S.++Hernandez">Andres S. Hernandez</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=David+S.++Nirschl">David S. Nirschl</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Rampulla">Richard A. Rampulla</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Arvind++Mathur">Arvind Mathur</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Min++Zhou">Min Zhou</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Gary++Cao">Gary Cao</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Chunshan++Xie">Chunshan Xie</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Biji++Jacob">Biji Jacob</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hong++Cai">Hong Cai</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tao++Wang">Tao Wang</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brian+J.++Murphy">Brian J. Murphy</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Heng++Liu">Heng Liu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Carrie++Xu">Carrie Xu</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Lori+K.++Kunselman">Lori K. Kunselman</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+B.++Hicks">Michael B. Hicks</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Qin++Sun">Qin Sun</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dora+M.++Schnur">Dora M. Schnur</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Doree+F.++Sitkoff">Doree F. Sitkoff</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Elizabeth+A.++Dierks">Elizabeth A. Dierks</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Atsu++Apedo">Atsu Apedo</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Douglas+B.++Moore">Douglas B. Moore</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kimberly+A.++Foster">Kimberly A. Foster</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mary+Ellen++Cvijic">Mary Ellen Cvijic</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Reshma++Panemangalore">Reshma Panemangalore</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Neil+A.++Flynn">Neil A. Flynn</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brad+D.++Maxwell">Brad D. Maxwell</a></span><span class="loa-info-orcid"><a href="http://orcid.org/0000-0001-8507-2078" title="Orcid link"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img></a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yang++Hong">Yang Hong</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Yuan++Tian">Yuan Tian</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason+J.++Wilkes">Jason J. Wilkes</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bradley+A.++Zinker">Bradley A. Zinker</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jean+M.++Whaley">Jean M. Whaley</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joel+C.++Barrish">Joel C. Barrish</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+A.++Robl">Jeffrey A. Robl</a></span></span></li><span class="comma-separator">,Â </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=William+R.++Ewing">William R. Ewing</a></span></span></li><span class="comma-separator">,Â andÂ </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+A.++Ellsworth">Bruce A. Ellsworth</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Research and Development, Bristol-Myers Squibb, Co., P.O. Box 4000, Princeton, New Jersey 08540-4000, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +1-609-466-5049. Fax: +1-609-818-3550. E-mail: <a href="/cdn-cgi/l/email-protection#febb9297849f9c9b8a96d0b48b8c979d9fbe9c938dd09d9193"><span class="__cf_email__" data-cfemail="7f3a1316051e1d1a0b1751350a0d161c1e3f1d120c511c1012">[emailÂ protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01559&amp;href=/doi/10.1021%2Facs.jmedchem.6b01559" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2017</span></span><span class="cit-volume">, 60</span><span class="cit-issue">, 4</span><span class="cit-pageRange">, 1417â1431</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">January 23, 2017</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>31 October 2016</li><li><span class="item_label"><b>Published</b> online</span>9 February 2017</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 February 2017</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.6b01559" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01559</a></div><div class="article_header-article-copyright"><strong>Copyright Â© 2017 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1417%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DElizabeth%2BA.%2BJurica%252C%2BXimao%2BWu%252C%2BKristin%2BN.%2BWilliams%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D60%26issueNum%3D4%26contentID%3Dacs.jmedchem.6b01559%26title%3DDiscovery%2Bof%2BPyrrolidine-Containing%2BGPR40%2BAgonists%253A%2BStereochemistry%2BEffects%2Ba%2BChange%2Bin%2BBinding%2BMode%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D1431%26publicationDate%3DFebruary%2B2017">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.6b01559"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2465</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">14</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.6b01559" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;A. Jurica&quot;},{&quot;first_name&quot;:&quot;Ximao&quot;,&quot;last_name&quot;:&quot;Wu&quot;},{&quot;first_name&quot;:&quot;Kristin&quot;,&quot;last_name&quot;:&quot;N. Williams&quot;},{&quot;first_name&quot;:&quot;Andres&quot;,&quot;last_name&quot;:&quot;S. Hernandez&quot;},{&quot;first_name&quot;:&quot;David&quot;,&quot;last_name&quot;:&quot;S. Nirschl&quot;},{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Rampulla&quot;},{&quot;first_name&quot;:&quot;Arvind&quot;,&quot;last_name&quot;:&quot;Mathur&quot;},{&quot;first_name&quot;:&quot;Min&quot;,&quot;last_name&quot;:&quot;Zhou&quot;},{&quot;first_name&quot;:&quot;Gary&quot;,&quot;last_name&quot;:&quot;Cao&quot;},{&quot;first_name&quot;:&quot;Chunshan&quot;,&quot;last_name&quot;:&quot;Xie&quot;},{&quot;first_name&quot;:&quot;Biji&quot;,&quot;last_name&quot;:&quot;Jacob&quot;},{&quot;first_name&quot;:&quot;Hong&quot;,&quot;last_name&quot;:&quot;Cai&quot;},{&quot;first_name&quot;:&quot;Tao&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;J. Murphy&quot;},{&quot;first_name&quot;:&quot;Heng&quot;,&quot;last_name&quot;:&quot;Liu&quot;},{&quot;first_name&quot;:&quot;Carrie&quot;,&quot;last_name&quot;:&quot;Xu&quot;},{&quot;first_name&quot;:&quot;Lori&quot;,&quot;last_name&quot;:&quot;K. Kunselman&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;B. Hicks&quot;},{&quot;first_name&quot;:&quot;Qin&quot;,&quot;last_name&quot;:&quot;Sun&quot;},{&quot;first_name&quot;:&quot;Dora&quot;,&quot;last_name&quot;:&quot;M. Schnur&quot;},{&quot;first_name&quot;:&quot;Doree&quot;,&quot;last_name&quot;:&quot;F. Sitkoff&quot;},{&quot;first_name&quot;:&quot;Elizabeth&quot;,&quot;last_name&quot;:&quot;A. Dierks&quot;},{&quot;first_name&quot;:&quot;Atsu&quot;,&quot;last_name&quot;:&quot;Apedo&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;B. Moore&quot;},{&quot;first_name&quot;:&quot;Kimberly&quot;,&quot;last_name&quot;:&quot;A. Foster&quot;},{&quot;first_name&quot;:&quot;Mary&quot;,&quot;last_name&quot;:&quot;Ellen Cvijic&quot;},{&quot;first_name&quot;:&quot;Reshma&quot;,&quot;last_name&quot;:&quot;Panemangalore&quot;},{&quot;first_name&quot;:&quot;Neil&quot;,&quot;last_name&quot;:&quot;A. Flynn&quot;},{&quot;first_name&quot;:&quot;Brad&quot;,&quot;last_name&quot;:&quot;D. Maxwell&quot;},{&quot;first_name&quot;:&quot;Yang&quot;,&quot;last_name&quot;:&quot;Hong&quot;},{&quot;first_name&quot;:&quot;Yuan&quot;,&quot;last_name&quot;:&quot;Tian&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;J. Wilkes&quot;},{&quot;first_name&quot;:&quot;Bradley&quot;,&quot;last_name&quot;:&quot;A. Zinker&quot;},{&quot;first_name&quot;:&quot;Jean&quot;,&quot;last_name&quot;:&quot;M. Whaley&quot;},{&quot;first_name&quot;:&quot;Joel&quot;,&quot;last_name&quot;:&quot;C. Barrish&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;A. Robl&quot;},{&quot;first_name&quot;:&quot;William&quot;,&quot;last_name&quot;:&quot;R. Ewing&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;A. Ellsworth&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2017&quot;,&quot;month&quot;:&quot;02&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;4&quot;,&quot;volume&quot;:&quot;60&quot;,&quot;pages&quot;:&quot;1417-1431&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.6b01559&quot;},&quot;abstract&quot;:&quot;A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-cis-CF3 to the pyrrolidine improves the human GPR40 binding Ki and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers (R,R)-68 and (S,S)-68 have differential effects on the radioligand used for the binding assay, with (R,R)-68 potentiating the radioligand and (S,S)-68 displacing the radioligand. Compound (R,R)-68 activates both Gq-coupled intracellular Ca2+ flux and Gs-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound (R,R)-68, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound (R,R)-68 significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging &quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01559&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01559" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01559&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01559" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.6b01559&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01559" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.6b01559&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.6b01559&amp;href=/doi/10.1021/acs.jmedchem.6b01559" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.6b01559" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.6b01559" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (2 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01559&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.6b01559%26sid%3Dliteratum%253Aachs%26pmid%3D28112924%26genre%3Darticle%26aulast%3DJurica%26date%3D2017%26atitle%3DDiscovery%2Bof%2BPyrrolidine-Containing%2BGPR40%2BAgonists%253A%2BStereochemistry%2BEffects%2Ba%2BChange%2Bin%2BBinding%2BMode%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D60%26issue%3D4%26spage%3D1417%26epage%3D1431%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (4)</span><span class="article_header-suppInfo-arrow">Â»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292164" title="Pyrrolidines">Pyrrolidines</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292186" title="Receptors">Receptors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/60/4" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/jmcmar.2017.60.issue-4/20170223/jmcmar.2017.60.issue-4.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of pyrrolidine-containing GPR40 agonists is described as a potential treatment for type 2 diabetes. The initial pyrrolidine hit was modified by moving the position of the carboxylic acid, a key pharmacophore for GPR40. Addition of a 4-<i>cis</i>-CF<sub>3</sub> to the pyrrolidine improves the human GPR40 binding <i>K</i><sub>i</sub> and agonist efficacy. After further optimization, the discovery of a minor enantiomeric impurity with agonist activity led to the finding that enantiomers <b>(</b><i><b>R,R</b></i><b>)-68</b> and <b>(</b><i><b>S,S</b></i><b>)-68</b> have differential effects on the radioligand used for the binding assay, with <b>(</b><i><b>R,R</b></i><b>)-68</b> potentiating the radioligand and <b>(</b><i><b>S,S</b></i><b>)-68</b> displacing the radioligand. Compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> activates both G<sub>q</sub>-coupled intracellular Ca<sup>2+</sup> flux and G<sub>s</sub>-coupled cAMP accumulation. This signaling bias results in a dual mechanism of action for compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b>, demonstrating glucose-dependent insulin and GLP-1 secretion in vitro. In vivo, compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> significantly lowers plasma glucose levels in mice during an oral glucose challenge, encouraging further development of the series.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56250" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56250" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The International Diabetes Federation estimates that in 2014 more than 387 million people were living with diabetes, and 4.9 million deaths were attributed to diabetic complications, making diabetes a worldwide epidemic affecting 1 in 11 adults.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Nearly, half of the population with diabetes is undiagnosed,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> but the progressive nature of the disease means that their condition will likely (rapidly) decline, affecting quality of life if left untreated. Type 2 diabetes, representing 95% of all diabetes cases, is characterized by an insufficiency of insulin action that results in high blood glucose levels. Increased blood glucose can cause a variety of microvascular complications such as nephropathy, retinopathy, and neuropathy as well as macrovascular complications such as heart disease and stroke in type 2 diabetes patients.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a></div><div class="NLM_p">GPR40, also known as free fatty acid receptor 1 (FFAR1), is a nutrient-sensing G-protein-coupled receptor (GPCR) that is primarily expressed in the Î²-cells of the pancreas, where it mediates glucose-stimulated insulin secretion.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> GPR40 is commonly reported to be a G<sub>q</sub>-coupled GPCR that is most potently activated by long-chain unsaturated fatty acids (C > 10) at micromolar concentrations. GPR40-dependent modulation of insulin secretion is glucose-dependent, suggesting that drugs targeting this receptor could improve glycemic control with low risk of hypoglycemia<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> in contrast to the clinical experience with nonglucose dependent insulin secretagogues such as sulfonylureas.</div><div class="NLM_p">Fasiglifam (<b>1</b>, TAK-875, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) is a GPR40 agonist that progressed to phase III clinical trials, validating this target as an approach for the treatment of type 2 diabetes. It is a partial agonist of GPR40 that promotes G<sub>q</sub>-dependent Ca<sup>2+</sup> accumulation in Î²-cells, amplifying the effect of glucose on insulin secretion.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a> In the clinic, <b>1</b> reduced glycated hemoglobin (HbA1c), an integrated measure of glycemic control, by â¼1% in type 2 diabetic patients.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> At the 50 mg dose used in phase III clinical trials, <b>1</b> primarily demonstrated improvement on fasting plasma glucose levels with increased insulin secretion observed. At this dose, there was no effect on the gut hormones GIP and GLP-1 (vide infra). The development of <b>1</b> was halted during phase III clinical trials due to concerns about liver safety but since GPR40 is not expressed in the liver, the findings are unlikely to be a direct result of GPR40 agonism.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(10, 11)</a> The clinical efficacy of <b>1</b> suggests that a chemically distinct GPR40 agonist with improved liver safety would be a valuable treatment for type 2 diabetes.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0001.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of GPR40 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Recently, GPR40 was shown to have three distinct ligand binding sites.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> AMG 837 (<b>2</b>) and AM-1638 (<b>3</b>) were demonstrated, via radioligand binding studies, to occupy distinct sites on GPR40 (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>). Interestingly, there is cross-talk between these sites, and ligands can exhibit positive cooperative binding. Several compounds, including <b>3</b>, were found to elicit a greater Ymax than endogenous fatty acid ligands. These compounds were labeled âsuperagonistsâ due to their superior ability to control glucose levels.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> These full activators of GPR40 show greater potency and efficacy in vivo at lower plasma exposures relative to partial agonists in an oral glucose tolerance test.</div><div class="NLM_p">GPR40 is also expressed in enteroendocrine cells where it is important for secretion of gut hormones such as glucagon-like peptide-1 (GLP-1),<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> but many synthetic GPR40 agonists, including <b>1</b>, were not known to increase GLP-1 secretion. Compound <b>3</b> is the first reported small molecule agonist to demonstrate GPR40-dependent GLP-1 secretion.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> The ability to promote GLP-1 secretion brings the possibility of an additional benefit of GPR40 agonism for the treatment of diabetes, since GLP-1 is known to have effects on gastric emptying in the gut and glucose-dependent insulin secretion in the pancreas. The native peptide has a short half-life in plasma,<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> but mechanisms that target the preservation of GLP-1, such as DPP-4 inhibitors, and metabolically stable GLP-1 mimetics are clinically efficacious for the treatment of diabetes.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15, 16)</a> By developing GPR40 agonists with this dual mechanism of action (i.e., promoting glucose-dependent insulin and GLP-1 secretion), we hoped to discover compounds with greater glucose lowering capacity than <b>1</b> or other agonists that employ a single insulin secretagogue mechanism of action.</div><div class="NLM_p">To establish a novel starting point for our medicinal chemistry program, we performed a virtual search of the Bristol-Myers Squibb compound collection. It was known in the literature that a carboxylic acid or acid mimetic was required for GPR40 agonism, and several agonists (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>) included chirality at the Î²-position relative to the carboxylic acid.<a onclick="showRef(event, 'ref8 ref17 ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref8 ref17 ref18 ref19 ref20">(8, 17-20)</a> We searched for structures with a cyclic constraint bearing a carboxylic acid that might confer GPR40 potency and efficacy. This exploration led to the discovery of racemic compound <b>4</b> (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>) that was found to be a weak partial agonist of the human GPR40 receptor (hGPR40 EC<sub>50</sub> = 5.0 Î¼M). Despite its weak activity, we decided to employ compound <b>4</b> as a starting point since we felt the aniline nitrogen and the novel cyclic structure might serve to constrain the carboxylic acid in a bioactive conformation. By removing the lactam carbonyl in compound <b>5</b>, the potency was improved 2-fold, suggesting that the lactam carbonyl was not important for agonist activity. In a search for the optimal spacing between the aryl group and the carboxylic acid, we homologated the acid moiety as found in compound <b>6</b>, but this modification led to reduced GPR40 agonist activity. Since the distance between the carboxylic acid and aryl group seemed critical for GPR40 activity, we varied the placement of the acid on the ring, resulting in the discovery of <b>(</b><i><b>S</b></i><b>)-7</b> and <b>(</b><i><b>R</b></i><b>)-7</b> (<a class="ref internalNav" href="#fig2" aria-label="Table 2">Table 2</a>) with submicromolar hGPR40 activity. Because of the improved potency of <b>(</b><i><b>S</b></i><b>)-7</b> relative to the starting point (compound <b>4</b>), we focused on developing the SAR around this homoproline analogue.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Effect of A Ring Size on GPR40 Activity</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0015.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound number</th><th class="colsep0 rowsep0" align="center">ring size</th><th class="colsep0 rowsep0" align="center"><i>h</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a> Â± S.D.<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>hK</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>m</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t1fn3" aria-label="c">c</a> Â±Â S.D.<a class="ref internalNav" href="#t1fn4" aria-label="d">d</a> (Ymax)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>S</b></i><b>)-23</b></td><td class="colsep0 rowsep0" align="left">4(<i>n</i>Â =Â 0)</td><td class="colsep0 rowsep0" align="left">0.26Â Â±Â 0.12</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">0.44Â Â±Â 0.38 (88%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>R</b></i><b>)-23</b></td><td class="colsep0 rowsep0" align="left">4(<i>n</i>Â =Â 0)</td><td class="colsep0 rowsep0" align="left">13<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>S</b></i><b>)-7</b></td><td class="colsep0 rowsep0" align="left">5(<i>n</i>Â =Â 1)</td><td class="colsep0 rowsep0" align="left">0.34Â Â±Â 0.20</td><td class="colsep0 rowsep0" align="left">0.89<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">4.5Â Â±Â 1.8 (66%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>R</b></i><b>)-7</b></td><td class="colsep0 rowsep0" align="left">5(<i>n</i>Â =Â 1)</td><td class="colsep0 rowsep0" align="left">0.88Â Â±Â 0.061</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>17<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24Â (enantiomerÂ 1)</b></td><td class="colsep0 rowsep0" align="left">6(<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">>33</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24Â (enantiomerÂ 2)</b></td><td class="colsep0 rowsep0" align="left">6(<i>n</i>Â =Â 2)</td><td class="colsep0 rowsep0" align="left">>17</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25Â (enantiomerÂ 1)</b></td><td class="colsep0 rowsep0" align="left">7(<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">6.4<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25Â (enantiomerÂ 2)</b></td><td class="colsep0 rowsep0" align="left">7(<i>n</i>Â =Â 3)</td><td class="colsep0 rowsep0" align="left">11<a class="ref internalNav" href="#t1fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>a</sup><p class="last">hGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t1fn2"><sup>b</sup><p class="last">Human binding <i>K</i><sub>i</sub> versus a radioligand.</p></div><div class="footnote" id="t1fn3"><sup>c</sup><p class="last">mGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t1fn4"><sup>d</sup><p class="last">Mean of at least two runs.</p></div><div class="footnote" id="t1fn5"><sup>e</sup><p class="last"><i>N</i> = 1.</p></div></div></div><div class="NLM_p last">While compound <b>(</b><i><b>S</b></i><b>)-7</b> was an attractive starting point, we wanted to improve upon several features to improve its druggability. Initially, we wished to increase potency versus the hGPR40 receptor, but we also hoped to improve both potency and efficacy versus the mGPR40 receptor to facilitate preclinical characterization in efficacy models. Additionally, compound <b>(</b><i><b>S</b></i><b>)-7</b> possessed a weak cardiac Na<sup>+</sup> channel antagonist activity (4.0 Î¼M) and weak peroxisome proliferator-activated receptor gamma (PPARÎ³) transactivation (17 Â± 10 Î¼M, 54% Ymax), which was not desired. There is a possible synergy between the insulin-sensitizing mechanism of PPARÎ³ agonism and the increased insulin secretion via GPR40 agonism that could lead to greater efficacy against diabetes. However, since the safety and efficacy of GPR40 agonists are not fully clinically validated, we did not want to complicate evaluation of the mechanism of action with the regulatory burdens of PPARÎ³ activation.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_11117" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_11117" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Early syntheses of pyrrolidine-2-acetic acids, such as <b>7</b>, were (purposefully) racemic so that both enantiomers could be separated and tested for GPR40 activity. The initial route to analogues such as <b>7</b> employed tosylate <b>9</b>, the product of the ring opening of tetrahydrofuran 2-acetic acid ethyl ester (<b>8</b>) with LHMDS. In a single step, compound <b>9</b> was reacted neat with aniline <b>10</b> at 130 Â°C to both displace the tosylate and concomitantly cyclize to form pyrrolidine <b>11</b> in low to modest yields. The racemic mixture was separated by chiral supercritical fluid chromatography (SFC) to provide single enantiomers. The (<i>S</i>)-enantiomer was taken forward for further elaboration. When a benzyl ether was used as a protecting group for analogue synthesis, the benzyl group was removed by hydrogenolysis using Pd/C. Phenol <b>12</b> was reacted with benzyl halide <b>13</b> to give ester <b>14</b>, which was hydrolyzed with LiOH to give the carboxylic acid <b>(</b><i><b>S</b></i><b>)-7</b>.</div><div class="NLM_p">The route depicted in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> was short, convergent, and it served our initial needs; but, as we found that the (<i>S</i>)-isomers were consistently more potent (see table in <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>), we sought a new route that would tap the chiral pool of substituted pyrrolidines to synthesize single isomers. Pyrrolidine analogues were synthesized from substituted <span class="smallcaps smallerCapital">l</span>-prolines that were commercially available. Aryl iodides, such as compound <b>16</b>, could be synthesized by in situ formation of diazonium salts and displacement with KI (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). From substituted prolines such as <b>17</b>, the desired prolinol <b>18</b> was synthesized via transient (Boc) amine protection and reduction of the carboxylic acid followed by <i>N</i>-Boc deprotection. Unfortunately, direct N-arylation of the homologated proline esters via Pd- and Cu-catalyzed couplings mostly led to oligomerization of the proline, resulting in poor yields of N-arylated homoproline analogues. These problems could be circumvented by coupling the reduced Î²-amino alcohol <b>19</b> to an aryl iodide <b>16</b><a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> to give alcohol <b>20</b> followed by mesylation and cyanation that, after basic hydrolysis of nitrile <b>21</b>, led to homologated acid <b>22</b>. Acidic (HCl) nitrile hydrolysis conditions were unacceptable as these conditions led to epimerization of the acetic group. The above methods form the basis of the synthesis of all <i>N</i>-aryl heterocyclic carboxylic acids reported herein.</div><figure id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0012.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Representative Synthesis of Pyrrolidine 2-Acetic Acid Analogues, As Depicted for Compound <b>(</b><i><b>S</b></i><b>)-7</b><sup>a</sup>,<sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions. (a) i. LHMDS, THF; ii. TsCl, 60%; (b) 130 Â°C, neat, 16%; (c) chiral separation; (d) Pd/C, H<sub>2</sub>, MeOH/EtOH, 88%; (e) K<sub>2</sub>CO<sub>3</sub>, DMF, 93%; (f) LiOH, THF/water, 44%.</p><p class="last"><span class="fn-label">Scheme b</span>See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for other compounds that were synthesized via this general route.</p></p></figure><figure id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0002.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pyrrolidine series evolution.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0013.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthesis of Chiral Pyrrolidine GPR40 Agonists, As Depicted for Compound <b>22</b><sup>a</sup>,<sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions. (a) TsOH, NaNO<sub>2</sub>, KI, 74%; (b) <i>i</i>-BuO<sub>2</sub>CCl, NMM, THF; NaBH<sub>4</sub>, H<sub>2</sub>O, 95%; (c) HCl, dioxane, quant.; (d) CuI, NaOH, <i>i</i>-PrOH, 90 Â°C, 74%; (e) MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (f) NaCN, DMSO, 50 Â°C, 100% (2 steps); (g) KOH, EtOH/H<sub>2</sub>O, 120 Â°C, 43%.</p><p class="last"><span class="fn-label">Scheme b</span>Similar compounds made using an analogous method; see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></p></figure><div class="NLM_p">GPR40 is characterized as a G<sub>q</sub>-coupled GPCR that promotes intracellular Ca<sup>2+</sup> accumulation. As such, we primarily tested compounds in a Ca<sup>2+</sup>-coupled fluorescence assay, searching for full agonists that elicited high Ymax in CHO cell lines expressing either human or mouse GPR40. Later (vide infra), we found that the CHO cell line used for screening highly overexpressed hGPR40, and compounds with lower efficacy were indistinguishable from compounds with higher efficacy due to receptor reserve. For this reason, Ymax values are not reported here for human EC<sub>50</sub> values in the CHO cell assay since all compounds produced 100% Ymax. A HEK cell line with an inducible GPR40 expression vector was employed when we wished to distinguish partial and full activators,<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> but this assay system had relatively low throughput and inconsistent receptor expression across different induction experiments so it was not used for routine screening. For rapid screening, we also employed a CHO cell line expressing the mouse GPR40 receptor, which seemed to be somewhat more discriminatory for intrinsic efficacy differences (Ymax) among compounds. In practice, we used mGPR40 efficacy (Ymax) as a surrogate for hGPR40 intrinsic activity and only followed up on select compounds using inducible expression systems to assign compounds as full or partial hGPR40 agonists.</div><div class="NLM_p">Variations in the <i>N</i>-heterocyclic ring size were explored to determine if a five-membered ring with (<i>S</i>)-stereochemistry had the optimal size and stereochemistry for GPR40 agonist efficacy. For descriptive purposes, the saturated nitrogen heterocycle is referred to as the A ring, the central aromatic ring as the B ring, and the appended aryl ring as the C ring (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). The A ring was modified to explore the effect of ring size (4â7) on GPR40 activity in combination with a 2,4-dichlorobenzyl-linked C ring (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>). Azetidine <b>(</b><i><b>S</b></i><b>)-23</b> had submicromolar GPR40 agonist activity in both the human and the mouse GPR40 cell lines, but the compound proved to be chemically unstable due to Î²-elimination to the open form. Azetidine <b>(<i>R</i>)-23</b> had greatly reduced GPR40 agonist activity in comparison to that of azetidine <b>(<i>S</i>)-23</b>. In contrast, pyrrolidine <b>(</b><i><b>S</b></i><b>)-7</b> was equipotent versus hGPR40, but it showed reduced potency versus the mouse receptor as compared to the corresponding azetidine analog. Both individual isomers of the 6- and 7-membered ring compounds (<b>24 (enantiomer 1)</b>, <b>24 (enantiomer 2)</b>, <b>25 (enantiomer 1)</b>, and <b>25 (enantiomer 2)</b>) lost significant GPR40 agonist activity (absolute stereochemistry was not determined) versus the 5-membered analogues <b>(</b><i><b>S</b></i><b>)-7</b> and <b>(</b><i><b>R</b></i><b>)-7</b>. These results provided confidence that the original five-membered ring with (<i>S</i>)-stereochemistry, as found in <b>(</b><i><b>S</b></i><b>)-7</b>, was preferred due to good hGPR40 activity and chemical stability, so further SAR explorations employed a pyrrolidine A-ring.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0003.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Arbitrary nomenclature (AâC) for rings on the pyrrolidine chemotype of GPR40 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">With a focus on optimizing the agonist activity of the pyrrolidine-2-acetic series, we next sought to optimize the B ring via heteroaryl replacements and pendant substituents. This investigation was accomplished by substitution of a nitrogen or introduction of a methyl group at the 2- and 3-positions of the aryl ring. For comparison purposes, the effect of these changes is illustrated with use of either a 2,4-dichlorobenzyl C ring or a 2-methylbenzyl C ring (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>). While the GPR40 activity of a 2,4-dichlorobenzyl moiety in compound <b>(</b><i><b>S</b></i><b>)-7</b> versus 2-methylbenzyl group in compound <b>28</b> are not significantly different, the 2,4-dichlorobenzyl analogues had off-target activities (Na<sup>+</sup> channel antagonist, PXR), which led us to focus upon the 2-methyl derivatives for later analogues. Both the 2- and 3-pyridine-containing analogues (compounds <b>26</b> and <b>29</b>) had similar hGR40 potency to that of the parent phenyl analogue <b>(</b><i><b>S</b></i><b>)-7</b>, but they demonstrated a significant loss of mGPR40 activity. The 2- and 3-methyl substitutions (compounds <b>27</b> and <b>30</b>) were not tolerated on the B ring for either human or mouse GPR40 potency, suggesting that this group may occupy a very narrow pocket in the receptor.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of B Ring Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0016.gif" alt="" id="fx2" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound number</th><th class="colsep0 rowsep0" align="center">B ring</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>h</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a> Â±Â S.D.<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>hK</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>m</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t2fn3" aria-label="c">c</a> Â±Â S.D.<a class="ref internalNav" href="#t2fn4" aria-label="d">d</a> (Ymax)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>S</b></i><b>)-7</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">2,4-Cl</td><td class="colsep0 rowsep0" align="left">0.34Â Â±Â 0.20</td><td class="colsep0 rowsep0" align="left">0.89<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">4.5Â Â±Â 1.8 (66%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">2-pyridyl</td><td class="colsep0 rowsep0" align="left">2,4-Cl</td><td class="colsep0 rowsep0" align="left">0.22Â Â±Â 0.047</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">2-Me-Ph</td><td class="colsep0 rowsep0" align="left">2,4-Cl</td><td class="colsep0 rowsep0" align="left">8.9<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">14 (70%)<a class="ref internalNav" href="#t2fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">Ph</td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="left">0.19Â Â±Â 0.080</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">3.4Â Â±Â 2.2 (41%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">3-pyridyl</td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="left">0.45Â Â±Â 0.060</td><td class="colsep0 rowsep0" align="left">1.8Â Â±Â 0.29</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">3-Me-Ph</td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="left">>33</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">hGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Human binding <i>K</i><sub>i</sub> versus a radioligand.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">mGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t2fn4"><sup>d</sup><p class="last">Mean of at least two runs.</p></div><div class="footnote" id="t2fn5"><sup>e</sup><p class="last"><i>N</i> = 1.</p></div></div></div><div class="NLM_p">The linkage between the B and C rings was studied to examine the effects of length on SAR for GPR40 agonist activity (<a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>). A two atom linker, as in benzyl ether <b>28</b>, showed good hGPR40 potency. Shortening the linker to a methylene resulted in similar human potency. The biaryl ether linker <b>32</b> provided the best hGPR40 agonist potency. The sulfoxide, sulfone, and carbonyl linkers (compounds <b>33</b>, <b>35</b>, and <b>36</b>) were not tolerated, suggesting that either a change in conformation or polarity at this position was not tolerated. These results suggest that a one atom linker was preferred for GPR40 activity. The one atom linker was also beneficial because <b>(</b><i><b>S</b></i><b>)-7</b> (X = CH<sub>2</sub>O) displayed undesired PPARÎ³ transactivation (17 Â± 10 Î¼M, 54% Ymax in a Gal4 gene reporter assay); whereas, compound <b>31</b> (X = CH<sub>2</sub>) showed no PPARÎ³ transactivation, and compound <b>32</b> (X = O) showed only weak PPARÎ³ transactivation (32 Â± 19 Î¼M, 27% Ymax).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. SAR of B- and C-Ring Linker, X</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0017.gif" alt="" id="fx3" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound number</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center"><i>h</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a> Â± S.D.<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>hK</i><sub><b>i</b></sub> (Î¼M)<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>m</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a> Â±Â S.D.<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> (Ymax)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.19Â Â±Â 0.080</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">3.4Â Â±Â 2.2 (73%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.15Â Â±Â 0.075</td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.53</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">0.074Â Â±Â 0.039</td><td class="colsep0 rowsep0" align="left">4.4Â Â±Â 1.8</td><td class="colsep0 rowsep0" align="left">5.6Â Â±Â 3.3 (69%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">S</td><td class="colsep0 rowsep0" align="left">0.57Â Â±Â 0.31</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">SO<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>33</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">SO<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>33</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>36</b></td><td class="colsep0 rowsep0" align="left">CO</td><td class="colsep0 rowsep0" align="left">4.6<a class="ref internalNav" href="#t3fn6" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="left">>33</td><td class="colsep0 rowsep0" align="left">>33</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">hGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Human binding <i>K</i><sub>i</sub> versus a radioligand.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">mGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">Mean of at least two runs.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Mixture of diastereomers at sulfur.</p></div><div class="footnote" id="t3fn6"><sup>f</sup><p class="last"><i>N</i> = 1.</p></div></div></div><div class="NLM_p">Having optimized the disposition of the carboxylic acid relative to the A-B-C rings, we sought to explore C-ring substituents (<a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>). Relative to the unsubstituted phenyl analogue <b>37</b> (hGPR40 EC<sub>50</sub> = 0.56 Î¼M), a 2,4-dichloro group retained similar potency, as found in compound <b>38</b>. Introduction of a methyl group at the C-ring 2-position (compound <b>32</b>) resulted in almost a 10-fold improvement in hGPR40 agonist potency compared to that of the unsubstituted compound <b>37</b>. The 2-methyl substituent seemed optimal since a 2-fluoro or a 2-ethoxy group resulted in potency losses (compounds <b>39</b> and <b>40</b>), indicating the GPR40 receptor pocket preferred a small group at the ortho position. Larger groups, such as 2-<i>t</i>-Bu and 2-Ph (compounds <b>42</b> and <b>43</b>) decreased potency as well, suggesting a small binding pocket. Small substituents in the 3- and 4-positions were tolerated (compounds <b>44</b>â<b>48</b>), but they did not substantially affect potency as compared to the 2-position. However, these modifications did not lead to a significant increase in mGPR40 potency and efficacy, which was desired to enable preclinical evaluation of GPR40 pharmacology.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. SAR of Substitution on C Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0018.gif" alt="" id="fx4" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound number</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>h</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a> Â±Â S.D.<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>hK</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>m</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> Â±Â S.D.<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> (Ymax)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>37</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.56Â Â±Â 0.29</td><td class="colsep0 rowsep0" align="left">6.5Â Â±Â 0.33</td><td class="colsep0 rowsep0" align="left">>16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>38</b></td><td class="colsep0 rowsep0" align="left">2,4-Cl</td><td class="colsep0 rowsep0" align="left">0.36<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">3.2<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a> (120%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="left">0.074Â Â±Â 0.039</td><td class="colsep0 rowsep0" align="left">4.4Â Â±Â 1.8</td><td class="colsep0 rowsep0" align="left">5.6Â Â±Â 3.3 (69%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>39</b></td><td class="colsep0 rowsep0" align="left">2-F</td><td class="colsep0 rowsep0" align="left">0.15Â Â±Â 0.10</td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.0010</td><td class="colsep0 rowsep0" align="left">6.9Â Â±Â 2.4 (50%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>40</b></td><td class="colsep0 rowsep0" align="left">2-OEt</td><td class="colsep0 rowsep0" align="left">1.7<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="left">3-Me</td><td class="colsep0 rowsep0" align="left">0.26Â Â±Â 0.17</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">2.4Â Â±Â 0.98 (83%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="left">2-<i>t</i>-Bu</td><td class="colsep0 rowsep0" align="left">6.5<a class="ref internalNav" href="#t4fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>17</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43</b></td><td class="colsep0 rowsep0" align="left">2-Ph</td><td class="colsep0 rowsep0" align="left">3.5Â Â±Â 0.48</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.68 (72%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>44</b></td><td class="colsep0 rowsep0" align="left">3-Cl</td><td class="colsep0 rowsep0" align="left">0.68Â Â±Â 0.18</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>45</b></td><td class="colsep0 rowsep0" align="left">3-NMe<sub>2</sub></td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.56</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>46</b></td><td class="colsep0 rowsep0" align="left">4-Me</td><td class="colsep0 rowsep0" align="left">0.49Â Â±Â 0.14</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">4-Cl</td><td class="colsep0 rowsep0" align="left">0.29Â Â±Â 0.089</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>48</b></td><td class="colsep0 rowsep0" align="left">4-OMe</td><td class="colsep0 rowsep0" align="left">0.52Â Â±Â 0.33</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">hGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Human binding <i>K</i><sub>i</sub> versus a radioligand.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">mGPR40 EC<sub>50</sub> in the Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Mean of at least two runs.</p></div><div class="footnote" id="t4fn5"><sup>e</sup><p class="last"><i>N</i> = 1.</p></div></div></div><div class="NLM_p">Having made significant changes to the linking moiety and C-ring substituent, we looked to reoptimize the pyrrolidine A ring, exploiting the synthetic intermediacy of prolinol derivatives, many of which are readily available. Introduction of a methyl group at the 2- or 5-positions dramatically reduced potency (compounds <b>49</b> and <b>57</b>, <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>). These SAR points suggest the importance of the pyrrolidine heterocycle and the aniline planarity with the aryl ring. Small substituents at the 3- and 4-positions (compounds <b>50</b> and <b>52</b>) improved agonist potency against both human and mouse GPR40, but unexpectedly, the 4-<i>cis</i>-fluoro substituent (compound <b>53</b>), while enhancing hGPR40 potency exhibited attenuated potency versus the mouse receptor. These results prompted us to synthesize the 4-<i>cis</i>-CF<sub>3</sub> analogue <b>54</b>, providing for the first time in this series submicromolar agonist potency versus the mouse receptor. A similar result was obtained with the oxygen linker, as seen in compound <b>22</b> (first depicted in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>). In contrast to the 4-<i>cis</i>-CF<sub>3</sub> substituent, the polar 4-<i>cis</i>-OMe and larger 4-<i>cis</i>-phenyl groups were disfavored (compounds <b>55</b> and <b>56</b>). We hypothesized that one role of the 4-<i>cis</i>-CF<sub>3</sub> group is to alter the conformation of the pyrrolidine ring. Indeed, an energetic exploration of the A and B rings of unsubstituted analogue <b>32</b> and analogue <b>22</b> reveals that the unsubstituted pyrrolidine <b>32</b> weakly prefers to have the acid group pseudoequatorial (by 2.2 kcal/mol), while the pseudoaxial conformation of the acid group is more accessible with the 4-CF<sub>3</sub>-substituted pyrrolidine <b>22</b> (negligible energy difference for the conformations) (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). The favorable profile afforded by the 4-<i>cis</i>-CF<sub>3</sub> substituent led us to utilize this moiety for future SAR explorations. With the optimized 4-<i>cis</i>-CF<sub>3</sub> group on the pyrrolidine A ring, our attention was again refocused on further substitution of the phenyl C ring (<a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>). The 2-Me group in compound <b>22</b> was required for optimal potency. Substitution at the 3-, 4-, and 6-positions (compounds <b>60</b>â<b>64</b>) led to analogues with potency similar to that of compound <b>22</b>.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. SAR of Substitution on the A Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0019.gif" alt="" id="fx5" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound number</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center"><i>h</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a> Â±Â S.D.<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>hK</i><sub>i</sub> (Î¼M)<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>m</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a> Â±Â S.D.<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a> (Ymax)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.15Â Â±Â 0.075</td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.53</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>49</b></td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>33</td><td class="colsep0 rowsep0" align="left">23<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>50</b></td><td class="colsep0 rowsep0" align="left">3-<i>trans</i>-Me</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.12Â Â±Â 0.065</td><td class="colsep0 rowsep0" align="left">0.31Â Â±Â 0.0050</td><td class="colsep0 rowsep0" align="left">1.9Â Â±Â 0.98 (27%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>51</b></td><td class="colsep0 rowsep0" align="left">3-<i>trans</i>-Ph</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">11Â Â±Â 6.1</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>52</b></td><td class="colsep0 rowsep0" align="left">4-<i>cis</i>-Me</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.14Â Â±Â 0.050</td><td class="colsep0 rowsep0" align="left">0.36</td><td class="colsep0 rowsep0" align="left">1.1Â Â±Â 0.75 (43%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>53</b></td><td class="colsep0 rowsep0" align="left">4-<i>cis</i>-F</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.074Â Â±Â 0.037</td><td class="colsep0 rowsep0" align="left">0.18Â Â±Â 0.067</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>54</b></td><td class="colsep0 rowsep0" align="left">4<i>-cis</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">0.067Â Â±Â 0.026</td><td class="colsep0 rowsep0" align="left">0.073Â Â±Â 0.010</td><td class="colsep0 rowsep0" align="left">0.71Â Â±Â 0.30 (54%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">4-<i>cis</i>-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">0.073Â Â±Â 0.047</td><td class="colsep0 rowsep0" align="left">0.035Â Â±Â 0.027</td><td class="colsep0 rowsep0" align="left">0.33Â Â±Â 0.33 (84%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">4-<i>cis</i>-OMe</td><td class="colsep0 rowsep0" align="left">O</td><td class="colsep0 rowsep0" align="left">2.3Â Â±Â 1.2</td><td class="colsep0 rowsep0" align="left">9.0Â Â±Â 3.9</td><td class="colsep0 rowsep0" align="left">0.96Â Â±Â 0.17 (76%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">4-<i>cis</i>-Ph</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">>17</td><td class="colsep0 rowsep0" align="left">>25</td><td class="colsep0 rowsep0" align="left">>33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">5-<i>cis</i>-Me</td><td class="colsep0 rowsep0" align="left">CH<sub>2</sub></td><td class="colsep0 rowsep0" align="left">6.2<a class="ref internalNav" href="#t5fn5" aria-label="e">e</a></td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">>33</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">hGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Human binding <i>K</i><sub>i</sub> versus a radioligand.</p></div><div class="footnote" id="t5fn3"><sup>c</sup><p class="last">mGPR40 EC<sub>50</sub> in the Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t5fn4"><sup>d</sup><p class="last">Mean of at least two runs.</p></div><div class="footnote" id="t5fn5"><sup>e</sup><p class="last"><i>N</i> = 1.</p></div></div></div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0004.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overlay of low energy conformations of compounds <b>32</b> and <b>22</b> A and B rings only, demonstrating the influence of a 4-<i>cis</i>-CF<sub>3</sub> group on the pyrrolidine ring structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Effect of C Ring Substitutions on GPR40 Activity in CF<sub>3</sub>-Containing Pyrrolidine Analogues</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0020.gif" alt="" id="fx6" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound number</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center"><i>h</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> Â±Â S.D.<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a></th><th class="colsep0 rowsep0" align="center"><i>hK</i><sub><b>i</b></sub> (Î¼M)<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center"><i>m</i>EC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> Â±Â S.D.<a class="ref internalNav" href="#t6fn4" aria-label="d">d</a> (Ymax)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">2-Me</td><td class="colsep0 rowsep0" align="left">0.073Â Â±Â 0.047</td><td class="colsep0 rowsep0" align="left">0.039Â Â±Â 0.027</td><td class="colsep0 rowsep0" align="left">0.33Â Â±Â 0.12 (84%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">2-CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.31Â Â±Â 0.11</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">1.3Â Â±Â 0.26 (42%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">2-OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">0.17Â Â±Â 0.067</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">0.74Â Â±Â 0.35 (44%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">2-Me, 4-OBn</td><td class="colsep0 rowsep0" align="left">0.12Â Â±Â 0.049</td><td class="colsep0 rowsep0" align="left">0.010Â Â±Â 0.0060</td><td class="colsep0 rowsep0" align="left">1.5Â Â±Â 0.86 (34%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">2-Me, 4-OMe</td><td class="colsep0 rowsep0" align="left">0.055Â Â±Â 0.025</td><td class="colsep0 rowsep0" align="left">0.039Â Â±Â 0.018</td><td class="colsep0 rowsep0" align="left">0.17Â Â±Â 0.041 (41%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">2-Me, 3-Me</td><td class="colsep0 rowsep0" align="left">0.11Â Â±Â 0.090</td><td class="colsep0 rowsep0" align="left">0.06Â Â±Â 0.02</td><td class="colsep0 rowsep0" align="left">0.50Â Â±Â 0.42 (100%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">2-Me, 3-Cl</td><td class="colsep0 rowsep0" align="left">0.082Â Â±Â 0.054</td><td class="colsep0 rowsep0" align="left">0.013Â Â±Â 0.007</td><td class="colsep0 rowsep0" align="left">0.43Â Â±Â 0.11 (50%)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">2-Me, 6-Me</td><td class="colsep0 rowsep0" align="left">0.082Â Â±Â 0.024</td><td class="colsep0 rowsep0" align="left">n.d.</td><td class="colsep0 rowsep0" align="left">0.27Â Â±Â 0.049 (36%)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">hGPR40 EC<sub>50</sub> in Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Human binding <i>K</i><sub>i</sub> versus a radioligand.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">mGPR40 EC<sub>50</sub> in the Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t6fn4"><sup>d</sup><p class="last">Mean of at least two runs.</p></div></div></div><div class="NLM_p">While we thought that improved potency was possible,<a onclick="showRef(event, 'ref24 ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref24 ref25 ref26">(24-26)</a> we hoped that compound <b>22</b> would be of sufficient potency to blunt a glucose excursion in an intraperitoneal glucose tolerance test (iGTT) in a normal lean mouse. The compound achieved a <i>C</i><sub>max</sub> of 4.7 Î¼M (AUC<sub>0â4h</sub> = 7.0 Î¼MÂ·h) when it was administered orally at 10 mg/kg in mice, but there was no reduction in plasma glucose excursion after a glucose challenge. Even a 100 mg/kg dose was not efficacious, suggesting that greater agonist potency and/or efficacy (Ymax) was required.</div><div class="NLM_p">We wondered if the intrinsic efficacy (Ymax = 84%) of compound <b>22</b> in the Ca<sup>2+</sup> FLIPR assay may have been misleading due to the artificial overexpression in the CHO cell line outlined earlier. We suspected the suboptimal intrinsic efficacy may have contributed to the lack of an in vivo effect in the mouse. As such, we decided to perform an in-depth examination of its agonist activity in hGPR40-expressing HEK cells. While it appeared that all of our compounds were full agonists in the hGPR40 overexpressing CHO cell line, an inducible expression revealed partial versus full agonists. Under conditions that induced high expression of hGPR40, compound <b>22</b> appeared to be a full activator as compared to linoleic acid (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). However, when tested under conditions that induced low expression of hGPR40, we found that <b>22</b> was a partial activator of hGPR40. While a similar experiment in the mouse cell line was not performed, we surmised the lack of in vivo activity in the mouse pharmacology model was due to its partial agonism. Additionally, when tested for in vitro GLP-1 secretion in STC-1 cells, a GPR40-expressing murine enteroendocrine cell line that produces GLP-1, compound <b>22</b>, did not produce a response.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0005.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Inducible hGPR40 assay with high expression of GPR40. (B) Inducible hGPR40 assay with low expression of GPR40.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We noticed that many GPR40 ligands, including linoleic acid/DHA, are significantly longer than compound <b>22</b>, and given the sensitivity of GPR40 to ligand length (vis-Ã -vis medium and short-chain fatty acids), we suspected that we may need to add substituents to the C-ring to improve agonist efficacy and/or potency. Given that the C-ring was permissive to substitution at the 3- and 4-positions, it made sense to append aryl and benzyl groups at these positions. In a similar manner, scientists at Amgen had employed changes (meta versus para) to the central linkage of their chemotype in conjunction with placement of a fluoro-methoxyphenyl terminal substituent.<a onclick="showRef(event, 'ref17 ref27'); return false;" href="javascript:void(0);" class="ref ref17 ref27">(17, 27)</a> This combination resulted in a more robust agonist efficacy response in their chemical series. A 2-F,5-OMe phenyl group was thus appended to biarylmethane and biarylether substituents in both the unsubstituted and 4-<i>cis</i>-CF<sub>3</sub>-substituted (<i>S</i>)-pyrrolidines (e.g., compounds <b>31</b> and <b>22</b>). Appending the aryl ring to the 4-position of the phenyl C-ring (compound <b>66)</b> resulted in similar human GPR40 potency as compared with that of compound <b>31</b> (<a class="ref internalNav" href="#tbl7" aria-label="Table 7">Table 7</a>); however, it exhibited surprisingly robust agonist efficacy (Ymax = 160%) at the mouse receptor with micromolar potency. In the 4-CF<sub>3</sub>-substituted pyrrolidine series, connecting a 2-F, 5-OMe phenyl group to the 3-position of the phenyl C ring resulted in a reduction of hGPR40 activity as compared to <b>22</b>, although Ymax (170%) was significantly enhanced. Appending the 2-F,5-OMe phenyl group to the 4-position of the C-ring in compound <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>-68)</b> resulted in reduced human and mouse potency but very potent binding.</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Substitution of Aryl Groups on the Phenyl C Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0021.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0022.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup>Table a</sup><p class="last">hGPR40 EC<sub>50</sub> in the Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t7fn2"><sup>Table b</sup><p class="last">Human binding <i>K</i><sub>i</sub> versus a radioligand.</p></div><div class="footnote" id="t7fn3"><sup>Table c</sup><p class="last">mGPR40 EC<sub>50</sub> in the Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t7fn4"><sup>Table d</sup><p class="last">Mean of at least two runs.</p></div><div class="footnote" id="t7fn5"><sup>Table e</sup><p class="last"><i>N</i> = 1.</p></div></div><div></div></div><div class="NLM_p">However, it is notable that in the earlier SAR developed for partial activators with the CF<sub>3</sub>-pyrrolidine, including compound <b>22</b>, the compounds were synthesized using commercial (2<i>S</i>,4<i>S</i>)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid, resulting in enantiopure (>99% ee) compounds. When compound <b>68</b> was initially synthesized, it was the first CF<sub>3</sub>-pyrrolidine analogue we made using CF<sub>3</sub>-prolinol that was synthesized in-house for scale-up and analogue synthesis following a literature route.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> To evaluate the impact of agonist efficacy on in vivo pharmacology, we scaled up compound <b>68</b>, and upon rigorous characterization, found that <b>68</b> contained â¼10â20% of its enantiomer as a result of epimerization of an intermediate in the synthesis of the 4-CF<sub>3</sub>-prolinol.</div><div class="NLM_p">The synthetic route to compound <b>68</b> begins with the oxidation of (2<i>S</i>,4<i>R</i>)-2-benzyl 1-<i>tert</i>-butyl 4-hydroxypyrrolidine-1,2-dicarboxylate <b>69</b> with PCC to give the carbonyl <b>70</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>). The tertiary alcohol <b>71</b> was formed by reaction with CF<sub>3</sub>TMS and TBAF, and it was eliminated through the use of SOCl<sub>2</sub> and pyridine. We postulate that ester <b>72</b> was partially racemized at this step since this stereocenter controls the formation of the CF<sub>3</sub> stereocenter, and no diastereomers were observed in subsequent steps. The olefin was reduced concomitantly with hydrogenolysis of the benzyl ester via H<sub>2</sub> and Pd/C to give acid <b>73</b> possessing a cis relationship between the CF<sub>3</sub> and the carboxylic acid functionalities. The carboxylic acid was reduced using mixed anhydride formation and NaBH<sub>4</sub> reduction, and the Boc group was removed to give prolinol salt <b>75</b>. CF<sub>3</sub>âProlinol <b>75</b> was coupled to 1-bromo-4-iodobenzene followed by homologation via mesylation and NaCN displacement to provide nitrile <b>77</b>.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0014.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> and <b>68</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) PCC, CH<sub>2</sub>Cl<sub>2</sub>, 80%; (b) CF<sub>3</sub>TMS, TBAF, 79%; (c) SOCl<sub>2</sub>, pyridine, DIPEA, Boc<sub>2</sub>O, 62%; (d) H<sub>2</sub>, Pd/C, EtOH, 90%; (e) NMM, <i>i</i>-BuCOCl, NaBH<sub>4</sub>, THF/water, 84%; (f) HCl/dioxane, 93%; (g) 1-bromo-4-iodobenzene, CuI, NaOH, <i>i</i>-PrOH, 77%; (h) MsCl, TEA, CH<sub>2</sub>Cl<sub>2</sub>; NaCN, DMSO, 87% (2 steps); (i) TBAB, Pd(Ph<sub>3</sub>P)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, water, (92%); (j) LAH, THF, 89%; (k) LiBr, MsCl, TEA, THF, 89%; (l) Zn, TMS-Cl, ethylene dibromide; Pd(Ph<sub>3</sub>P)<sub>4</sub>, THF, 86%; (m) KOH, EtOH/water, 70%; (n) SFC chiral separation.</p></p></figure><div class="NLM_p">The CD ring system was formed via Suzuki coupling of (2-fluoro-5-methoxyphenyl)boronic acid <b>78</b> and 4-bromo-2-methylbenzoic acid <b>79</b> in good yield. The carboxylic acid was reduced with LAH to give alcohol <b>81</b>, which was converted to bromide <b>82</b> via reaction with MsCl and LiBr. An organozinc reagent of bromide <b>82</b> was generated using activated zinc, and this organometallic reagent was reacted with bromide <b>77</b> in good yield. Acid <b>68</b> was formed by KOH-mediated hydrolysis of the nitrile to give <b>68</b> as a scalemic mixture (as an 85:15 ratio of <b><i>S</i>,<i>S</i></b>:<i><b>R</b></i>,<i><b>R</b></i>). The enantiomers were separated by chiral SFC. Later, enantiopure prolinol was obtained following an alternative literature route<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> and/or via crystallization of a diastereomeric amine salt with (1<i>R</i>)-(â)-10-camphorsulfonic acid (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</div><div class="NLM_p">Compound <b>68</b> was initially tested in in vitro assays as a scalemic mixture since it appeared to be very potent and efficacious (high Ymax) in both human and mouse FLIPR assays. The intrinsic efficacy compound <b>68</b> was evaluated using a cell line with inducible expression of hGPR40 (<a class="ref internalNav" href="#fig5" aria-label="Figure 5">Figure 5</a>). The inducible assay results showed that scalemic <b>68</b> exhibited full activation of GPR40 even at low expression levels of receptor. A similar observation was made in a mouse inducible expression cell line (data not shown). The interspecies consistency of GPR40 agonism enabled preclinical characterization of <b>68</b> in mouse with improved confidence that it could model human pharmacology.</div><div class="NLM_p">Once the enantiomers were separated, we were surprised to find that <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> (as a single enantiomer) retained potent hGPR40 binding (0.045 Î¼M) but <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was the more potent and efficacious agonist (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). Furthermore, compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> occupied a binding mode that positively potentiated the radioligand used for the binding assay, while <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> displaced the radioligand (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0006.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Impact of pyrrolidine substituent stereoisomers on GPR40 binding potency and agonist efficacy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0007.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding assay results with compounds <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> and <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> (negative slope indicates radiolabel displacement; positive slope indicates increase in radiolabel binding).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In an effort to deduce which chiral center was responsible for the change in binding mode and agonist efficacy, the (2<i>S</i>,4<i>R</i>)- and (2<i>R</i>,4<i>S</i>)-(trifluoromethyl)-analogues of <b>68</b> were synthesized. Compound <b>84</b> with (2<i>S</i>)-stereochemistry remained a micromolar partial activator, while (2<i>R</i>)-analogue <b>85</b> retained full activation and good potency, suggesting that the (<i>R</i>)-acetic substituent potently influenced agonist activity in combination with the 2-F,5-OMe phenyl ring (<a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>). We were surprised to find that <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was the most potent analogue since earlier work in the chemotype indicated that the (<i>S</i>)-enantiomer was always more potent across 40 different enantiomeric pairs tested (see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>). It was subsequently reported in the literature that others had also observed that a change in stereochemistry in different chemotypes could result in complementary binding modes and full agonist efficacy.<a onclick="showRef(event, 'ref13 ref27'); return false;" href="javascript:void(0);" class="ref ref13 ref27">(13, 27)</a></div><div class="NLM_p">Since free fatty acids are present in circulation, we studied the activation of hGPR40 by compounds <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> and <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> in combination with DHA, a potent and efficacious endogenous long chain fatty acid<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> (<a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>). At subefficacious (3 nM) concentrations, compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> significantly enhances the agonist activity of DHA and left shifts the concentration response curve. On the other hand, <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> does not significantly potentiate the activity of DHA in vitro. Even concentrations of <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> that show significant agonism do not shift the DHA curve (data not shown). These data support a change in binding mode, suggesting that compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> can be a full agonist and a positive allosteric modulator of DHAâs effect on hGPR40.</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0008.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Potency of DHA versus DHA + 3 nM compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b>. (B) Potency of DHA versus DHA + 10 nM compound <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">We evaluated the effect of compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> on insulin and GLP-1 secretion in vitro. In isolated primary mouse islets, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> showed a dose-dependent (0.016â2.0 Î¼M) increase in insulin secretion (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), demonstrating that <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> promoted glucose-stimulated insulin secretion. Compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was also quite potent in the STC-1 cell line, a mouse enteroendocrine cell line,<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30, 31)</a> showing a 0.33 Î¼M EC<sub>50</sub> for GLP-1 secretion (<a class="ref internalNav" href="#fig10" aria-label="Figure 10">Figure 10</a>). Interestingly, enantiopure <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> also exhibited GLP-1 secretion but with an EC<sub>50</sub> of 3.2 Î¼M, (10-fold less potent than its enantiomer). These findings demonstrated that these full activators show a robust dual mechanism of action as compared to partial agonists, effecting both glucose-stimulated insulin secretion as well as GLP-1 secretion. However, it remained unclear if the dual mechanism of action was due to its binding mode, agonist efficacy, or another determinant.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0009.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vitro insulin secretion from isolated primary mouse islets.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0010.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. GLP-1 secretion in STC-1 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">While GPR40 has been traditionally known to signal through the G<sub>q</sub>-coupled pathways, in a recent publication<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> it was reported that synthetic agonists can promote GPR40-dependent cAMP accumulation via a G<sub>s</sub>-coupled pathway. The G<sub>q</sub> + G<sub>s</sub>-coupled agonists showed substantially higher in vivo glucose lowering efficacy via increased GLP-1 as compared with agonists with only G<sub>q</sub>-coupled activity. Endogenous long chain fatty acids as well as partial activators (such as <b>1</b>) only act through the G<sub>q</sub>-coupled pathway. Partial agonists <b>22</b> and <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> as well as full agonist <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> were screened for G<sub>s</sub>-coupled activity in a cAMP assay in a hGPR40-expressing HEK cell line, demonstrating that <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> potently activated cAMP accumulation with good efficacy, while <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> showed lower potency and efficacy (<a class="ref internalNav" href="#tbl8" aria-label="Table 8">Table 8</a>). Compound <b>22</b> was inactive in the cAMP assay. These results are consistent with othersâ findings that ligands that promote GPR40-dependent activation of G<sub>q</sub>- and G<sub>s</sub>-coupled pathways demonstrate a dual mode of action (i.e., insulin and incretin secretion).<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. cAMP Assay for GPR40 Partial and Full Agonists</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound number</th><th class="colsep0 rowsep0" align="center">hEC<sub>50</sub> (Î¼M)<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> Â±Â S.D.<a class="ref internalNav" href="#t8fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Ymax</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">>20</td><td class="colsep0 rowsep0" align="left">5%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b></td><td class="colsep0 rowsep0" align="left">2.4</td><td class="colsep0 rowsep0" align="left">28%</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b></td><td class="colsep0 rowsep0" align="left">0.21</td><td class="colsep0 rowsep0" align="left">140%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup>a</sup><p class="last">hGPR40 EC<sub>50</sub> in the Ca<sup>2+</sup> FLIPR assay.</p></div><div class="footnote" id="t8fn2"><sup>b</sup><p class="last">Mean of at least two runs.</p></div></div></div><div class="NLM_p">To study the effects of intrinsic activity in vivo, the pure enantiomers <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> and <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> were evaluated for their ability to improve glycemic control in mice. The compounds were tested in an oral glucose tolerance test in C57BL/6J mice at 0.3 or 1 mg/kg doses (<a class="ref internalNav" href="#fig11" aria-label="Figure 11">Figure 11</a>). In this assay, the compounds were administered orally 1 h prior to an orally administered glucose bolus, and plasma glucose levels were measured at â60, â20, 0, 20, 40, 60, and 120 min time points. Statistically significant glucose lowering was not observed for the 0.3 mg/kg <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> or 1 mg/kg <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> doses. Relative to the vehicle, the 1 mg/kg dose of <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was highly effective in reducing glucose excursion (ÎAUC<sub>0â120â</sub> = 39%), leading to further focus on this compound.</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0011.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. In vivo evaluation of <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> and <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> efficacy in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Given the favorable in vivo efficacy profile and its desired dual mechanism of action, compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was extensively profiled for ADME properties (<a class="ref internalNav" href="#tbl9" aria-label="Table 9">Table 9</a>). Compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> had low clearance at 0.2 mL/min/kg with a 7 h elimination half-life and low volume of distribution (<i>V</i><sub>ss</sub> = 0.1 L/kg) when administered intravenously in mice. Good bioavailability (83%) was observed. The compound exhibited high plasma protein binding with free fractions of 1.1% and 0.1% in mouse and human plasma, respectively. Compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> is metabolically stable when incubated with human, mouse, and monkey (cyno) liver microsomes with a half-life >120 min. A major metabolite results from demethylation of the fluoro-methoxyphenyl D ring. A small amount of glutathione (GSH) adduct formation was observed in the presence of liver microsomes and NADPH, suggesting some metabolic reactivity of the compound.</div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Pharmacokinetic Profile of <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> in Mice</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">0.2</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>T</i><sub>1/2</sub> (h)</td><td class="colsep0 rowsep0" align="left">7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>V</i><sub>ss</sub> (L/kg)</td><td class="colsep0 rowsep0" align="left">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cl (mL/min/kg)</td><td class="colsep0 rowsep0" align="left">0.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>F</i> (%)</td><td class="colsep0 rowsep0" align="left">83<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup>a</sup><p class="last">0.5 mg/kg dose.</p></div></div></div><div class="NLM_p">Because of increased risk of cardiovascular (CV) pathology in type 2 diabetic patients, compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was evaluated in CV safety studies. To evaluate the potential for undesired CV effects, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was tested in a single-dose (80 mg/kg) study in male rats that were fitted with telemetry equipment for noninvasive heart rate and blood pressure measurement, and locomotor activity was also monitored. The compound had no effect on mean arterial blood pressure and heart rate, but mild transient hyperactivity was observed after administration of <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b>, highlighting one concern for advancement of this compound.</div><div class="NLM_p last">When <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was extensively counterscreened for off-target activities, it was found to have PPARÎ³ binding (1.6 Î¼M) and transactivation activity (EC<sub>50</sub> = 4.4 Î¼M, Ymax = 40%) in a Gal4 reporter assay. To further study its PPARÎ³ activity, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was incubated with 3T3L1 cells to assess effects on free glycerol levels as a marker of PPARÎ³-mediated adipocyte differentiation. In this assay, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> promoted 3T3L1 differentiation at 3 Î¼M, further suggesting that the compound could demonstrate in vitro PPARÎ³-related effects. PPARÎ³ agonists have many benefits in type 2 diabetes that have been clinically validated, acting to improve insulin sensitivity, and this effect could be beneficial in conjunction with the GPR40 insulin secretagogue effect to promote greater reductions in HbA1c.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> However, there are potential regulatory barriers to clinical advancement of PPARÎ³ agonists: the FDA requires studies to evaluate the risk of adverse CV events as well as risk assessment for bladder cancers and bone effects.<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> As such, we did not want to complicate development of a GPR40 agonist by introducing polypharmacology.<a onclick="showRef(event, 'ref34 ref35 ref36 ref37'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36 ref37">(34-37)</a> In addition to the PPARÎ³ activity, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> showed micromolar CYP inhibition (2C8 IC<sub>50</sub> = 2.1 Î¼M, 2C9 IC<sub>50</sub> = 3.8 Î¼M, and 3A4 IC<sub>50</sub> = 1.7 Î¼M), prompting concerns over drugâdrug interactions in the clinic. Furthermore, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> bound to other nuclear hormone receptors (progesterone receptor and androgen receptor). For these reasons, compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was not advanced, but it was viewed as a good lead for further optimization due to its dual mechanism of action and favorable ADME profile.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02663" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02663" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we report a series of novel pyrrolidine GPR40 agonists. In our early work, we found that a biaryl ether or biaryl methane linker was optimal with respect to the pyrrolidine-2-acetic moiety. Addition of a 4-<i>cis</i>-CF<sub>3</sub> group to the pyrrolidine ring increased in vitro mGPR40 potency as well as improved the human binding <i>K</i><sub>i</sub>, resulting in the identification of compound <b>22</b> as a program lead. However, upon more extensive evaluation, we found that compound <b>22</b> was a partial agonist versus both the mouse and human receptors, leading to an understanding that the overexpressed CHO cell line could not distinguish full and partial hGPR40 agonists. By optimizing the mGPR40 potency and efficacy to induce Ca<sup>2+</sup> flux in the CHO cell line, we identified compounds that were efficacious in mice as demonstrated by a reduction in glucose excursion in an oGTT. These compounds retained full agonist efficacy versus hGPR40, providing confidence that the observed rodent activity would translate into the clinic. In one exciting breakthrough, the discovery of a minor enantiomeric impurity <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> revealed that the two enantiomers occupied different binding sites on the receptor and that compounds binding in these different sites could enhance the binding and efficacy of the other. Inducible GPR40 expression studies demonstrated that <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was a full activator, while <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> remained a partial agonist. In addition to its ability to promote glucose-dependent insulin secretion from islets, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was also shown to stimulate GLP-1 secretion in the STC-1 assay, demonstrating a desirable dual mechanism of action. Compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was effective at lowering plasma glucose levels in mice in an oral glucose tolerance test at 1 mg/kg and also showed synergistic effects with free fatty acids in vitro. Compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> was well tolerated at high doses in mice and telemetrized rats and displayed a favorable ADME profile. In extensive profiling, compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> showed several off-target effects in vitro and in vivo (hyperactivity), and its advancement was halted for these reasons, as well as concern over irreversible metabolic conjugation with glutathione and off-target PPARÎ³ activity. Nevertheless, <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> served as a valuable research tool to explore the therapeutic utility of GPR40 agonists in vitro and in vivo. Further optimization will be reported in due course wherein reduced off target activity and increased in vivo potency were achieved.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_75010" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_75010" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Chemistry</h3><div class="NLM_p">All anhydrous reactions were carried out using oven-dried glassware under an atmosphere of argon or nitrogen. All reagents and solvents were obtained from commercial vendors and used without further purification unless otherwise indicated. NMR spectra (<sup>1</sup>H, <sup>13</sup>C) were recorded on JEOL JNM-ECP500, JEOL GSX400, and Bruker 400 spectrometers. Chemical shifts were given in parts per million (ppm) downfield from internal reference tetramethylsilane standard; coupling constants (<i>J</i> values) were given in hertz (Hz). LC/MS data were recorded on a Shimadzu LC-10AT equipped with a SIL-10A injector, a SPD-10AV detector normally operating at 220 nm and interfaced to a Micromass ZMD mass spectrometer. LC/MS or HPLC retention times were reported using a Phenomenex Luna C-18 4.6 mm Ã 50 mm column eluting with a 12 min gradient of 0â100% solvent B, where solvent A was 5:95:0.05 CH<sub>3</sub>CN-H<sub>2</sub>O-TFA, and solvent B was 95:5:0.05 CH<sub>3</sub>CN-H<sub>2</sub>O-TFA. Reactions were monitored by TLC using 0.25 mm E. Merck silica gel plates (60 F254) and were visualized using UV light. All compounds were found to be >95% pure by HPLC analysis unless otherwise noted.</div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i18" class="anchor-spacer"></div><h4 class="article-section__title" id="_i18"> 1-(4-Iodophenoxy)-2-methylbenzene (<b>16</b>)</h4><div class="NLM_p last">To a solution of 4-(<i>o</i>-tolyloxy)aniline <b>15</b> (0.50 g, 2.5 mmol) in CH<sub>3</sub>CN (10 mL) was added <i>p</i>-TsOH (1.4 g, 7.5 mmol). The thick suspension was cooled to 0 Â°C, and a solution of sodium nitrite (0.35 g, 5.0 mmol) and KI (1.0 g, 6.3 mmol) in water (1.5 mL) was added gradually. The reaction mixture was stirred for 1 min at 0 Â°C and then warmed to rt for 1 h. To the mixture was added water (40 mL), sat. NaHCO<sub>3</sub> (until pH 9â10) and 2 M aq. Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub> (5 mL). The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3Ã). The combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by silica gel chromatography to provide 1-(4-iodophenoxy)-2-methylbenzene (0.57 g, 1.9 mmol, 74% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.64â7.56 (m, 2H), 7.31â7.26 (m, 1H), 7.24â7.16 (m, 1H), 7.16â7.08 (m, 1H), 6.98â6.90 (m, 1H), 6.73â6.64 (m, 2H), 2.23 (s, 3H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i19" class="anchor-spacer"></div><h4 class="article-section__title" id="_i19"> (2<i>S</i>,4<i>S</i>)-<i>tert-</i>Butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (<b>18</b>)</h4><div class="NLM_p last">(2<i>S</i>,4<i>S</i>)-1-(<i>tert</i>-Butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid <b>17</b> (purchased from NeoMPS SA) (1.8 g, 6.3 mmol) was dissolved in dry THF (26 mL), and the solution was cooled to â10 Â°C. 4-Methylmorpholine (0.73 mL, 6.7 mmol) and isobutyl chloroformate (0.88 mL, 6.7 mmol) were added sequentially, and the mixture was stirred at â10 Â°C for 45 min. The mixture was filtered and added to a solution of NaBH<sub>4</sub> (0.48 g, 13 mmol) in water (3.4 mL) cooled to 0 Â°C. The reaction mixture was stirred for 2 h and slowly warmed to rt. The reaction was quenched with sat. aq. NH<sub>4</sub>Cl, and the product was extracted with EtOAc (3Ã). The combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by silica gel chromatography to provide (2<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (1.6 g, 6.1 mmol, 95% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>11</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>: 269.12, found [M + H] 270.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 4.89â4.67 (m, 1H), 4.09â3.94 (m, 1H), 3.90â3.77 (m, 1H), 3.77â3.59 (m, 3H), 3.33 (br t, <i>J</i> = 10.6 Hz, 1H), 2.91â2.77 (m, 1H), 2.36â2.22 (m, 1H), 1.48 (s, 9H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i20" class="anchor-spacer"></div><h4 class="article-section__title" id="_i20"> ((2<i>S</i>,4<i>S</i>)-4-(Trifluoromethyl)pyrrolidin-2-yl)methanol, HCl (<b>19</b>)</h4><div class="NLM_p last">(2<i>S</i>,4<i>S</i>)-<i>tert</i>-Butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (1.6 g, 6.1 mmol) was dissolved in a 4 N solution of HCl in dioxane (10 mL, 40 mmol) and stirred at rt for 1 h. The reaction mixture was concentrated and azeotroped with MeOH to give ((2<i>S</i>,4<i>S</i>)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol, HCl (1.3 g, 6.1 mmol, 100% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>6</sub>H<sub>10</sub>F<sub>3</sub>NO: 169.07, found [M + H] 170.0. <sup>1</sup>H NMR (400 MHz, METHANOL-<i>d</i><sub>4</sub>) Î´ 3.92â3.86 (m, <i>J</i> = 11.9, 3.5 Hz, 1H), 3.86â3.77 (m, 1H), 3.70 (dd, <i>J</i> = 11.7, 5.9 Hz, 1H), 3.61 (br d, <i>J</i> = 2.8 Hz, 1H), 3.51â3.37 (m, 2H), 2.42 (dt, <i>J</i> = 13.8, 6.9 Hz, 1H), 1.98 (ddd, <i>J</i> = 13.2, 10.6, 10.3 Hz, 1H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i21" class="anchor-spacer"></div><h4 class="article-section__title" id="_i21"> ((2<i>S</i>,4<i>S</i>)-1-(4-(<i>o</i>-Tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol (<b>20</b>)</h4><div class="NLM_p last">1-(4-Iodophenoxy)-2-methylbenzene (0.18 g, 0.59 mmol), ((2<i>S</i>,4<i>S</i>)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol, HCl (0.10 g, 0.49 mmol), CuI (2.3 mg, 0.012 mmol), and freshly powdered NaOH (0.059 g, 1.5 mmol) were combined in a capped vial, which was sealed and purged with argon. Isopropanol (3 mL) was added, and the reaction mixture was heated to 90 Â°C overnight. The reaction mixture was cooled to rt and diluted with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3Ã). The combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by silica gel chromatography to provide ((2<i>S</i>,4<i>S</i>)-1-(4-(<i>o</i>-tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol (0.13 g, 0.36 mmol, 74% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>19</sub>H<sub>20</sub>F<sub>3</sub>NO<sub>2</sub>: 351.14, found [M + H] 352.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.40 (br d, <i>J</i> = 7.1 Hz, 1H), 7.29â7.18 (m, 3H), 6.94 (d, <i>J</i> = 9.1 Hz, 1H), 6.71 (d, <i>J</i> = 9.1 Hz, 1H), 4.99 (s, 2H), 3.99â3.87 (m, <i>J</i> = 7.5, 7.5, 4.8, 2.8 Hz, 1H), 3.80 (ddd, <i>J</i> = 11.2, 4.4, 4.2 Hz, 1H), 3.69â3.58 (m, 2H), 3.51 (t, <i>J</i> = 9.2 Hz, 1H), 2.38 (s, 3H), 2.37â2.23 (m, 2H), 1.62 (dd, <i>J</i> = 7.7, 3.9 Hz, 1H), 1.27 (t, <i>J</i> = 7.1 Hz, 1H).</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i22" class="anchor-spacer"></div><h4 class="article-section__title" id="_i22"> 2-((2<i>S</i>,4<i>S</i>)-1-(4-(<i>o</i>-Tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (<b>21</b>)</h4><div class="NLM_p last">((2<i>S</i>,4<i>S</i>)-1-(4-(<i>o</i>-Tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol (0.073 g, 0.21 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL), and the solution was cooled to 0 Â°C. Methanesulfonyl chloride (0.024 mL, 0.31 mmol) and TEA (0.058 mL, 0.41 mmol) were added sequentially, and the reaction mixture was stirred at 0 Â°C for 1 h. The reaction mixture was diluted with EtOAc and washed with 1 N HCl, sat. aq. NaHCO<sub>3</sub>, and brine. The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The crude product was redissolved in DMSO (1 mL) and NaCN (0.041 g, 0.83 mmol) was added. The reaction mixture was stirred at 50 Â°C overnight. The reaction mixture was cooled to rt and water was added. The product was extracted with EtOAc (3Ã). The combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by silica gel chromatography to provide 2-((2<i>S</i>,4<i>S</i>)-1-(4-(<i>o</i>-tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (0.075 g, 0.21 mmol, 100% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>20</sub>H<sub>19</sub>F<sub>3</sub>N<sub>2</sub>O: 360.14, found [M + H] 360.9. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.24 (br d, <i>J</i> = 6.8 Hz, 1H), 7.16â7.09 (m, 1H), 7.06â6.97 (m, 1H), 6.91 (d, <i>J</i> = 9.1 Hz, 2H), 6.80 (d, <i>J</i> = 8.1 Hz, 1H), 6.62 (d, <i>J</i> = 9.1 Hz, 2H), 4.20 (dddd, <i>J</i> = 10.7, 5.7, 5.5, 3.2 Hz, 1H), 3.59 (d, <i>J</i> = 8.3 Hz, 2H), 3.18â3.00 (m, 1H), 2.79 (dd, <i>J</i> = 16.8, 3.2 Hz, 1H), 2.69 (ddd, <i>J</i> = 13.7, 9.3, 7.6 Hz, 1H), 2.47 (dd, <i>J</i> = 16.9, 8.8 Hz, 1H), 2.28 (s, 3H), 2.22 (ddd, <i>J</i> = 13.7, 8.0, 5.8 Hz, 1H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i23" class="anchor-spacer"></div><h4 class="article-section__title" id="_i23"> 2-((2<i>S</i>,4<i>S</i>)-1-(4-(<i>o</i>-Tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic Acid, TFA (<b>22</b>)</h4><div class="NLM_p last">2-((2<i>S</i>,4<i>S</i>)-1-(4-(<i>o</i>-Tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (0.036 g, 0.099 mmol) was dissolved in EtOH (1.5 mL) in a microwave tube, and 6 M aq. KOH (0.50 mL, 3.0 mmol) was added. The reaction was microwaved at 150 Â°C for 30 min. The reaction mixture was concentrated. The residue was acidified to pH 2 with 1 N aq. HCl, and the product was extracted with EtOAc (3Ã). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated. The crude product was purified by RP-Prep. HPLC. The HPLC fractions were lyophilized to give 2-((2<i>S</i>,4<i>S</i>)-1-(4-(o-tolyloxy)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic acid and TFA (0.021 g, 0.042 mmol, 43% yield) as a brown solid. LC-MS Anal Calcd for C<sub>20</sub>H<sub>20</sub>F<sub>3</sub>NO<sub>3</sub>: 379.14, found [M + H] 379.9. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ 7.25 (br d, <i>J</i> = 7.6 Hz, 1H), 7.13 (br t, <i>J</i> = 7.7 Hz, 1H), 7.01 (t, <i>J</i> = 7.3 Hz, 1H), 6.86 (d, <i>J</i> = 9.1 Hz, 2H), 6.75 (d, <i>J</i> = 8.1 Hz, 1H), 6.70 (d, <i>J</i> = 9.1 Hz, 2H), 4.26â4.14 (m, 1H), 3.60â3.45 (m, 2H), 3.27â3.08 (m, 1H), 2.81 (dd, <i>J</i> = 15.9, 3.0 Hz, 1H), 2.62 (ddd, <i>J</i> = 13.5, 9.3, 7.8 Hz, 1H), 2.24 (s, 3H), 2.31â2.19 (m, 1H), 2.04â1.96 (m, 1H). Analytical HPLC: RT = 9.8 min; HI, 98.6%.</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> (<i>S</i>)-2-Benzyl 1-<i>tert</i>-butyl 4-oxopyrrolidine-1,2-dicarboxylate (<b>70</b>)</h4><div class="NLM_p last">To a solution of (2<i>S</i>, 4<i>R</i>)-2-benzyl 1<i>-tert</i>-butyl 4-hydroxypyrrolidine-1,2-dicarboxylate <b>69</b> (20 g, 62 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (400 mL) was added pyridinium chlorochromate (200 g, 93 mmol). The resultant solution was stirred overnight at rt. The solution was filtered through a Celite pad and washed with sat. aq. NaHCO<sub>3</sub> and 10% citric acid. The solution was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude product was purified by silica gel chromatography to provide (<i>S</i>)-2-benzyl 1-<i>tert</i>-butyl 4-oxopyrrolidine-1,2-dicarboxylate (16 g, 50 mmol, 80% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>17</sub>H<sub>21</sub>NO<sub>5</sub>: 319.14, found [M+H-Boc] 221.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.34 (br d, <i>J</i> = 3.5 Hz, 5H), 5.36â5.06 (m, 2H), 4.96â4.66 (m, 1H), 3.96â3.78 (m, 2H), 3.04â2.78 (m, 1H), 2.56 (br d, <i>J</i> = 18.4 Hz, 1H), 1.51â1.32 (m, 9H).</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i25" class="anchor-spacer"></div><h4 class="article-section__title" id="_i25"> (2<i>S</i>)-2-Benzyl 1-<i>tert-</i>Butyl 4-hydroxy-4-(trifluoromethyl) pyrrolidine-1,2-dicarboxylate (<b>71</b>)</h4><div class="NLM_p last">To a solution of (<i>S</i>)-2-benzyl 1-<i>tert</i>-butyl 4-oxopyrrolidine-1,2-dicarboxylate (20 g, 62 mmol) at 0 Â°C in THF (300 mL) was added (trifluoromethyl)trimethylsilane (18 g, 130 mmol) and 1 M TBAF in THF (2.2 mL, 2.2 mmol). The reaction mixture was warmed to rt and stirred overnight. Sat. aq. NH<sub>4</sub>Cl (100 mL) was added, and the reaction mixture was stirred for 15 min. A 1 M solution of TBAF in THF (100 mL, 100 mmol) was added, and the mixture was stirred for 2 h. The layers were separated, and the aqueous layer was extracted with EtOAc (3 Ã 300 mL). The combined organic layers were washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. Purification via silica gel chromatography provided (2<i>S</i>)-2-benzyl 1-<i>tert</i>-butyl 4-hydroxy-4-(trifluoromethyl)pyrrolidine-1,2-dicarboxylate (19 g, 49 mmol, 79% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>18</sub>H<sub>22</sub>F<sub>3</sub>NO<sub>5</sub>: 389.15, found [M+H-Boc] 290.0. <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) Î´ 7.41â7.29 (m, 5H), 5.34â5.12 (m, 2H), 4.65â4.42 (d, <i>J</i> = 9.51 Hz, 1H), 3.87â3.60 (m, 2H), 2.66â2.46 (m, 1H), 2.19 (t, <i>J</i> = 15.3 Hz, 1H), 1.48â1.32 (m, 9H).</div></div><div id="sec4_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i26" class="anchor-spacer"></div><h4 class="article-section__title" id="_i26"> (<i>S</i>)-2-Benzyl 1-<i>tert-</i>butyl 4-(trifluoromethyl)-1<i>H</i>-pyrrole-1,2(2<i>H</i>,5<i>H</i>)-dicarboxylate (Scalemic Mixture) (<b>72</b>)</h4><div class="NLM_p last">To a solution of (2<i>S</i>)-2-benzyl 1-<i>tert</i>-butyl 4-hydroxy-4-(trifluoromethyl)pyrrolidine-1,2-dicarboxylate (10 g, 25 mmol) at 0 Â°C in pyridine (330 mL) was added SOCl<sub>2</sub> (20 mL). The reaction mixture was refluxed for 1 h. The reaction mixture was quenched with water and extracted with EtOAc (3 Ã 200 mL). The combined organic layer was dried (MgSO<sub>4</sub>) and concentrated. The residue was taken up in CH<sub>2</sub>Cl<sub>2</sub> (200 mL), and DIPEA (3.3 g, 25 mmol) and Boc<sub>2</sub>O (5.0 g, 25 mmol) were added. The reaction mixture was stirred at rt overnight. The reaction mixture was diluted with CH<sub>2</sub>Cl<sub>2</sub> (200 mL) and washed with 1 N HCl (100 mL), sat. aq. NaHCO<sub>3</sub> (100 mL), water (100 mL), and brine (50 mL), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The crude material was purified by silica gel chromatography to provide (<i>S</i>)-2-benzyl 1-<i>tert-</i>butyl 4-(trifluoromethyl)-1<i>H</i>-pyrrole-1,2(2<i>H</i>,5<i>H</i>)-dicarboxylate (6.0 g, 16 mmol, 65% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>18</sub>H<sub>20</sub>F<sub>3</sub>NO<sub>4</sub>: 371.13, found [M+H-Boc] 272.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.40â7.31 (m, 5H), 6.26 (dt, <i>J</i> = 15.3, 1.9 Hz, 1H), 5.29â5.09 (m, 3H), 4.45â4.30 (m, 2H), 1.49â1.34 (m, 9H).</div></div><div id="sec4_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i27" class="anchor-spacer"></div><h4 class="article-section__title" id="_i27"> (2<i>S</i>,4<i>S</i>)-1-(<i>tert-</i>Butoxycarbonyl)-4-(trifluoromethyl) pyrrolidine-2-carboxylic Acid (Scalemic Mixture) (<b>73</b>)</h4><div class="NLM_p last">Ten percent Pd/C (5.5 g) was added to a solution of (<i>S</i>)-2-benzyl 1-<i>tert</i>-butyl 4-(trifluoromethyl)-1<i>H</i>-pyrrole-1,2(2<i>H</i>, 5<i>H</i>)-dicarboxylate (6.0 g, 16 mmol) in EtOH (250 mL). The solution was stirred under hydrogen (1 atm) at rt overnight. The reaction mixture was filtered through Celite and concentrated. The crude material was recrystallized to give (2<i>S</i>,4<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid (4.1 g, 14 mmol, 90% yield) as a colorless solid. LC-MS Anal Calcd for C<sub>11</sub>H<sub>16</sub>F<sub>3</sub>NO<sub>4</sub>: 283.10, found [M+H-Boc] 184.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 4.55â4.26 (m, 1H), 3.98â3.79 (m, 1H), 3.54â3.41 (m, 1H), 3.02â2.89 (m, 1H), 2.67â2.48 (m, 1H), 2.41â2.13 (m, 1H), 1.52â1.39 (m, 9H).</div></div><div id="sec4_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i28" class="anchor-spacer"></div><h4 class="article-section__title" id="_i28"> (2<i>S</i>,4<i>S</i>)-<i>tert-</i>Butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (Scalemic Mixture) (<b>74</b>)</h4><div class="NLM_p last">To a solution of (2<i>S</i>,4<i>S</i>)-1-(<i>tert</i>-butoxycarbonyl)-4-(trifluoromethyl)pyrrolidine-2-carboxylic acid (4.8 g, 20 mmol) in THF (200 mL) cooled to â10 Â°C was added <i>N</i>-methyl morpholine (2.1 g, 21 mmol) and isobutyl chloroformate (2.9 g, 21 mmol). The reaction mixture was stirred at â10 Â°C for 1 h. The reaction mixture was filtered through Celite washed with THF. This solution was added dropwise to a solution of NaBH<sub>4</sub> (1.5 g, 40 mmol) in water (15 mL) at 0 Â°C. The reaction mixture was stirred at 0 Â°C for 2 h and then warmed to rt and stirred for 1 h. The reaction was quenched with sat. aq. NH<sub>4</sub>Cl (100 mL), and the solution was stirred for 15 min. The layers were separated, and the aqueous layer was extracted with EtOAc (3 Ã 200 mL). The combined organic layers were washed with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The crude material was purified by silica gel chromatography to afford (2<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (3.8 g, 14 mmol, 71% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>11</sub>H<sub>18</sub>F<sub>3</sub>NO<sub>3</sub>: 269.12, found [M+H-Boc] 170.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 4.87â4.78 (m, 1H), 4.06â3.95 (m, 1H), 3.91â3.77 (m, 1H), 3.77â3.61 (m, 3H), 3.33 (t, <i>J</i> = 10.4 Hz, 1H), 2.96â2.75 (m, 1H), 2.39â2.21 (m, 1H), 1.48 (s, 9H).</div></div><div id="sec4_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i29" class="anchor-spacer"></div><h4 class="article-section__title" id="_i29"> ((2<i>S</i>,4<i>S</i>)-4-(Trifluoromethyl) pyrrolidin-2-yl)methanol Hydrochloride (Scalemic Mixture) (<b>75</b>)</h4><div class="NLM_p last">To a solution of (2<i>S</i>,4<i>S</i>)-<i>tert</i>-butyl 2-(hydroxymethyl)-4-(trifluoromethyl)pyrrolidine-1-carboxylate (4.4 g, 16 mmol) in dioxane (10 mL) at 0 Â°C, a 4 M solution of HCl in dioxane (4.9 mL, 20 mmol) was added, and the reaction mixture was warmed to rt and stirred for 1 h. The reaction mixture was concentrated to give ((2<i>S</i>,4<i>S</i>)-4-(trifluoromethyl) pyrrolidin-2-yl)methanol hydrochloride (3.1 g, 15 mmol, 93% yield) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) Î´ 9.99â9.73 (br. s, 1H), 9.26â8.99 (br. s, 1H), 3.75â3.59 (m, 3H), 3.55â3.41 (m, 3H), 2.50 (m, 1H), 2.35â2.22 (m, 1H), 1.89â1.67 (m, 1H).</div></div><div id="sec4_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i30" class="anchor-spacer"></div><h4 class="article-section__title" id="_i30"> ((2<i>S</i>,4<i>S</i>)-1-(4-Bromophenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol (Scalemic Mixture) (<b>76</b>)</h4><div class="NLM_p last">1-Bromo-4-iodobenzene (3.8 g, 13 mmol), ((2<i>S</i>,4<i>S</i>)-4-(trifluoromethyl) pyrrolidin-2-yl)methanol hydrochloride (2.3 g, 11 mmol), CuI (0.053 g, 0.28 mmol), and NaOH (1.3 g, 33 mmol) were combined in a flask, which was purged with argon. <i>i-</i>PrOH (33 mL) was added, and the reaction mixture was refluxed for 16 h. The reaction mixture was cooled to rt and diluted with water. The product was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3Ã). The combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by silica gel chromatography to afford ((2<i>S</i>,4<i>S</i>)-1-(4-bromophenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol (2.8 g, 8.6 mmol, 77% yield) as an off white solid. LC-MS Anal Calcd for C<sub>12</sub>H<sub>13</sub>BrF<sub>3</sub>NO: 323.01, found [M + H] 323.9, 325.9. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.32 (td, <i>J</i> = 3.3, 9.1 Hz, 2H), 6.57 (td, <i>J</i> = 3.3, 8.8 Hz, 2H), 4.06â3.97 (m, 1H), 3.83â3.75 (m, 1H), 3.73â3.65 (m, 1H), 3.57 (d, <i>J</i> = 8.3 Hz, 2H), 3.08â2.89 (m, 1H), 2.44 (td, <i>J</i> = 8.2, 13.4 Hz, 1H), 2.30 (ddd, <i>J</i> = 7.1, 9.6, 13.4 Hz, 1H), 1.43 (dd, <i>J</i> = 4.5, 7.1 Hz, 1H).</div></div><div id="sec4_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> 2-((2<i>S</i>,4<i>S</i>)-(1-(4-Bromophenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (Scalemic Mixture) (<b>77</b>)</h4><div class="NLM_p last">((2<i>S</i>,4<i>S</i>)-1-(4-Bromophenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)methanol (2.8 g, 8.6 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (40 mL), and the solution was cooled to 0 Â°C. Triethylamine (2.4 mL, 17 mmol) and MsCl (1.0 mL, 13 mmol) were added sequentially, and the reaction mixture was stirred at 0 Â°C for 1 h. The reaction mixture was diluted with EtOAc and washed with 1 N HCl, sat. NaHCO<sub>3</sub> (aq.), and brine. The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The crude product was dissolved in DMSO (40 mL), and NaCN (1.7 g, 34 mmol) was added. The reaction mixture was stirred at 50 Â°C for 16 h. The reaction mixture was cooled to rt and quenched with water. The product was extracted with EtOAc (3Ã). The combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by silica gel chromatography to afford 2-((2<i>S</i>,4<i>S</i>)-(1-(4-bromophenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (2.5 g, 7.5 mmol, 87% yield) as a white solid. LC-MS Anal Calcd for C<sub>13</sub>H<sub>12</sub>BrF<sub>3</sub>N<sub>2</sub>: 332.01, found [M + H] 333.0, 335.0. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.37 (d, <i>J</i> = 8.8 Hz, 2H), 6.50 (d, <i>J</i> = 8.8 Hz, 2H), 4.33â4.09 (m, 1H), 3.71â3.50 (m, 2H), 3.22â3.00 (m, 1H), 2.86â2.63 (m, 2H), 2.49 (dd, <i>J</i> = 8.6, 16.7 Hz, 1H), 2.23 (ddd, <i>J</i> = 5.7, 8.1, 13.8 Hz, 1H).</div></div><div id="sec4_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i32" class="anchor-spacer"></div><h4 class="article-section__title" id="_i32"> 2â²-Fluoro-5â²-methoxy-3-methylbiphenyl-4-carboxylic Acid (<b>80</b>)</h4><div class="NLM_p last">2-Fluoro-5-methoxyphenylboronic acid <b>78</b> (1.0 g, 6.1 mmol), 4-bromo-2-methylbenzoic acid <b>79</b> (1.2 g, 5.6 mmol), TBAB (1.8 g, 5.6 mmol), Pd(Ph<sub>3</sub>P)<sub>4</sub> (0.13 g, 0.11 mmol), and Na<sub>2</sub>CO<sub>3</sub> (2.4 g, 22 mmol) were combined in a microwave tube, and degassed water (11 mL) was added. The vial was sealed and microwaved at 130 Â°C for 20 min. The reaction mixture was diluted with EtOAc/water and acidified to pH 1 with 1 N aq. HCl. The layers were separated, and the aqueous layer was extracted with EtOAc (2Ã). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated to give 2â²-fluoro-5â²-methoxy-3-methylbiphenyl-4-carboxylic acid (1.3 g, 5.1 mmol, 92% yield) as a pale yellow solid, which was used without further purification. LC-MS Anal Calcd for C<sub>15</sub>H<sub>13</sub>FO<sub>3</sub>: 260.08, found [M + H] 261.0. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 12.28 (br s, 1H), 8.16 (d, <i>J</i> = 8.5 Hz, 1H), 7.53â7.42 (m, 2H), 7.09 (t, <i>J</i> = 9.4 Hz, 1H), 6.97 (dd, <i>J</i> = 6.2, 3.2 Hz, 1H), 6.88 (dt, <i>J</i> = 9.0, 3.3 Hz, 1H), 3.84 (s, 3H), 2.74 (s, 3H).</div></div><div id="sec4_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> (2â²-Fluoro-5â²-methoxy-3-methylbiphenyl-4-yl)methanol (<b>81</b>)</h4><div class="NLM_p last">2â²-Fluoro-5â²-methoxy-3-methylbiphenyl-4-carboxylic acid (3.1 g, 12 mmol) was dissolved in THF (50 mL) and cooled to 0 Â°C. LAH (0.98 g, 26 mmol) was added in several portions. The reaction mixture was warmed to rt and stirred for 1 h. The reaction mixture was recooled to 0 Â°C and quenched by the addition of water (0.98 mL), 15% aq. NaOH (0.98 mL), and water (2.9 mL). The reaction mixture was warmed to rt and stirred for 30 min. The solids were filtered off, and the organic layer was dried (MgSO<sub>4</sub>) and concentrated. The crude product was purified by silica gel chromatography to afford (2â²-fluoro-5â²-methoxy-3-methylbiphenyl-4-yl)methanol (2.6 g, 10 mmol, 89% yield) as a colorless oil. LC-MS Anal Calcd for C<sub>15</sub>H<sub>15</sub>FO<sub>2</sub>: 246.11, found [M<sup>+</sup>âOH] 229.0. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 7.46â7.42 (m, <i>J</i> = 7.7 Hz, 1H), 7.41â7.35 (m, 2H), 7.07 (dd, <i>J</i> = 9.9, 9.1 Hz, 1H), 6.94 (dd, <i>J</i> = 6.3, 3.0 Hz, 1H), 6.83 (ddd, <i>J</i> = 8.9, 3.6, 3.4 Hz, 1H), 4.74 (s, 2H), 3.82 (s, 3H), 2.41 (s, 3H), 1.80 (s, 1H).</div></div><div id="sec4_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> 4â²-(Bromomethyl)-2-fluoro-5-methoxy-3â²-methylbiphenyl (<b>82</b>)</h4><div class="NLM_p last">Lithium bromide (1.1 g, 12 mmol) was added to dry THF (12 mL), and the reaction mixture was stirred for 10 min until the solids dissolved. The solution was cannulated into a flask containing (2â²-fluoro-5â²-methoxy-3-methylbiphenyl-4-yl)methanol (0.30 g, 1.2 mmol), and NEt<sub>3</sub> (0.85 mL, 6.1 mmol) was added. The reaction mixture was cooled to 0 Â°C, and MsCl (0.24 mL, 3.1 mmol) was added dropwise. The reaction mixture was stirred at 0 Â°C for 1.5 h. The reaction mixture was diluted with hexanes and washed with water and brine. The organic layer was dried (MgSO<sub>4</sub>) and concentrated. The crude product was purified by silica gel chromatography to afford 4â²-(bromomethyl)-2-fluoro-5-methoxy-3â²-methylbiphenyl (0.33 g, 1.1 mmol, 89% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) Î´ 7.43â7.32 (m, 3H), 7.06 (dd, <i>J</i> = 9.9, 9.1 Hz, 1H), 6.93 (dd, <i>J</i> = 6.3, 3.0 Hz, 1H), 6.83 (dt, <i>J</i> = 8.8, 3.4 Hz, 1H), 4.57 (s, 2H), 3.82 (s, 3H), 2.48 (s, 3H).</div></div><div id="sec4_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> 2-((2<i>S</i>,4<i>S</i>)-(1-(4-((2â²-Fluoro-5â²-methoxy-3-methylbiphenyl-4-yl)methyl)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (Scalemic Mixture) (<b>83</b>)</h4><div class="NLM_p last">To a suspension of zinc dust (0.61 g, 9.3 mmol) in anhydrous THF (3 mL) was sequentially added with stirring ethylene dibromide (0.021 mL, 0.24 mmol) and TMS-Cl (0.016 mL, 0.12 mmol) under argon. The mixture was heated with stirring at 65 Â°C for 20 min. A solution of 4â²-(bromomethyl)-2-fluoro-5-methoxy-3â²-methylbiphenyl (1.9 g, 6.2 mmol) in THF (5.9 mL) was added dropwise to the zinc. The reaction mixture was stirred at 65 Â°C for 2 h and cooled to rt. A solution of 2-((2<i>S</i>,4<i>S</i>)-(1-(4-bromophenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (1.3 g, 3.8 mmol) and Pd(Ph<sub>3</sub>P)<sub>4</sub> (0.18 g, 0.15 mmol) in THF (3.8 mL) was cannulated into the zinc solution, and the flask was rinsed with THF (1.5 mL). The reaction mixture was heated to 75 Â°C. After 1 h, the reaction mixture was cooled to rt and quenched with 1.5 M K<sub>2</sub>HPO<sub>4</sub>. The reaction mixture was diluted with EtOAc, and the layers were separated. The aqueous layer was extracted with EtOAc, and the combined organic layers were washed with brine, dried (MgSO<sub>4</sub>), and concentrated. The crude product was purified by silica gel chromatography to afford 2-((2<i>S</i>,4<i>S</i>)-(1-(4-((2â²-fluoro-5â²-methoxy-3-methylbiphenyl-4-yl)methyl)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (1.6 g, 3.3 mmol, 86% yield) as a yellow oil. LC-MS Anal Calcd for C<sub>28</sub>H<sub>26</sub>F<sub>4</sub>N<sub>2</sub>O: 482.20, found [M + H] 483.2. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) Î´ 7.37â7.29 (m, 2H), 7.15 (d, <i>J</i> = 8.0 Hz, 1H), 7.09 (d, <i>J</i> = 8.8 Hz, 2H), 7.05 (dd, <i>J</i> = 8.8, 9.9 Hz, 1H), 6.94 (dd, <i>J</i> = 3.2, 6.2 Hz, 1H), 6.81 (td, <i>J</i> = 3.5, 9.0 Hz, 1H), 6.60â6.55 (m, 2H), 4.24 (ddt, <i>J</i> = 3.0, 5.5, 8.3 Hz, 1H), 3.94 (s, 2H), 3.82 (s, 3H), 3.66â3.54 (m, 2H), 3.13â2.99 (m, 1H), 2.82 (dd, <i>J</i> = 3.2, 16.9 Hz, 1H), 2.69 (ddd, <i>J</i> = 7.7, 9.1, 13.8 Hz, 1H), 2.50â2.41 (m, 1H), 2.31 (s, 3H), 2.22 (ddd, <i>J</i> = 5.6, 8.1, 13.8 Hz, 1H).</div></div><div id="sec4_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> 2-((2<i>S</i>,4<i>S</i>)-1-(4-((2â²-Fluoro-5â²-methoxy-3-methyl-[1,1â²-biphenyl]-4-yl)methyl)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic Acid, HCl <b>(<i>S</i>,<i>S</i>,-68)</b>, and 2-((2<i>R</i>,4<i>R</i>)-1-(4-((2â²-fluoro-5â²-methoxy-3-methyl-[1,1â²-biphenyl]-4-yl)methyl)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetic Acid, HCl (<i><b>R</b></i>,<i><b>R</b></i><b>,-68</b>)</h4><div class="NLM_p last">2-((2<i>S</i>,4<i>S</i>)-(1-(4-((2â²-Fluoro-5â²-methoxy-3-methylbiphenyl-4-yl)methyl)phenyl)-4-(trifluoromethyl)pyrrolidin-2-yl)acetonitrile (1.1 g, 2.3 mmol) was dissolved in EtOH (23 mL) in a pressure vessel, and a 6 M solution of KOH (7.6 mL, 45 mmol) was added. The pressure vessel was sealed and heated to 120 Â°C for 2 h. The reaction mixture was cooled to rt, concentrated, and redissolved in EtOAc. The solution was acidified to pH 2 with 1 N HCl (aq.), and the product was extracted with EtOAc (3Ã). The combined organic layers were dried (MgSO<sub>4</sub>) and concentrated. The crude product was purified by RP-Prep. HPLC. The product was redissolved in CH<sub>3</sub>CN (5 mL), and 3 N HCl (aq.) (2 mL) was added. The mixture was concentrated, and the procedure was repeated (twice). The aqueous layer was lyophilized to give compound <b>68</b> as a scalemic mixture (light peach solid, 0.85 g, 1.4 mmol, 70% yield). Half (40 mg) of the mixture of isomers was separated by preparative SFC chromatography (Chiralpak AD-H, 250 Ã 21 cm ID, 5 Î¼m; 65 mL/min, 100 bar BP, 35 Â°C; 25% MeOH/75% CO<sub>2</sub>; 256 nm detector wavelength; 0.5 mL injection volume of 40 mg/mL solution in MeOH). The chiral purity of the samples was analyzed by analytical SFC chromatography (Chiralpak AD-H, 250 Ã 4.6 cm ID, 5 Î¼m; 3.0 mL/min, 100 bar BP, 35 Â°C; 25% MeOH/75% CO<sub>2</sub>; 220 nm detector wavelength; 10 Î¼L injection volume in MeOH). The product-containing fractions for each isomer were concentrated and redissolved in CH<sub>3</sub>CN (1 mL), and 3 N HCl (aq.) (0.5 mL) was added. The solutions were concentrated, and the procedure was repeated (2Ã) to ensure salt exchange. The aqueous layers were lyophilized to give the single enantiomers. Compound <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>,-68)</b> (beige powder, 21 mg, Chiralpak AD-H rt: 7.496, â¥ 99.6% er). LC-MS Anal Calcd for C<sub>28</sub>H<sub>27</sub>F<sub>4</sub>NO<sub>3</sub>: 501.19, found [M + H] 502.4. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ 7.38 (s, 1H), 7.37â7.31 (m, 1H), 7.24â7.14 (m, 5H), 7.11 (dd, <i>J</i> = 9.1, 10.4 Hz, 1H), 6.99 (dd, <i>J</i> = 3.2, 6.4 Hz, 1H), 6.88 (td, <i>J</i> = 3.5, 8.9 Hz, 1H), 4.28â4.19 (m, 1H), 4.00 (s, 2H), 3.81 (s, 3H), 3.80â3.73 (m, 1H), 3.65 (dd, <i>J</i> = 9.6, 11.1 Hz, 1H), 3.47â3.31 (m, 1H), 2.84 (dd, <i>J</i> = 3.8, 16.4 Hz, 1H), 2.74â2.59 (m, 2H), 2.30 (s, 3H), 2.14 (ddd, <i>J</i> = 8.7, 8.9, 13.2 Hz, 1H). Analytical HPLC: RT = 12.9 min; HI, 98.7%. Compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>-68)</b> (light pink solid, 4.0 mg, Chiralpak AD-H rt: 13.278, 97.3% er). LC-MS Anal Calcd for C<sub>28</sub>H<sub>27</sub>F<sub>4</sub>NO<sub>3</sub>: 501.19, found [M + H] 502.4. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>CN) Î´ 7.72 (d, <i>J</i> = 8.8 Hz, 2H), 7.43â7.31 (m, 4H), 7.21 (d, <i>J</i> = 8.2 Hz, 1H), 7.11 (dd, <i>J</i> = 8.8, 10.4 Hz, 1H), 6.98 (dd, <i>J</i> = 3.0, 6.3 Hz, 1H), 6.88 (td, <i>J</i> = 3.6, 8.8 Hz, 1H), 4.26 (tdd, <i>J</i> = 4.9, 9.2, 11.3 Hz, 1H), 4.13â4.01 (m, 3H), 3.80 (s, 3H), 3.77â3.70 (m, 1H), 3.69â3.57 (m, 1H), 3.08 (dd, <i>J</i> = 8.8, 17.0 Hz, 1H), 2.83 (dd, <i>J</i> = 4.4, 17.0 Hz, 1H), 2.75 (ddd, <i>J</i> = 5.5, 7.1, 12.6 Hz, 1H), 2.36â2.22 (m, 4H). Analytical HPLC: RT = 12.9 min; HI, 98.5%.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i37"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01559">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_72777" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_72777" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.6b01559" class="ext-link">10.1021/acs.jmedchem.6b01559</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Experimental procedures for the synthesis of compounds <b>5</b>â<b>85</b> and methods for in vitro and in vivo biological studies (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES data (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_002.csv" class="ext-link">CSV</a>)</p></li><li><p class="inline">Compound <b>22</b> A and B rings only (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_003.pdb" class="ext-link">PDB</a>)</p></li><li><p class="inline">Compound <b>32</b> A and B rings only (<a href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_004.pdb" class="ext-link">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_001.pdf">jm6b01559_si_001.pdf (2.59 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_002.csv">jm6b01559_si_002.csv (5.37 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_003.pdb">jm6b01559_si_003.pdb (3.55 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_004.pdb">jm6b01559_si_004.pdb (3.25 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.6b01559" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55254" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55254" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth A. Jurica</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-3689-5451" title="Orcid link">http://orcid.org/0000-0003-3689-5451</a>;Â 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#0d486164776c6f6879652347787f646e6c4d6f607e236e6260"><span class="__cf_email__" data-cfemail="06436a6f7c676463726e284c73746f656746646b752865696b">[emailÂ protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ximao Wu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kristin N. Williams</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Andres S. Hernandez</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">David S. Nirschl</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Rampulla</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Arvind Mathur</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Min Zhou</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Gary Cao</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Chunshan Xie</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Biji Jacob</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hong Cai</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tao Wang</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian J. Murphy</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Heng Liu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carrie Xu</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lori K. Kunselman</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael B. Hicks</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Qin Sun</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dora M. Schnur</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Doree F. Sitkoff</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Elizabeth A. Dierks</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Atsu Apedo</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas B. Moore</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kimberly A. Foster</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mary Ellen Cvijic</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Reshma Panemangalore</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neil A. Flynn</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brad D. Maxwell</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span>;Â 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-8507-2078" title="Orcid link">http://orcid.org/0000-0001-8507-2078</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yang Hong</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Yuan Tian</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason J. Wilkes</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bradley A. Zinker</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jean M. Whaley</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joel C. Barrish</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey A. Robl</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">William R. Ewing</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce A. Ellsworth</span> - <span class="hlFld-Affiliation affiliation">Research and Development, Bristol-Myers Squibb, Co., P.O. Box
4000, Princeton, New Jersey 08540-4000, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d52e6142-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_55230" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_55230" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank the GPR40 team at both Bristol-Myers Squibb and Biocon Bristol-Myers Squibb Research Center for their efforts and dedication. We thank Tatyana Zvyaga and Chi Sum for their assistance in manuscript preparation.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i39" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i39"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i40" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i40"> Abbreviations Used</h2><tr><td class="NLM_term">GPR40</td><td class="NLM_def"><p class="first last">free fatty acid receptor 1</p></td></tr><tr><td class="NLM_term">GPCR</td><td class="NLM_def"><p class="first last">G-protein-coupled receptor</p></td></tr><tr><td class="NLM_term">GLP-1</td><td class="NLM_def"><p class="first last">glucagon-like peptide-1</p></td></tr><tr><td class="NLM_term">GIP</td><td class="NLM_def"><p class="first last">gastric inhibitory polypeptide</p></td></tr><tr><td class="NLM_term">hGPR40</td><td class="NLM_def"><p class="first last">human GPR40 receptor</p></td></tr><tr><td class="NLM_term">mGPR40</td><td class="NLM_def"><p class="first last">mouse GPR40 receptor</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structureâactivity relationship</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">FLIPR</td><td class="NLM_def"><p class="first last">fluorescent imaging plate reader</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryonic kidney</p></td></tr><tr><td class="NLM_term">PPARÎ³</td><td class="NLM_def"><p class="first last">peroxisome proliferator-activated receptor gamma</p></td></tr><tr><td class="NLM_term">EC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal effective concentration</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">ADME</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, and excretion</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71652" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71652" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 37 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Bonow, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghiade, M.</span><span> </span><span class="NLM_article-title">The Diabetes Epidemic: A National and Global Crisis</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">â</span> <span class="NLM_lpage">10</span><span class="refDoi">Â DOI: 10.1016/j.amjmed.2003.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.amjmed.2003.10.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=2-10&author=R.+O.+Bonowauthor=M.+Gheorghiade&title=The+Diabetes+Epidemic%3A+A+National+and+Global+Crisis&doi=10.1016%2Fj.amjmed.2003.10.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2003.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2003.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DBonow%26aufirst%3DR.%2BO.%26aulast%3DGheorghiade%26aufirst%3DM.%26atitle%3DThe%2520Diabetes%2520Epidemic%253A%2520A%2520National%2520and%2520Global%2520Crisis%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2004%26volume%3D116%26spage%3D2%26epage%3D10%26doi%3D10.1016%2Fj.amjmed.2003.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span>Key Findings 2014 International Diabetes Foundation. <a href="http://www.idf.org/diabetesatlas/update-2014" class="extLink">http://www.idf.org/diabetesatlas/update-2014</a> (accessed Aug 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Key+Findings+2014+International+Diabetes+Foundation.+http%3A%2F%2Fwww.idf.org%2Fdiabetesatlas%2Fupdate-2014+%28accessed+Aug+17%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Nathan, D. M.</span><span> </span><span class="NLM_article-title">Long-Term Complications of Diabetes Mellitus</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x">, </span> <span class="NLM_fpage">1676</span><span class="NLM_x">â</span> <span class="NLM_lpage">1685</span><span class="refDoi">Â DOI: 10.1056/NEJM199306103282306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1056%2FNEJM199306103282306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=8487827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1993&pages=1676-1685&author=D.+M.+Nathan&title=Long-Term+Complications+of+Diabetes+Mellitus&doi=10.1056%2FNEJM199306103282306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term complications of diabetes mellitus</span></div><div class="casAuthors">Nathan D M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1676-85</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQeI2Wva4wSrWlSCSgBhwJFfW6udTcc2eYD6yspdlafXLntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D&md5=2a29d58d4dec1bf483f668b439055709</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM199306103282306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199306103282306%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DD.%2BM.%26atitle%3DLong-Term%2520Complications%2520of%2520Diabetes%2520Mellitus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D328%26spage%3D1676%26epage%3D1685%26doi%3D10.1056%2FNEJM199306103282306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Briscoe, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadayyon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilert, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdock, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabon, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinage, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strum, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekeres, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Way, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignar, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. I.</span><span> </span><span class="NLM_article-title">The Orphan G Protein-Coupled Receptor GPR40 is Activated by Medium and Long Chain Fatty Acids</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">11303</span><span class="NLM_x">â</span> <span class="NLM_lpage">11311</span><span class="refDoi">Â DOI: 10.1074/jbc.M211495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1074%2Fjbc.M211495200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=11303-11311&author=C.+P.+Briscoeauthor=M.+Tadayyonauthor=J.+L.+Andrewsauthor=W.+G.+Bensonauthor=J.+K.+Chambersauthor=M.+M.+Eilertauthor=C.+Ellisauthor=N.+A.+Elshourbagyauthor=A.+S.+Goetzauthor=D.+T.+Minnickauthor=P.+R.+Murdockauthor=H.+R.+Saulsauthor=U.+Shabonauthor=L.+D.+Spinageauthor=J.+C.+Strumauthor=P.+G.+Szekeresauthor=K.+B.+Tanauthor=J.+M.+Wayauthor=D.+M.+Ignarauthor=S.+Wilsonauthor=A.+I.+Muir&title=The+Orphan+G+Protein-Coupled+Receptor+GPR40+is+Activated+by+Medium+and+Long+Chain+Fatty+Acids&doi=10.1074%2Fjbc.M211495200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M211495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M211495200%26sid%3Dliteratum%253Aachs%26aulast%3DBriscoe%26aufirst%3DC.%2BP.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DJ.%2BL.%26aulast%3DBenson%26aufirst%3DW.%2BG.%26aulast%3DChambers%26aufirst%3DJ.%2BK.%26aulast%3DEilert%26aufirst%3DM.%2BM.%26aulast%3DEllis%26aufirst%3DC.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DGoetz%26aufirst%3DA.%2BS.%26aulast%3DMinnick%26aufirst%3DD.%2BT.%26aulast%3DMurdock%26aufirst%3DP.%2BR.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DShabon%26aufirst%3DU.%26aulast%3DSpinage%26aufirst%3DL.%2BD.%26aulast%3DStrum%26aufirst%3DJ.%2BC.%26aulast%3DSzekeres%26aufirst%3DP.%2BG.%26aulast%3DTan%26aufirst%3DK.%2BB.%26aulast%3DWay%26aufirst%3DJ.%2BM.%26aulast%3DIgnar%26aufirst%3DD.%2BM.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DA.%2BI.%26atitle%3DThe%2520Orphan%2520G%2520Protein-Coupled%2520Receptor%2520GPR40%2520is%2520Activated%2520by%2520Medium%2520and%2520Long%2520Chain%2520Fatty%2520Acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D11303%26epage%3D11311%26doi%3D10.1074%2Fjbc.M211495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Itoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukusumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uejima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">Free Fatty Acids Regulate Insulin Secretion from Pancreatic Î² Cells through GPR40</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">422</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">176</span><span class="refDoi">Â DOI: 10.1038/nature01478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1038%2Fnature01478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=12629551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=173-176&author=Y.+Itohauthor=Y.+Kawamataauthor=M.+Haradaauthor=M.+Kobayashiauthor=R.+Fujiiauthor=S.+Fukusumiauthor=K.+Ogiauthor=M.+Hosoyaauthor=Y.+Tanakaauthor=H.+Uejimaauthor=H.+Tanakaauthor=M.+Maruyamaauthor=R.+Satohauthor=S.+Okuboauthor=H.+Kizawaauthor=H.+Komatsuauthor=F.+Matsumuraauthor=Y.+Noguchiauthor=T.+Shinoharaauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=Free+Fatty+Acids+Regulate+Insulin+Secretion+from+Pancreatic+%CE%B2+Cells+through+GPR40&doi=10.1038%2Fnature01478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids regulate insulin secretion from pancreatic Î² cells through GPR40</span></div><div class="casAuthors">Itoh, Yasuaki; Kawamata, Yuji; Harada, Masataka; Kobayashi, Makoto; Fujii, Ryo; Fukusumi, Shoji; Ogi, Kazuhiro; Hosoya, Masaki; Tanaka, Yasuhiro; Uejima, Hiroshi; Tanaka, Hideyuki; Maruyama, Minoru; Satoh, Rie; Okubo, Shoichi; Kizawa, Hideki; Komatsu, Hidetoshi; Matsumura, Fumika; Noguchi, Yuko; Shinohara, Tokuyuki; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6928</span>),
    <span class="NLM_cas:pages">173-176</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diabetes, a disease in which carbohydrate and lipid metab. are regulated improperly by insulin, is a serious worldwide health issue.  Insulin is secreted from pancreatic Î² cells in response to elevated plasma glucose, with various factors modifying its secretion.  Free fatty acids (FFAs) provide an important energy source as nutrients, and they also act as signaling mols. in various cellular processes, including insulin secretion.  Although FFAs are thought to promote insulin secretion in an acute phase, this mechanism is not clearly understood.  A G-protein-coupled receptor, GPR40, which is abundantly expressed in the pancreas, functions as a receptor for long-chain FFAs.  Furthermore, the authors show that long-chain FFAs amplify glucose-stimulated insulin secretion from pancreatic Î² cells by activating GPR40.  The authors' results indicate that GPR40 agonists and/or antagonists show potential for the development of new anti-diabetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Y9oes-9VG7Vg90H21EOLACvtfcHk0lg3r81puHc1ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D&md5=96af869fb87b235a482ad6c0c42db5e3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature01478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01478%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DUejima%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DR.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DKizawa%26aufirst%3DH.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMatsumura%26aufirst%3DF.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DFree%2520Fatty%2520Acids%2520Regulate%2520Insulin%2520Secretion%2520from%2520Pancreatic%2520%25CE%25B2%2520Cells%2520through%2520GPR40%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D173%26epage%3D176%26doi%3D10.1038%2Fnature01478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Burant, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakilynejad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leifke, E.</span><span> </span><span class="NLM_article-title">TAK-875 Versus Placebo or Glimepiride in Type 2 Diabetes Mellitus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Tsrial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">â</span> <span class="NLM_lpage">1411</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(11)61879-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2FS0140-6736%2811%2961879-5" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1403-1411&author=C.+F.+Burantauthor=P.+Viswanathanauthor=J.+Marcinakauthor=C.+Caoauthor=M.+Vakilynejadauthor=B.+Xieauthor=E.+Leifke&title=TAK-875+Versus+Placebo+or+Glimepiride+in+Type+2+Diabetes+Mellitus%3A+A+Phase+2%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Tsrial&doi=10.1016%2FS0140-6736%2811%2961879-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2961879-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252961879-5%26sid%3Dliteratum%253Aachs%26aulast%3DBurant%26aufirst%3DC.%2BF.%26aulast%3DViswanathan%26aufirst%3DP.%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DVakilynejad%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DLeifke%26aufirst%3DE.%26atitle%3DTAK-875%2520Versus%2520Placebo%2520or%2520Glimepiride%2520in%2520Type%25202%2520Diabetes%2520Mellitus%253A%2520A%2520Phase%25202%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Tsrial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1403%26epage%3D1411%26doi%3D10.1016%2FS0140-6736%2811%2961879-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Yabuki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujihata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda-Nagasumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span> </span><span class="NLM_article-title">A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e76280</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0076280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1371%2Fjournal.pone.0076280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=24130766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cjsr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e76280&author=C.+Yabukiauthor=H.+Komatsuauthor=Y.+Tsujihataauthor=R.+Maedaauthor=R.+Itoauthor=K.+Matsuda-Nagasumiauthor=K.+Sakumaauthor=K.+Miyawakiauthor=N.+Kikuchiauthor=K.+Takeuchiauthor=Y.+Habataauthor=M.+Mori&title=A+Novel+Antidiabetic+Drug%2C+Fasiglifam%2FTAK-875%2C+Acts+as+an+Ago-Allosteric+Modulator+of+FFAR1&doi=10.1371%2Fjournal.pone.0076280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1</span></div><div class="casAuthors">Yabuki, Chiori; Komatsu, Hidetoshi; Tsujihata, Yoshiyuki; Maeda, Risa; Ito, Ryo; Matsuda-Nagasumi, Kae; Sakuma, Kensuke; Miyawaki, Kazumasa; Kikuchi, Naoya; Takeuchi, Koji; Habata, Yugo; Mori, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e76280</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic Î² cells.  Although fasiglifam significantly improved glycemic control in type 2 diabetes patients with a min. risk of hypoglycemia in a phase 2 study, the precise mechanisms of its potent pharmacol. effects are not fully understood.  Here we demonstrate that fasiglifam acts as an ago-allosteric modulator with a partial agonistic activity for FFAR1.  In both Ca2+ influx and insulin secretion assays using cell lines and mouse islets, fasiglifam showed pos. cooperativity with the FFAR1 ligand Î³-linolenic acid (Î³-LA).  Augmentation of glucose-induced insulin secretion by fasiglifam, Î³-LA, or their combination was completely abolished in pancreatic islets of FFAR1-knockout mice.  In diabetic rats, the insulinotropic effect of fasiglifam was suppressed by pharmacol. redn. of plasma free fatty acid (FFA) levels using a lipolysis inhibitor, suggesting that fasiglifam potentiates insulin release in conjunction with plasma FFAs in vivo.  Point mutations of FFAR1 differentially affected Ca2+ influx activities of fasiglifam and Î³-LA, further indicating that these agonists may bind to distinct binding sites.  Our results strongly suggest that fasiglifam is an ago-allosteric modulator of FFAR1 that exerts its effects by acting cooperatively with endogenous plasma FFAs in human patients as well as diabetic animals.  These findings contribute to our understanding of fasiglifam as an attractive antidiabetic drug with a novel mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZkQC0HrqVbVg90H21EOLACvtfcHk0lg3r81puHc1ag"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cjsr7J&md5=788b16750f7de0ab4c7fcce79cd7c857</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0076280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0076280%26sid%3Dliteratum%253Aachs%26aulast%3DYabuki%26aufirst%3DC.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DR.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DMatsuda-Nagasumi%26aufirst%3DK.%26aulast%3DSakuma%26aufirst%3DK.%26aulast%3DMiyawaki%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHabata%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DM.%26atitle%3DA%2520Novel%2520Antidiabetic%2520Drug%252C%2520Fasiglifam%252FTAK-875%252C%2520Acts%2520as%2520an%2520Ago-Allosteric%2520Modulator%2520of%2520FFAR1%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De76280%26doi%3D10.1371%2Fjournal.pone.0076280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Negoro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujihata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogame, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momose, Y.</span><span> </span><span class="NLM_article-title">Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">â</span> <span class="NLM_lpage">294</span><span class="refDoi">Â DOI: 10.1021/ml1000855</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1000855" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=290-294&author=N.+Negoroauthor=S.+Sasakiauthor=S.+Mikamiauthor=M.+Itoauthor=M.+Suzukiauthor=Y.+Tsujihataauthor=R.+Itoauthor=A.+Haradaauthor=K.+Takeuchiauthor=N.+Suzukiauthor=J.+Miyazakiauthor=T.+Santouauthor=T.+Odaniauthor=N.+Kanzakiauthor=M.+Funamiauthor=T.+Tanakaauthor=A.+Kogameauthor=S.+Matsunagaauthor=T.+Yasumaauthor=Y.+Momose&title=Discovery+of+TAK-875%3A+A+Potent%2C+Selective%2C+and+Orally+Bioavailable+GPR40+Agonist&doi=10.1021%2Fml1000855"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fml1000855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1000855%26sid%3Dliteratum%253Aachs%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DHarada%26aufirst%3DA.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DJ.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DOdani%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DFunami%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKogame%26aufirst%3DA.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520TAK-875%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520GPR40%2520Agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D290%26epage%3D294%26doi%3D10.1021%2Fml1000855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Leifke, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naik, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeManno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipnes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakilynejad, M.</span><span> </span><span class="NLM_article-title">A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects with Type 2 Diabetes</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">â</span> <span class="NLM_lpage">39</span><span class="refDoi">Â DOI: 10.1038/clpt.2012.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1038%2Fclpt.2012.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22669289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGmur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=29-39&author=E.+Leifkeauthor=H.+Naikauthor=J.+Wuauthor=P.+Viswanathanauthor=D.+DeMannoauthor=M.+Kipnesauthor=M.+Vakilynejad&title=A+Multiple-Ascending-Dose+Study+to+Evaluate+Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+Novel+GPR40+Agonist%2C+TAK-875%2C+in+Subjects+with+Type+2+Diabetes&doi=10.1038%2Fclpt.2012.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes</span></div><div class="casAuthors">Leifke, E.; Naik, H.; Wu, J.; Viswanathan, P.; DeManno, D.; Kipnes, M.; Vakilynejad, M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptor 40 (GPR40), highly expressed in pancreatic Î²-cells, mediates free fatty acid (FFA)-induced insulin secretion.  This phase I, double-blind, randomized study investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel, glucose-lowering GPR40 agonist, TAK-875 (q.d., orally Ã 14 days), in type 2 diabetics (placebo, n = 14; at 25, 50, 100, 200, or 400 mg, n = 45).  Approx. dose-proportional increases in AUC0-24 and Cmax occurred.  TAK-875 showed good tolerability with no dose-limiting side effects.  Two subjects (on TAK-875) had mild hypoglycemia, probably related to prolonged fasting after oral glucose tolerance tests (OGTTs).  TAK-875 showed redns. from baseline in fasting (2 to -93 mg/dL) and post-OGTT glucose (26 to -172 mg/dL), with an apparent dose-dependent increase in post-OGTT C-peptide over 14 days.  Consistent with preclin. data, TAK-875 apparently acts as a glucose-dependent insulinotropic agent with low hypoglycemic risk.  Its PK is suitable for once-daily oral administration.  Clin. Pharmacol. & Therapeutics (2012); 92 1, 29-39. doi:10.1038/clpt.2012.43.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJYd5s3KIC27Vg90H21EOLACvtfcHk0lidMwR6kuLuWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGmur4%253D&md5=ba8cb45d0ad71c894a6942731ec0f9bc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.43%26sid%3Dliteratum%253Aachs%26aulast%3DLeifke%26aufirst%3DE.%26aulast%3DNaik%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DViswanathan%26aufirst%3DP.%26aulast%3DDeManno%26aufirst%3DD.%26aulast%3DKipnes%26aufirst%3DM.%26aulast%3DVakilynejad%26aufirst%3DM.%26atitle%3DA%2520Multiple-Ascending-Dose%2520Study%2520to%2520Evaluate%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520Novel%2520GPR40%2520Agonist%252C%2520TAK-875%252C%2520in%2520Subjects%2520with%2520Type%25202%2520Diabetes%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D29%26epage%3D39%26doi%3D10.1038%2Fclpt.2012.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span>Takeda Announces Termination of Fasiglifam (TAK-875) Development. <a href="http://www.takeda.com/news/2013/20131227_6117.html" class="extLink">http://www.takeda.com/news/2013/20131227_6117.html</a> (accessed Dec 27,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Takeda+Announces+Termination+of+Fasiglifam+%28TAK-875%29+Development.+http%3A%2F%2Fwww.takeda.com%2Fnews%2F2013%2F20131227_6117.html+%28accessed+Dec+27%2C+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Mancini, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poitout, V.</span><span> </span><span class="NLM_article-title">GPR40 Agonists for the Treatment of Type 2 Diabetes: Life After âTAKingâ a Hit</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">â</span> <span class="NLM_lpage">629</span><span class="refDoi">Â DOI: 10.1111/dom.12442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1111%2Fdom.12442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=25604916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOnurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=622-629&author=A.+D.+Manciniauthor=V.+Poitout&title=GPR40+Agonists+for+the+Treatment+of+Type+2+Diabetes%3A+Life+After+%E2%80%98TAKing%E2%80%99+a+Hit&doi=10.1111%2Fdom.12442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit</span></div><div class="casAuthors">Mancini, A. D.; Poitout, V.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">622-629</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The free fatty acid receptor GPR40 has been proposed as a potential target for type 2 diabetes (T2D) pharmacotherapy.  This idea has been validated in both preclin. and clin. studies, in which activation of GPR40 was shown to improve glycemic control by stimulating glucose-dependent insulin secretion; however, the recent termination of phase III clin. trials using the GPR40 agonist TAK-875 (fasiglifam) has raised important questions regarding the long-term safety and viability of targeting GPR40 and, more specifically, about our understanding of this receptor's basic biol.  In the present review, we provide a summary of established and novel concepts related to GPR40's pharmacobiol. and discuss the current status and future outlook for GPR40-based drug development for the treatment of T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroqi3di5RzzrVg90H21EOLACvtfcHk0lidMwR6kuLuWA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOnurzK&md5=223c353aaa30bd0621fd1d5d50bf68df</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fdom.12442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12442%26sid%3Dliteratum%253Aachs%26aulast%3DMancini%26aufirst%3DA.%2BD.%26aulast%3DPoitout%26aufirst%3DV.%26atitle%3DGPR40%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%253A%2520Life%2520After%2520%25E2%2580%2598TAKing%25E2%2580%2599%2520a%2520Hit%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2015%26volume%3D17%26spage%3D622%26epage%3D629%26doi%3D10.1111%2Fdom.12442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Lin, D. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birdsall, N. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span> </span><span class="NLM_article-title">Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">â</span> <span class="NLM_lpage">859</span><span class="refDoi">Â DOI: 10.1124/mol.112.079640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1124%2Fmol.112.079640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22859723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=843-859&author=D.+C.-H.+Linauthor=Q.+Guoauthor=J.+Luoauthor=J.+Zhangauthor=K.+Nguyenauthor=M.+Chenauthor=T.+Tranauthor=P.+J.+Dransfieldauthor=S.+P.+Brownauthor=J.+Houzeauthor=M.+Vimolratanaauthor=X.+Y.+Jiaoauthor=Y.+Wangauthor=N.+J.+M.+Birdsallauthor=G.+Swaminath&title=Identification+and+Pharmacological+Characterization+of+Multiple+Allosteric+Binding+Sites+on+the+Free+Fatty+Acid+1+Receptor&doi=10.1124%2Fmol.112.079640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor</span></div><div class="casAuthors">Lin, Daniel C.-H.; Guo, Qi; Luo, Jian; Zhang, Jane; Nguyen, Kathy; Chen, Michael; Tran, Thanh; Dransfield, Paul J.; Brown, Sean P.; Houze, Jonathan; Vimolratana, Marc; Jiao, Xian Yun; Wang, Yingcai; Birdsall, Nigel J. M.; Swaminath, Gayathri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">843-859</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activation of FFA1 (GPR40), a member of G protein-coupling receptor family A, is mediated by medium- and long-chain fatty acids and leads to amplification of glucose-stimulated insulin secretion, suggesting a potential role for free fatty acid 1 (FFA1) as a target for type 2 diabetes.  It was assumed previously that there is a single binding site for fatty acids and synthetic FFA1 agonists.  However, using members of two chem. series of partial and full agonists that have been identified, radioligand binding interaction studies revealed that the full agonists do not bind to the same site as the partial agonists but exhibit pos. heterotropic cooperativity.  Anal. of functional data reveals pos. functional cooperativity between the full agonists and partial agonists in various functional assays (in vitro and ex vivo) and also in vivo.  Furthermore, the endogenous fatty acid docosahexaenoic acid (DHA) shows neg. or neutral cooperativity with members of both series of agonists in binding assays but displays pos. cooperativity in functional assays.  Another synthetic agonist is allosteric with members of both agonist series, but apparently competitive with DHA.  Therefore, there appear to be three allosterically linked binding sites on FFA1 with agonists specific for each of these sites.  Activation of free fatty acid 1 receptor (FFAR1) by each of these agonists is differentially affected by mutations of two arginine residues, previously found to be important for FFAR1 binding and activation.  These ligands with their high potencies and strong pos. functional cooperativity with endogenous fatty acids, demonstrated in vitro and in vivo, have the potential to deliver therapeutic benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-mJkDwpnmbVg90H21EOLACvtfcHk0ljS-D-0-1sL_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE&md5=2437a31476d8c7d7b4fb06972e1f43d6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.079640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.079640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DSwaminath%26aufirst%3DG.%26atitle%3DIdentification%2520and%2520Pharmacological%2520Characterization%2520of%2520Multiple%2520Allosteric%2520Binding%2520Sites%2520on%2520the%2520Free%2520Fatty%2520Acid%25201%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D843%26epage%3D859%26doi%3D10.1124%2Fmol.112.079640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toteva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span> </span><span class="NLM_article-title">A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e46300</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0046300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1371%2Fjournal.pone.0046300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=23056280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKjtb%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e46300&author=J.+Luoauthor=G.+Swaminathauthor=S.+P.+Brownauthor=J.+Zhangauthor=Q.+Guoauthor=M.+Chenauthor=K.+Nguyenauthor=T.+Tranauthor=L.+Miaoauthor=P.+J.+Dransfieldauthor=M.+Vimolratanaauthor=J.+B.+Houzeauthor=S.+Wongauthor=M.+Totevaauthor=B.+Shanauthor=F.+Liauthor=R.+Zhuangauthor=D.+C.+H.+Lin&title=A+Potent+Class+of+GPR40+Full+Agonists+Engages+the+EnteroInsular+Axis+to+Promote+Glucose+Control+in+Rodents&doi=10.1371%2Fjournal.pone.0046300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents</span></div><div class="casAuthors">Luo, Jian; Swaminath, Gayathri; Brown, Sean P.; Zhang, Jane; Guo, Qi; Chen, Michael; Nguyen, Kathy; Tran, Thanhvien; Miao, Lynn; Dransfield, Paul J.; Vimolratana, Marc; Houze, Jonathan B.; Wong, Simon; Toteva, Maria; Shan, Bei; Li, Frank; Zhuang, Run; Lin, Daniel C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e46300</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Type 2 diabetes is characterized by impaired glucose homeostasis due to defects in insulin secretion, insulin resistance and the incretin response.  GPR40 (FFAR1 or FFA1) is a G-protein-coupled receptor (GPCR), primarily expressed in insulin-producing pancreatic Î²-cells and incretin-producing enteroendocrine cells of the small intestine.  Several GPR40 agonists, including AMG 837 and TAK-875, have been disclosed, but no GPR40 synthetic agonists have been reported that engage both the insulinogenic and incretinogenic axes.  In this report we provide a mol. explanation and describe the discovery of a unique and potent class of GPR40 full agonists that engages the enteroinsular axis to promote dramatic improvement in glucose control in rodents.  GPR40 full agonists AM-1638 and AM-6226 stimulate GLP-1 and GIP secretion from intestinal enteroendocrine cells and increase GSIS from pancreatic islets, leading to enhanced glucose control in the high fat fed, streptozotocin treated and NONcNZO10/LtJ mouse models of type 2 diabetes.  The improvement in hyperglycemia by AM-1638 was reduced in the presence of the GLP-1 receptor antagonist Ex(9-39)NH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtvpODI2wMLVg90H21EOLACvtfcHk0ljS-D-0-1sL_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKjtb%252FN&md5=7f500c96809b644b3f3ba440564f90da</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0046300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0046300%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DToteva%26aufirst%3DM.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26atitle%3DA%2520Potent%2520Class%2520of%2520GPR40%2520Full%2520Agonists%2520Engages%2520the%2520EnteroInsular%2520Axis%2520to%2520Promote%2520Glucose%2520Control%2520in%2520Rodents%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De46300%26doi%3D10.1371%2Fjournal.pone.0046300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Bodmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KrÃ¤henbÃ¼hl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jick, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, C. R.</span><span> </span><span class="NLM_article-title">Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A Nested Case-Control Analysis</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2086</span><span class="NLM_x">â</span> <span class="NLM_lpage">2091</span><span class="refDoi">Â DOI: 10.2337/dc08-1171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.2337%2Fdc08-1171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=18782901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=2086-2091&author=M.+Bodmerauthor=C.+Meierauthor=S.+Kr%C3%A4henb%C3%BChlauthor=S.+S.+Jickauthor=C.+R.+Meier&title=Metformin%2C+Sulfonylureas%2C+or+Other+Antidiabetes+Drugs+and+the+Risk+of+Lactic+Acidosis+or+Hypoglycemia%3A+A+Nested+Case-Control+Analysis&doi=10.2337%2Fdc08-1171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis</span></div><div class="casAuthors">Bodmer, Michael; Meier, Christian; Krahenbuhl, Stephan; Jick, Susan S.; Meier, Christoph R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2086-2091</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Lactic acidosis has been assocd. with use of metformin.  Hypoglycemia is a major concern using sulfonylureas.  The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs.  This study is a nested case-control anal. using the U.K.-based General Practice Research Database to identify patients with type 2 diabetes who used oral antidiabetes drugs.  Within the study population, all incident cases of lactic acidosis and hypoglycemia were identified, and hypoglycemia case subjects were matched to up to four control patients based on age, sex, practice, and calendar time.  - Among the study population of 50,048 type 2 diabetic subjects, six cases of lactic acidosis during current use of oral antidiabetes drugs were identified, yielding a crude incidence rate of 3.3 cases per 100,000 person-years among metformin users and 4.8 cases per 100,000 person-years among users of sulfonylureas.  Relevant comorbidities known as risk factors for lactic acidosis could be identified in all case subjects.  A total of 2025 case subjects with hypoglycemia and 7278 matched control subjects were identified.  Use of sulfonylureas was assocd. with a materially elevated risk of hypoglycemia.  The adjusted odds ratio for current use of sulfonylureas was 2.79 (95% CI 2.23-3.50) compared with current metformin use.  Lactic acidosis during current use of oral antidiabetes drugs was very rare and was assocd. with concurrent comorbidity.  Hypoglycemic episodes were substantially more common among sulfonylurea users than among users of metformin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuiCyJ59PPibVg90H21EOLACvtfcHk0ljS-D-0-1sL_w"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLzL&md5=dfe11decd59a50c0b021380fd77e8941</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2337%2Fdc08-1171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc08-1171%26sid%3Dliteratum%253Aachs%26aulast%3DBodmer%26aufirst%3DM.%26aulast%3DMeier%26aufirst%3DC.%26aulast%3DKr%25C3%25A4henb%25C3%25BChl%26aufirst%3DS.%26aulast%3DJick%26aufirst%3DS.%2BS.%26aulast%3DMeier%26aufirst%3DC.%2BR.%26atitle%3DMetformin%252C%2520Sulfonylureas%252C%2520or%2520Other%2520Antidiabetes%2520Drugs%2520and%2520the%2520Risk%2520of%2520Lactic%2520Acidosis%2520or%2520Hypoglycemia%253A%2520A%2520Nested%2520Case-Control%2520Analysis%26jtitle%3DDiabetes%2520Care%26date%3D2008%26volume%3D31%26spage%3D2086%26epage%3D2091%26doi%3D10.2337%2Fdc08-1171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">AhrÃ©n, B.</span><span> </span><span class="NLM_article-title">GLP-1-Based Therapy of Type 2 Diabetes: GLP-1 Mimetics and DPP-IV Inhibitors</span> <span class="citation_source-journal">Curr. Diabetes Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">â</span> <span class="NLM_lpage">347</span><span class="refDoi">Â DOI: 10.1007/s11892-007-0056-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1007%2Fs11892-007-0056-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=18173966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvFShtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=340-347&author=B.+Ahr%C3%A9n&title=GLP-1-Based+Therapy+of+Type+2+Diabetes%3A+GLP-1+Mimetics+and+DPP-IV+Inhibitors&doi=10.1007%2Fs11892-007-0056-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors</span></div><div class="casAuthors">Ahren, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Current Diabetes Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">340-347</span>CODEN:
                <span class="NLM_cas:coden">CDRUAK</span>;
        ISSN:<span class="NLM_cas:issn">1534-4827</span>.
    
            (<span class="NLM_cas:orgname">Current Medicine Group LLC</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes.  It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors.  In type 2 diabetes, the two strategies reduce Hb A1c by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%.  They are efficient both in monotherapy and in combination with metformin or thiazolidinediones.  Both treatments are well tolerated with low risk of hypoglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsNMAnSNTTvLVg90H21EOLACvtfcHk0ljGgYetnzcYCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvFShtw%253D%253D&md5=bf777156385d9785e46b4afc0dafe993</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11892-007-0056-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-007-0056-9%26sid%3Dliteratum%253Aachs%26aulast%3DAhr%25C3%25A9n%26aufirst%3DB.%26atitle%3DGLP-1-Based%2520Therapy%2520of%2520Type%25202%2520Diabetes%253A%2520GLP-1%2520Mimetics%2520and%2520DPP-IV%2520Inhibitors%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2007%26volume%3D7%26spage%3D340%26epage%3D347%26doi%3D10.1007%2Fs11892-007-0056-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Pais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, F.</span><span> </span><span class="NLM_article-title">Stimulation of Incretin Secreting Cells</span> <span class="citation_source-journal">Ther. Adv. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">â</span> <span class="NLM_lpage">42</span><span class="refDoi">Â DOI: 10.1177/2042018815618177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1177%2F2042018815618177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=26885360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A280%3ADC%252BC28jhslaltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=24-42&author=R.+Paisauthor=F.+M.+Gribbleauthor=F.+Reimann&title=Stimulation+of+Incretin+Secreting+Cells&doi=10.1177%2F2042018815618177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of incretin secreting cells</span></div><div class="casAuthors">Pais Ramona; Gribble Fiona M; Reimann Frank</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in endocrinology and metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-42</span>
        ISSN:<span class="NLM_cas:issn">2042-0188</span>.
    </div><div class="casAbstract">The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) are secreted from enteroendocrine cells in the gut and regulate physiological and homeostatic functions related to glucose control, metabolism and food intake.  This review provides a systematic summary of the molecular mechanisms underlying secretion from incretin cells, and an understanding of how they sense and interact with lumen and vascular factors and the enteric nervous system through transporters and G-protein coupled receptors (GPCRs) present on their surface to ultimately culminate in hormone release.  Some of the molecules described below such as sodium coupled glucose transporter 1 (SGLT1), G-protein coupled receptor (GPR) 119 and GPR40 are targets of novel therapeutics designed to enhance endogenous gut hormone release.  Synthetic ligands at these receptors aimed at treating obesity and type 2 diabetes are currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRdC2ThtY1Qy86Js-BCLiifW6udTcc2eYmSqW22fG3Q7ntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhslaltg%253D%253D&md5=80f26d4b71d3d6bfedf2c03ab4df9050</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1177%2F2042018815618177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2042018815618177%26sid%3Dliteratum%253Aachs%26aulast%3DPais%26aufirst%3DR.%26aulast%3DGribble%26aufirst%3DF.%2BM.%26aulast%3DReimann%26aufirst%3DF.%26atitle%3DStimulation%2520of%2520Incretin%2520Secreting%2520Cells%26jtitle%3DTher.%2520Adv.%2520Endocrinol.%2520Metab.%26date%3D2016%26volume%3D7%26spage%3D24%26epage%3D42%26doi%3D10.1177%2F2042018815618177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J. B.</span><span> </span><span class="NLM_article-title">Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">â</span> <span class="NLM_lpage">730</span><span class="refDoi">Â DOI: 10.1021/ml300133f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300133f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=726-730&author=S.+P.+Brownauthor=P.+J.+Dransfieldauthor=M.+Vimolratanaauthor=X.+Jiaoauthor=L.+Zhuauthor=V.+Pattaropongauthor=Y.+Sunauthor=J.+Liuauthor=J.+Luoauthor=J.+Zhangauthor=S.+Wongauthor=R.+Zhuangauthor=Q.+Guoauthor=F.+Liauthor=J.+C.+Medinaauthor=G.+Swaminathauthor=D.+C.+H.+Linauthor=J.+B.+Houze&title=Discovery+of+AM-1638%3A+A+Potent+and+Orally+Bioavailable+GPR40%2FFFA1+Full+Agonist&doi=10.1021%2Fml300133f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist</span></div><div class="casAuthors">Brown, Sean P.; Dransfield, Paul J.; Vimolratana, Marc; Jiao, XianYun; Zhu, Liusheng; Pattaropong, Vatee; Sun, Ying; Liu, Jinqian; Luo, Jian; Zhang, Jane; Wong, Simon; Zhuang, Run; Guo, Qi; Li, Frank; Medina, Julio C.; Swaminath, Gayathri; Lin, Daniel C.-H.; Houze, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-730</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels.  A potent, orally bioavailable small mol. GPR40 agonist is hypothesized to be an effective antidiabetic posing little or no risk of hypoglycemia.  The authors recently reported the discovery of AMG 837 (I), a potent partial agonist of GPR40.  Herein, they present the optimization from the GPR40 partial agonist I to the structurally and pharmacol. distinct GPR40 full agonist AM-1638 (II).  Moreover, they demonstrate the improved in vivo efficacy that GPR40 full agonist II exhibits in BDF/DIO mice as compared to partial agonist I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooInVzD6ZYdrVg90H21EOLACvtfcHk0ljGgYetnzcYCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI&md5=d2abd60e8e86d96b0d0683b0401b62c8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fml300133f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300133f%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520AM-1638%253A%2520A%2520Potent%2520and%2520Orally%2520Bioavailable%2520GPR40%252FFFA1%2520Full%2520Agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D726%26epage%3D730%26doi%3D10.1021%2Fml300133f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Walsh, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">3-Substituted 3-(4-Aryloxyaryl)-Propanoic Acids as GPR40 Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3390</span><span class="NLM_x">â</span> <span class="NLM_lpage">3394</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.03.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.bmcl.2011.03.114" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3390-3394&author=S.+P.+Walshauthor=A.+Severinoauthor=C.+Zhouauthor=J.+Heauthor=G.-B.+Liangauthor=C.+P.+Tanauthor=J.+Caoauthor=G.+J.+Eiermannauthor=L.+Xuauthor=G.+Salituroauthor=A.+D.+Howardauthor=S.+G.+Millsauthor=L.+Yang&title=3-Substituted+3-%284-Aryloxyaryl%29-Propanoic+Acids+as+GPR40+Agonists&doi=10.1016%2Fj.bmcl.2011.03.114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.114%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DSeverino%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DG.-B.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3D3-Substituted%25203-%25284-Aryloxyaryl%2529-Propanoic%2520Acids%2520as%2520GPR40%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3390%26epage%3D3394%26doi%3D10.1016%2Fj.bmcl.2011.03.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Houze, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reagan, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span> </span><span class="NLM_article-title">AMG 837: A Potent, Orally Bioavailable GPR40 Agonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">â</span> <span class="NLM_lpage">1270</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.bmcl.2011.10.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22217876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1267-1270&author=J.+B.+Houzeauthor=L.+Zhuauthor=Y.+Sunauthor=M.+Akermanauthor=W.+Qiuauthor=A.+J.+Zhangauthor=R.+Sharmaauthor=M.+Schmittauthor=Y.+Wangauthor=J.+Liuauthor=J.+Liuauthor=J.+C.+Medinaauthor=J.+D.+Reaganauthor=J.+Luoauthor=G.+Tonnauthor=J.+Zhangauthor=J.+Y.-L.+Luauthor=M.+Chenauthor=E.+Lopezauthor=K.+Nguyenauthor=L.+Yangauthor=L.+Tangauthor=H.+Tianauthor=S.+J.+Shuttleworthauthor=D.+C.+H.+Lin&title=AMG+837%3A+A+Potent%2C+Orally+Bioavailable+GPR40+Agonist&doi=10.1016%2Fj.bmcl.2011.10.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 837: A potent, orally bioavailable GPR40 agonist</span></div><div class="casAuthors">Houze, Jonathan B.; Zhu, Liusheng; Sun, Ying; Akerman, Michelle; Qiu, Wei; Zhang, Alex J.; Sharma, Rajiv; Schmitt, Michael; Wang, Yingcai; Liu, Jiwen; Liu, Jinqian; Medina, Julio C.; Reagan, Jeff D.; Luo, Jian; Tonn, George; Zhang, Jane; Lu, Jenny Ying-Lin; Chen, Michael; Lopez, Edwin; Nguyen, Kathy; Yang, Li; Tang, Liang; Tian, Hui; Shuttleworth, Steven J.; Lin, Daniel C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1267-1270</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents.  Optimization of a series of Î²-substituted phenylpropanoic acids led to the identification of (S)-3-(4-((4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMJp4-u_YDyLVg90H21EOLACvtfcHk0ljZxXjPx7Bkhg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D&md5=7e7d38679794abb7244d5a64d6f5ecd7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAkerman%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DReagan%26aufirst%3DJ.%2BD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTonn%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BY.-L.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26atitle%3DAMG%2520837%253A%2520A%2520Potent%252C%2520Orally%2520Bioavailable%2520GPR40%2520Agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1267%26epage%3D1270%26doi%3D10.1016%2Fj.bmcl.2011.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cline, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">Discovery of 5-Aryloxy-2,4-Thiazolidinediones as Potent GPR40 Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">â</span> <span class="NLM_lpage">1301</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.bmcl.2009.10.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1298-1301&author=C.+Zhouauthor=C.+Tangauthor=E.+Changauthor=M.+Geauthor=S.+Linauthor=E.+Clineauthor=C.+P.+Tanauthor=Y.+Fengauthor=Y.-P.+Zhouauthor=G.+J.+Eiermannauthor=A.+Petrovauthor=G.+Salituroauthor=P.+Meinkeauthor=R.+Mosleyauthor=T.+E.+Akiyamaauthor=M.+Einsteinauthor=S.+Kumarauthor=J.+Bergerauthor=A.+D.+Howardauthor=N.+Thornberryauthor=S.+G.+Millsauthor=L.+Yang&title=Discovery+of+5-Aryloxy-2%2C4-Thiazolidinediones+as+Potent+GPR40+Agonists&doi=10.1016%2Fj.bmcl.2009.10.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DGe%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DCline%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.-P.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DMeinke%26aufirst%3DP.%26aulast%3DMosley%26aufirst%3DR.%26aulast%3DAkiyama%26aufirst%3DT.%2BE.%26aulast%3DEinstein%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DThornberry%26aufirst%3DN.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25205-Aryloxy-2%252C4-Thiazolidinediones%2520as%2520Potent%2520GPR40%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1298%26epage%3D1301%26doi%3D10.1016%2Fj.bmcl.2009.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">U.S. Department of Health and Human Services, Food and Drug Administration</span><span class="NLM_x">, </span> <span class="citation_source-book">Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention</span>; <span class="NLM_publisher-name">Center for Drug Evaluation and Research (CDER)</span>: <span class="NLM_publisher-loc">Rockville, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=U.S.+Department+of+Health+and+Human+Services%2C+Food+and+Drug+Administration&title=Guidance+for+Industry%2C+Diabetes+Mellitus%3A+Developing+Drugs+and+Therapeutic+Biologics+for+Treatment+and+Prevention"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DGuidance%2520for%2520Industry%252C%2520Diabetes%2520Mellitus%253A%2520Developing%2520Drugs%2520and%2520Therapeutic%2520Biologics%2520for%2520Treatment%2520and%2520Prevention%26pub%3DCenter%2520for%2520Drug%2520Evaluation%2520and%2520Research%2520%2528CDER%2529%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Job, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klapars, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Copper-Catalyzed Coupling of Amides and Carbamates with Vinyl Halides</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3667</span><span class="NLM_x">â</span> <span class="NLM_lpage">3669</span><span class="refDoi">Â DOI: 10.1021/ol035355c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol035355c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1OnsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=3667-3669&author=L.+Jiangauthor=G.+E.+Jobauthor=A.+Klaparsauthor=S.+L.+Buchwald&title=Copper-Catalyzed+Coupling+of+Amides+and+Carbamates+with+Vinyl+Halides&doi=10.1021%2Fol035355c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-catalyzed coupling of amides and carbamates with vinyl halides</span></div><div class="casAuthors">Jiang, Lei; Job, Gabriel E.; Klapars, Artis; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3667-3669</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general and efficient copper-catalyzed method for the amidation of vinyl bromides and iodides was developed.  This protocol uses a combination of 5 mol % copper iodide and 20 mol % N,N'-dimethyl ethylenediamine.  Substrates bearing ester, silyl ether, and amino groups were successfully coupled under the reaction conditions.  The double bond geometry of the vinyl halides was retained under the reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkzwHM3lXNL7Vg90H21EOLACvtfcHk0lhbk5vt_EXtig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1OnsLo%253D&md5=83985d31d5e9e4ab995932566a4ed9da</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fol035355c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol035355c%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DJob%26aufirst%3DG.%2BE.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DCopper-Catalyzed%2520Coupling%2520of%2520Amides%2520and%2520Carbamates%2520with%2520Vinyl%2520Halides%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D3667%26epage%3D3669%26doi%3D10.1021%2Fol035355c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Signalling Bias in New Drug Discovery: Detection, Quantification and Therapeutic Impact</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">â</span> <span class="NLM_lpage">216</span><span class="refDoi">Â DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+Bias+in+New+Drug+Discovery%3A+Detection%2C+Quantification+and+Therapeutic+Impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0lhbk5vt_EXtig"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520Bias%2520in%2520New%2520Drug%2520Discovery%253A%2520Detection%252C%2520Quantification%2520and%2520Therapeutic%2520Impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Christiansen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Due-Hansen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SchrÃ¶der, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cawthorne, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostenis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassack, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulven, T.</span><span> </span><span class="NLM_article-title">Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6624</span><span class="NLM_x">â</span> <span class="NLM_lpage">6628</span><span class="refDoi">Â DOI: 10.1021/jm3002026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3002026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6624-6628&author=E.+Christiansenauthor=M.+E.+Due-Hansenauthor=C.+Urbanauthor=M.+Grundmannauthor=R.+Schr%C3%B6derauthor=B.+D.+Hudsonauthor=G.+Milliganauthor=M.+A.+Cawthorneauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=T.+Ulven&title=Free+Fatty+Acid+Receptor+1+%28FFA1%2FGPR40%29+Agonists%3A+Mesylpropoxy+Appendage+Lowers+Lipophilicity+and+Improves+ADME+Properties&doi=10.1021%2Fjm3002026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm3002026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002026%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DR.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DCawthorne%26aufirst%3DM.%2BA.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DFree%2520Fatty%2520Acid%2520Receptor%25201%2520%2528FFA1%252FGPR40%2529%2520Agonists%253A%2520Mesylpropoxy%2520Appendage%2520Lowers%2520Lipophilicity%2520and%2520Improves%2520ADME%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6624%26epage%3D6628%26doi%3D10.1021%2Fjm3002026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Christiansen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Due-Hansen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merten, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfleiderer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsen, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensgaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamacher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristiansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostenis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassack, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulven, T.</span><span> </span><span class="NLM_article-title">StructureâActivity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">â</span> <span class="NLM_lpage">349</span><span class="refDoi">Â DOI: 10.1021/ml100106c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100106c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=345-349&author=E.+Christiansenauthor=M.+E.+Due-Hansenauthor=C.+Urbanauthor=N.+Mertenauthor=M.+Pfleidererauthor=K.+K.+Karlsenauthor=S.+S.+Rasmussenauthor=M.+Steensgaardauthor=A.+Hamacherauthor=J.+Schmidtauthor=C.+Drewkeauthor=R.+K.+Petersenauthor=K.+Kristiansenauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=T.+Ulven&title=Structure%E2%80%93Activity+Study+of+Dihydrocinnamic+Acids+and+Discovery+of+the+Potent+FFA1+%28GPR40%29+Agonist+TUG-469&doi=10.1021%2Fml100106c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span></div><div class="casAuthors">Christiansen, Elisabeth; Due-Hansen, Maria E.; Urban, Christian; Merten, Nicole; Pfleiderer, Michael; Karlsen, Kasper K.; Rasmussen, Sanne S.; Steensgaard, Mette; Hamacher, Alexandra; Schmidt, Johannes; Drewke, Christel; Petersen, Rasmus Koefoed; Kristiansen, Karsten; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias U.; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">345-349</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic Î²-cells and amplifies glucose-stimulated insulin secretion, has emerged as an attractive target for the treatment of type 2 diabetes.  Several FFA1 agonists contg. the para-substituted dihydrocinnamic acid moiety are known.  We here present a structure-activity relationship study of this compd. family suggesting that the central methyleneoxy linker is preferable for the smaller compds., whereas the central methyleneamine linker gives higher potency to the larger compds.  The study resulted in the discovery of the potent and selective full FFA1 agonist TUG-469 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Ue5bdjcoY7Vg90H21EOLACvtfcHk0ljNaKWQyLvJfQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D&md5=e3a7642f2fd42b1bc932fa9470cfb75c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fml100106c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100106c%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DPfleiderer%26aufirst%3DM.%26aulast%3DKarlsen%26aufirst%3DK.%2BK.%26aulast%3DRasmussen%26aufirst%3DS.%2BS.%26aulast%3DSteensgaard%26aufirst%3DM.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DDrewke%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DR.%2BK.%26aulast%3DKristiansen%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DStructure%25E2%2580%2593Activity%2520Study%2520of%2520Dihydrocinnamic%2520Acids%2520and%2520Discovery%2520of%2520the%2520Potent%2520FFA1%2520%2528GPR40%2529%2520Agonist%2520TUG-469%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D345%26epage%3D349%26doi%3D10.1021%2Fml100106c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Mikami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negoro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujihata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momose, Y.</span><span> </span><span class="NLM_article-title">Discovery of Phenylpropanoic Acid Derivatives Containing Polar Functionalities as Potent and Orally Bioavailable G Protein-Coupled Receptor 40 Agonists for the Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3756</span><span class="NLM_x">â</span> <span class="NLM_lpage">3776</span><span class="refDoi">Â DOI: 10.1021/jm2016123</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2016123" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3756-3776&author=S.+Mikamiauthor=S.+Kitamuraauthor=N.+Negoroauthor=S.+Sasakiauthor=M.+Suzukiauthor=Y.+Tsujihataauthor=T.+Miyazakiauthor=R.+Itoauthor=N.+Suzukiauthor=J.+Miyazakiauthor=T.+Santouauthor=N.+Kanzakiauthor=M.+Funamiauthor=T.+Tanakaauthor=T.+Yasumaauthor=Y.+Momose&title=Discovery+of+Phenylpropanoic+Acid+Derivatives+Containing+Polar+Functionalities+as+Potent+and+Orally+Bioavailable+G+Protein-Coupled+Receptor+40+Agonists+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm2016123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm2016123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2016123%26sid%3Dliteratum%253Aachs%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DJ.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DFunami%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Phenylpropanoic%2520Acid%2520Derivatives%2520Containing%2520Polar%2520Functionalities%2520as%2520Potent%2520and%2520Orally%2520Bioavailable%2520G%2520Protein-Coupled%2520Receptor%252040%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3756%26epage%3D3776%26doi%3D10.1021%2Fjm2016123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.-r.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasparian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correll, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span><span class="refDoi">Â DOI: 10.1021/ml300427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=551-555&author=Y.+Wangauthor=J.+Liuauthor=P.+J.+Dransfieldauthor=L.+Zhuauthor=Z.+Wangauthor=X.+Duauthor=X.+Jiaoauthor=Y.+Suauthor=A.-r.+Liauthor=S.+P.+Brownauthor=A.+Kasparianauthor=M.+Vimolratanaauthor=M.+Yuauthor=V.+Pattaropongauthor=J.+B.+Houzeauthor=G.+Swaminathauthor=T.+Tranauthor=K.+Nguyenauthor=Q.+Guoauthor=J.+Zhangauthor=R.+Zhuangauthor=F.+Liauthor=L.+Miaoauthor=M.+D.+Bartbergerauthor=T.+L.+Correllauthor=D.+Chowauthor=S.+Wongauthor=J.+Luoauthor=D.+C.+H.+Linauthor=J.+C.+Medina&title=Discovery+and+Optimization+of+Potent+GPR40+Full+Agonists+Containing+Tricyclic+Spirocycles&doi=10.1021%2Fml300427u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml300427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300427u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DA.-r.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DKasparian%26aufirst%3DA.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCorrell%26aufirst%3DT.%2BL.%26aulast%3DChow%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Potent%2520GPR40%2520Full%2520Agonists%2520Containing%2520Tricyclic%2520Spirocycles%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D551%26epage%3D555%26doi%3D10.1021%2Fml300427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Qiu, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qing, F.</span><span> </span><span class="NLM_article-title">-l. Practical Synthesis of Boc-Protected <i>cis</i>-4-Trifluoromethyl and <i>cis</i>-4-Difluoromethyl-<i>L</i>-Prolines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7162</span><span class="NLM_x">â</span> <span class="NLM_lpage">7164</span><span class="refDoi">Â DOI: 10.1021/jo0257400</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0257400" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=7162-7164&author=X.-l.+Qiuauthor=F.+Qing&title=-l.+Practical+Synthesis+of+Boc-Protected+cis-4-Trifluoromethyl+and+cis-4-Difluoromethyl-L-Prolines&doi=10.1021%2Fjo0257400"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo0257400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0257400%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DX.-l.%26aulast%3DQing%26aufirst%3DF.%26atitle%3D-l.%2520Practical%2520Synthesis%2520of%2520Boc-Protected%2520cis-4-Trifluoromethyl%2520and%2520cis-4-Difluoromethyl-L-Prolines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D7162%26epage%3D7164%26doi%3D10.1021%2Fjo0257400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Del Valle, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, M.</span><span> </span><span class="NLM_article-title">Stereoselective Synthesis of Boc-Protected <i>cis</i> and <i>trans</i>-4-Trifluoromethylprolines by Asymmetric Hydrogenation Reactions</span> <span class="citation_source-journal">Angew. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1670</span><span class="NLM_x">â</span> <span class="NLM_lpage">1672</span><span class="refDoi">Â DOI: 10.1002/1521-3757(20020503)114:9<1670::AID-ANGE1670>3.0.CO;2-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2002&pages=1670-1672&author=J.+R.+Del+Valleauthor=M.+Goodman&title=Stereoselective+Synthesis+of+Boc-Protected+cis+and+trans-4-Trifluoromethylprolines+by+Asymmetric+Hydrogenation+Reactions&doi=10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3757%252820020503%2529114%253A9%253C1670%253A%253AAID-ANGE1670%253E3.0.CO%253B2-1%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BValle%26aufirst%3DJ.%2BR.%26aulast%3DGoodman%26aufirst%3DM.%26atitle%3DStereoselective%2520Synthesis%2520of%2520Boc-Protected%2520cis%2520and%2520trans-4-Trifluoromethylprolines%2520by%2520Asymmetric%2520Hydrogenation%2520Reactions%26jtitle%3DAngew.%2520Chem.%26date%3D2002%26volume%3D114%26spage%3D1670%26epage%3D1672%26doi%3D10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Grant, S. G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bautch, V. L.</span><span> </span><span class="NLM_article-title">Early Invasiveness Characterizes Metastatic Carcinoid Tumors in Transgenic Mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4917</span><span class="NLM_x">â</span> <span class="NLM_lpage">4923</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=4917-4923&author=S.+G.+N.+Grantauthor=I.+Seidmanauthor=D.+Hanahanauthor=V.+L.+Bautch&title=Early+Invasiveness+Characterizes+Metastatic+Carcinoid+Tumors+in+Transgenic+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%2BG.%2BN.%26aulast%3DSeidman%26aufirst%3DI.%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DBautch%26aufirst%3DV.%2BL.%26atitle%3DEarly%2520Invasiveness%2520Characterizes%2520Metastatic%2520Carcinoid%2520Tumors%2520in%2520Transgenic%2520Mice%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D4917%26epage%3D4923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Rindi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yiangou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bautch, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solcia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polak, J. M.</span><span> </span><span class="NLM_article-title">Development of Neuroendocrine Tumors in the Gastrointestinal Tract of Transgenic Mice. Heterogeneity of Hormone Expression</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">1349</span><span class="NLM_x">â</span> <span class="NLM_lpage">1363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=2162628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADyaK3MXktV2h" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1990&pages=1349-1363&author=G.+Rindiauthor=S.+G.+Grantauthor=Y.+Yiangouauthor=M.+A.+Ghateiauthor=S.+R.+Bloomauthor=V.+L.+Bautchauthor=E.+Solciaauthor=J.+M.+Polak&title=Development+of+Neuroendocrine+Tumors+in+the+Gastrointestinal+Tract+of+Transgenic+Mice.+Heterogeneity+of+Hormone+Expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice.  Heterogeneity of hormone expression</span></div><div class="casAuthors">Rindi, Guido; Grant, Seth G. N.; Yiangou, Yiangos; Ghatei, Mohammed A.; Bloom, Stephen R.; Bautch, Victoria L.; Solcia, Enrico; Polak, Julia M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1349-63</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">Expression of hormones in endocrine tumors and derived cell lines of transgenic mice carrying insulin-promoted oncogenes has been investigated by histochem., immunohistochem., ultrastructural, and radioimmunol. means.  Tumors of the pancreas, small intestine, mesentery, and liver were examd.  Insulin-immunoreactive cells were prevalent in pancreatic tumors, with a significant subpopulation of pancreatic polypeptide-immunoreactive elements.  Conventional ultrastructural and immunogold anal. identified insulin-storing Î²-granules in pancreatic tumor cells.  In contrast, the largest immunoreactive subpopulation of intestinal tumors expressed secretin (53% of total cells), followed by proglucagon-related peptides (15%), glucose-dependent insulinotropic polypeptide (7%), gastrin (7%), pancreatic polypeptide (2%), neurotensin (2%), and somatostatin (1%).  No detectable immunoreactivity for either insulin or serotonin was obsd.  Electron microscopy and immunogold labeling showed that intestinal tumor cells contained secretin-storing S-type granules.  Lymph node and liver tumors contained secretin-immunoreactive cells with ultrastructural features similar to those of intestinal tumors.  In addn., high levels of circulating insulinlike and secretinlike immnoreactants were detectable.  Analogous hormone profiles were identified in tumor cell lines and culture media.  Large T-antigen immunoreactivity was detected in all the nuclei of neoplastic cells, as well as in insulin-immunoreactive elements of non-neoplastic islets and pancreatic ducts and in some secretin-immunoreactive cells of small intestinal mucosa.  These data indicate that neuroendocrine tumors arise both in Î²-cell and S-cell subpopulations of transgenic mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_sj64TWYwNrVg90H21EOLACvtfcHk0li2EroW28c0Fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXktV2h&md5=097c4ad56e31d546c13b803dabe113c6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRindi%26aufirst%3DG.%26aulast%3DGrant%26aufirst%3DS.%2BG.%26aulast%3DYiangou%26aufirst%3DY.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26aulast%3DBautch%26aufirst%3DV.%2BL.%26aulast%3DSolcia%26aufirst%3DE.%26aulast%3DPolak%26aufirst%3DJ.%2BM.%26atitle%3DDevelopment%2520of%2520Neuroendocrine%2520Tumors%2520in%2520the%2520Gastrointestinal%2520Tract%2520of%2520Transgenic%2520Mice.%2520Heterogeneity%2520of%2520Hormone%2520Expression%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1990%26volume%3D136%26spage%3D1349%26epage%3D1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Hauge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestmar, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekberg, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinglass, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelstoft, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¼ckmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimurer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, T. W.</span><span> </span><span class="NLM_article-title">GPR40 (FFAR1) â Combined Gs and Gq Signaling in vitro is Associated with Robust Incretin Secretagogue Action ex vivo and in vivo</span> <span class="citation_source-journal">Mol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">â</span> <span class="NLM_lpage">14</span><span class="refDoi">Â DOI: 10.1016/j.molmet.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.molmet.2014.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=25685685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=3-14&author=M.+Haugeauthor=M.+A.+Vestmarauthor=A.+S.+Hustedauthor=J.+P.+Ekbergauthor=M.+J.+Wrightauthor=J.+Di+Salvoauthor=A.+B.+Weinglassauthor=M.+S.+Engelstoftauthor=A.+N.+Madsenauthor=M.+L%C3%BCckmannauthor=M.+W.+Millerauthor=M.+E.+Trujilloauthor=T.+M.+Frimurerauthor=B.+Holstauthor=A.+D.+Howardauthor=T.+W.+Schwartz&title=GPR40+%28FFAR1%29+%E2%80%93+Combined+Gs+and+Gq+Signaling+in+vitro+is+Associated+with+Robust+Incretin+Secretagogue+Action+ex+vivo+and+in+vivo&doi=10.1016%2Fj.molmet.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo</span></div><div class="casAuthors">Hauge, Maria; Vestmar, Marie A.; Husted, Anna S.; Ekberg, Jeppe P.; Wright, Michael J.; Di Salvo, Jerry; Weinglass, Adam B.; Engelstoft, Maja S.; Madsen, Andreas N.; Luckmann, Michael; Miller, Michael W.; Trujillo, Maria E.; Frimurer, Thomas M.; Holst, Birgitte; Howard, Andrew D.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">GPR40 (FFAR1), a clin. proven anti-diabetes target, is a Gq-coupled receptor for long chain fatty acids (LCFA) stimulating insulin secretion directly and mediating a major part of the dietary triglyceride-induced secretion of the incretins GLP-1 and GIP.  In phase-II studies the GPR40 agonist TAK-875 decreased blood glucose but surprisingly without stimulating incretins.  Here we find that GPR40 can signal through not only Gq and IP3 but also Gs and cAMP when stimulated with certain agonists such as AM-1638 and AM-5262 in contrast to the endogenous LCFA ligands and agonists such as TAK-875 and AM-837, which only signal through Gq.  In competition binding against [3H]AM-1638 and [3H]L358 the Gq + Gs and the Gq-only agonists either competed for or showed pos. cooperativity by increasing the binding of the two different radio-ligands, in opposite ways.  Nevertheless, both the Gq-only and the Gq + Gs agonists all docked surprisingly well into the binding site for TAK-875 in the X-ray structure of GPR40.  In murine intestinal primary cell-cultures the endogenous LCFAs and the Gq-only agonists stimulated GLP-1 secretion with rather poor efficacy as compared with the high efficacy Gq + Gs GPR40 agonists and a prototype GPR119 agonist.  Similarly, in fasting both male and female mice the Gq + Gs agonists showed significantly higher efficacy than the Gq-only agonists in respect of increasing plasma GLP-1 and plasma GIP in a GPR40-dependent manner.  It is concluded that stimulation of GPR40 by endogenous LCFAs or by Gq-only synthetic agonists result in a rather limited incretin response, whereas Gq + Gs GPR40 agonists stimulate incretin secretion robustly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZyjcjTNd0QbVg90H21EOLACvtfcHk0li2EroW28c0Fw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN&md5=895136bef8c9542711e6daf5fa57219c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHauge%26aufirst%3DM.%26aulast%3DVestmar%26aufirst%3DM.%2BA.%26aulast%3DHusted%26aufirst%3DA.%2BS.%26aulast%3DEkberg%26aufirst%3DJ.%2BP.%26aulast%3DWright%26aufirst%3DM.%2BJ.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DEngelstoft%26aufirst%3DM.%2BS.%26aulast%3DMadsen%26aufirst%3DA.%2BN.%26aulast%3DL%25C3%25BCckmann%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DTrujillo%26aufirst%3DM.%2BE.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DGPR40%2520%2528FFAR1%2529%2520%25E2%2580%2593%2520Combined%2520Gs%2520and%2520Gq%2520Signaling%2520in%2520vitro%2520is%2520Associated%2520with%2520Robust%2520Incretin%2520Secretagogue%2520Action%2520ex%2520vivo%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Metab.%26date%3D2015%26volume%3D4%26spage%3D3%26epage%3D14%26doi%3D10.1016%2Fj.molmet.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Staels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruchart, J.-C.</span><span> </span><span class="NLM_article-title">Therapeutic Roles of Peroxisome ProliferatorâActivated Receptor Agonists</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2460</span><span class="NLM_x">â</span> <span class="NLM_lpage">2470</span><span class="refDoi">Â DOI: 10.2337/diabetes.54.8.2460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.2337%2Fdiabetes.54.8.2460" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2460-2470&author=B.+Staelsauthor=J.-C.+Fruchart&title=Therapeutic+Roles+of+Peroxisome+Proliferator%E2%80%93Activated+Receptor+Agonists&doi=10.2337%2Fdiabetes.54.8.2460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.54.8.2460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.54.8.2460%26sid%3Dliteratum%253Aachs%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DFruchart%26aufirst%3DJ.-C.%26atitle%3DTherapeutic%2520Roles%2520of%2520Peroxisome%2520Proliferator%25E2%2580%2593Activated%2520Receptor%2520Agonists%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26spage%3D2460%26epage%3D2470%26doi%3D10.2337%2Fdiabetes.54.8.2460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Azoulay, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filion, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assayag, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majdan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suissa, S.</span><span> </span><span class="NLM_article-title">The Use of Pioglitazone and the Risk of Bladder Cancer in People with Type 2 Diabetes: Nested Case-Control Study</span> <span class="citation_source-journal">BMJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3645</span><span class="refDoi">Â DOI: 10.1136/bmj.e3645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1136%2Fbmj.e3645" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2012&pages=e3645&author=L.+Azoulayauthor=H.+Yinauthor=K.+B.+Filionauthor=J.+Assayagauthor=A.+Majdanauthor=M.+N.+Pollakauthor=S.+Suissa&title=The+Use+of+Pioglitazone+and+the+Risk+of+Bladder+Cancer+in+People+with+Type+2+Diabetes%3A+Nested+Case-Control+Study&doi=10.1136%2Fbmj.e3645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fbmj.e3645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.e3645%26sid%3Dliteratum%253Aachs%26aulast%3DAzoulay%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DFilion%26aufirst%3DK.%2BB.%26aulast%3DAssayag%26aufirst%3DJ.%26aulast%3DMajdan%26aufirst%3DA.%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DSuissa%26aufirst%3DS.%26atitle%3DThe%2520Use%2520of%2520Pioglitazone%2520and%2520the%2520Risk%2520of%2520Bladder%2520Cancer%2520in%2520People%2520with%2520Type%25202%2520Diabetes%253A%2520Nested%2520Case-Control%2520Study%26jtitle%3DBMJ%26date%3D2012%26volume%3D344%26spage%3De3645%26doi%3D10.1136%2Fbmj.e3645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Mamtani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilker, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strom, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. D.</span><span> </span><span class="NLM_article-title">Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1411</span><span class="NLM_x">â</span> <span class="NLM_lpage">1421</span><span class="refDoi">Â DOI: 10.1093/jnci/djs328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1093%2Fjnci%2Fdjs328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22878886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWgtb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=1411-1421&author=R.+Mamtaniauthor=K.+Haynesauthor=W.+B.+Bilkerauthor=D.+J.+Vaughnauthor=B.+L.+Stromauthor=K.+Glanzauthor=J.+D.+Lewis&title=Association+Between+Longer+Therapy+With+Thiazolidinediones+and+Risk+of+Bladder+Cancer%3A+A+Cohort+Study&doi=10.1093%2Fjnci%2Fdjs328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study</span></div><div class="casAuthors">Mamtani, Ronac; Haynes, Kevin; Bilker, Warren B.; Vaughn, David J.; Strom, Brian L.; Glanz, Karen; Lewis, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1411-1421</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: The use of pioglitazone, a thiazolidinedione (TZD), may increase the risk of bladder cancer in patients with type 2 diabetes.  In this study, we assessed the risk of bladder cancer assocd. with the use of TZDs and between pioglitazone and rosiglitazone, an alternative TZD.  Methods: We conducted a retrospective cohort study of patients with type 2 diabetes mellitus who initiated treatment with a TZD (n = 18 459 patients) or a sulfonylurea (SU) (n = 41 396 patients) between July 1, 2000, and August 31, 2010, using The Health Improvement Network database in the United Kingdom.  Incident cancers were identified for 196 708 person-years of follow-up.  Cox proportional hazards regression models were used to est. hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of bladder cancer in the TZD cohort compared with the SU cohort (referent), adjusted for potential confounders.  Risk assocd. with increasing duration of drug exposure was also examd.  All statistical tests were two-sided.  Results: We identified 60 incident bladder cancers in the TZD cohort and 137 cancers in the SU cohort.  No difference in bladder cancer risk was found between the two cohorts (TZD vs SU, HR = 0.93, 95% CI = 0.68 to 1.29) in analyses that did not account for duration of exposure.  However, the risk of bladder cancer was increased among patients with the longest duration of TZD vs SU therapy (â¥5 years of use, HR = 3.25, 95% CI = 1.08 to 9.71) and among those with the longest time since initiation of therapy (â¥5 years since first use, HR = 2.53, 95% CI = 1.12 to 5.77).  Risk of bladder cancer also increased with increasing time since initiation of pioglitazone (Ptrend < .001) and rosiglitazone (Ptrend = .006).  Comparison of pioglitazone to rosiglitazone use did not demonstrate difference in cancer risk (P = .49).  Conclusion: Long-term TZD therapy (â¥5 years) in patients with type 2 diabetes may be assocd. with an increased risk of bladder cancer, which may be common to all TZDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsEIfUELvjMbVg90H21EOLACvtfcHk0lgRcWNjFawlCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWgtb%252FJ&md5=c0ed848df5d55c6a57ca326135a84ee2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjs328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjs328%26sid%3Dliteratum%253Aachs%26aulast%3DMamtani%26aufirst%3DR.%26aulast%3DHaynes%26aufirst%3DK.%26aulast%3DBilker%26aufirst%3DW.%2BB.%26aulast%3DVaughn%26aufirst%3DD.%2BJ.%26aulast%3DStrom%26aufirst%3DB.%2BL.%26aulast%3DGlanz%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DJ.%2BD.%26atitle%3DAssociation%2520Between%2520Longer%2520Therapy%2520With%2520Thiazolidinediones%2520and%2520Risk%2520of%2520Bladder%2520Cancer%253A%2520A%2520Cohort%2520Study%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D1411%26epage%3D1421%26doi%3D10.1093%2Fjnci%2Fdjs328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Nissen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolski, K.</span><span> </span><span class="NLM_article-title">Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">â</span> <span class="NLM_lpage">2471</span><span class="refDoi">Â DOI: 10.1056/NEJMoa072761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1056%2FNEJMoa072761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=17517853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1SisrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2457-2471&author=S.+E.+Nissenauthor=K.+Wolski&title=Effect+of+Rosiglitazone+on+the+Risk+of+Myocardial+Infarction+and+Death+from+Cardiovascular+Causes&doi=10.1056%2FNEJMoa072761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</span></div><div class="casAuthors">Nissen, Steven E.; Woslki, Kathy</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2457-2471</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been detd.  We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clin.-trials registry maintained by the drug manufacturer (GlaxoSmithKline).  Criteria for inclusion in our meta-anal. included a study duration of more than 24 wk, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes.  Of 116 potentially relevant studies, 42 trials met the inclusion criteria.  We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.  Data were combined by means of a fixed-effects model.  In the 42 trials, the mean age of the subjects was approx. 56 years, and the mean baseline glycated Hb level was approx. 8.2%.  In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).  Rosiglitazone was assocd. with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance.  Our study was limited by a lack of access to original source data, which would have enabled time-to-event anal.  Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnruxfTnPBe7Vg90H21EOLACvtfcHk0lgRcWNjFawlCA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1SisrY%253D&md5=0cf21e448c286873e88c3e2eec6106a8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa072761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa072761%26sid%3Dliteratum%253Aachs%26aulast%3DNissen%26aufirst%3DS.%2BE.%26aulast%3DWolski%26aufirst%3DK.%26atitle%3DEffect%2520of%2520Rosiglitazone%2520on%2520the%2520Risk%2520of%2520Myocardial%2520Infarction%2520and%2520Death%2520from%2520Cardiovascular%2520Causes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2457%26epage%3D2471%26doi%3D10.1056%2FNEJMoa072761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Nissen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topol, E. J.</span><span> </span><span class="NLM_article-title">Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">2581</span><span class="NLM_x">â</span> <span class="NLM_lpage">2586</span><span class="refDoi">Â DOI: 10.1001/jama.294.20.joc50147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1001%2Fjama.294.20.joc50147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=16239637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KisLjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2005&pages=2581-2586&author=S.+E.+Nissenauthor=K.+Wolskiauthor=E.+J.+Topol&title=Effect+of+Muraglitazar+on+Death+and+Major+Adverse+Cardiovascular+Events+in+Patients+with+Type+2+Diabetes+Mellitus&doi=10.1001%2Fjama.294.20.joc50147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 Diabetes Mellitus</span></div><div class="casAuthors">Nissen, Steven E.; Wolski, Kathy; Topol, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2581-2586</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that modulate gene expression.  Therapeutic agents targeting 2 distinct families of PPARs (Î± and Î³) have been introduced in the United States.  The first dual-PPAR agonist, muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory committee on Sept. 9, 2005, resulting in a vote of 8:1 recommending approval for its use in controlling blood glucose levels in patients with type 2 diabetes.  Objective: To evaluate the incidence of death, myocardial infarction (MI), stroke, congestive heart failure (CHF), and transient ischemic attack (TIA) in diabetic patients treated with muraglitazar compared with controls.  Design, Setting, and Participants: The source material for this anal. consisted of documents about phase 2 and 3 clin. trials released under public disclosure laws for the FDA advisory committee meeting.  All reviewed trials were prospective, randomized, double-blind, multicenter studies enrolling patients with type 2 diabetes and Hb Arc levels between 7% and 10%.  Patients (N = 3725) were randomized to receive differing doses of muraglitazar, pioglitazone, or placebo as monotherapy or in combination with metformin or glyburide in trials ranging from 24 to 104 wk.  Main Outcome Measures: The primary outcome was the incidence of death, non-fatal MI, or nonfatal stroke.  A more comprehensive composite outcome included these events plus the incidence of CHF and TIA.  Results In the muraglitazar-treated patients, death, MI, or stroke occurred in 35 of 2374 (1.47%) patients compared with 9 of 1351 (0.67%) patients in the combined placebo and pioglitazone treatment groups (controls) (relative risk [RR], 2.23; 95% confidence interval [CI], 1.07 - 4.66; P = .03).  For the more comprehensive outcome measure that included TIA and CHF, the incidence was 50 of 2374 (2.11%) for muraglitazar compared with 11 of 1351 (0.81%) for controls (RR, 2.62; 95% CI, 1.36 - 5.05; P = .004).  Relative risks for each of the individual components of the composite end point exceeded 2.1 but were not statistically significant.  Incidence of adjudicated CHF was 13 of 2374 (0.55%) muraglitazar-treated patients and 1 of 1351 controls (0.07%) (RR, 7.43; 95% CI, 0.97 - 56.8; P = .053).  Conclusions: Compared with placebo or pioglitazone, muraglitazar was assocd. with an excess incidence of the composite end point of death, major adverse cardiovascular events (MI, stroke, TIA), and CHF.  This agent should not be approved to treat diabetes based on lab. end points until safety is documented in a dedicated cardiovascular events trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHR4RoUDPpmrVg90H21EOLACvtfcHk0lihDCMOJa0loQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KisLjJ&md5=f35a6103fdab2ab9303f5bd37f2475bc</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1001%2Fjama.294.20.joc50147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.294.20.joc50147%26sid%3Dliteratum%253Aachs%26aulast%3DNissen%26aufirst%3DS.%2BE.%26aulast%3DWolski%26aufirst%3DK.%26aulast%3DTopol%26aufirst%3DE.%2BJ.%26atitle%3DEffect%2520of%2520Muraglitazar%2520on%2520Death%2520and%2520Major%2520Adverse%2520Cardiovascular%2520Events%2520in%2520Patients%2520with%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DJAMA%26date%3D2005%26volume%3D294%26spage%3D2581%26epage%3D2586%26doi%3D10.1001%2Fjama.294.20.joc50147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 14 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jun  Shi</span>, <span class="hlFld-ContribAuthor ">Zhengxiang  Gu</span>, <span class="hlFld-ContribAuthor ">Elizabeth Anne  Jurica</span>, <span class="hlFld-ContribAuthor ">Ximao  Wu</span>, <span class="hlFld-ContribAuthor ">Lauren E.  Haque</span>, <span class="hlFld-ContribAuthor ">Kristin N.  Williams</span>, <span class="hlFld-ContribAuthor ">Andres S.  Hernandez</span>, <span class="hlFld-ContribAuthor ">Zhenqiu  Hong</span>, <span class="hlFld-ContribAuthor ">Qi  Gao</span>, <span class="hlFld-ContribAuthor ">Marta  Dabros</span>, <span class="hlFld-ContribAuthor ">Akin H.  Davulcu</span>, <span class="hlFld-ContribAuthor ">Arvind  Mathur</span>, <span class="hlFld-ContribAuthor ">Richard A.  Rampulla</span>, <span class="hlFld-ContribAuthor ">Arun Kumar  Gupta</span>, <span class="hlFld-ContribAuthor ">Ramya  Jayaram</span>, <span class="hlFld-ContribAuthor ">Atsu  Apedo</span>, <span class="hlFld-ContribAuthor ">Douglas B.  Moore</span>, <span class="hlFld-ContribAuthor ">Heng  Liu</span>, <span class="hlFld-ContribAuthor ">Lori K.  Kunselman</span>, <span class="hlFld-ContribAuthor ">Edward J.  Brady</span>, <span class="hlFld-ContribAuthor ">Jason J.  Wilkes</span>, <span class="hlFld-ContribAuthor ">Bradley A.  Zinker</span>, <span class="hlFld-ContribAuthor ">Hong  Cai</span>, <span class="hlFld-ContribAuthor ">Yue-Zhong  Shu</span>, <span class="hlFld-ContribAuthor ">Qin  Sun</span>, <span class="hlFld-ContribAuthor ">Elizabeth A.  Dierks</span>, <span class="hlFld-ContribAuthor ">Kimberly A.  Foster</span>, <span class="hlFld-ContribAuthor ">Carrie  Xu</span>, <span class="hlFld-ContribAuthor ">Tao  Wang</span>, <span class="hlFld-ContribAuthor ">Reshma  Panemangalore</span>, <span class="hlFld-ContribAuthor ">Mary Ellen  Cvijic</span>, <span class="hlFld-ContribAuthor ">Chunshan  Xie</span>, <span class="hlFld-ContribAuthor ">Gary G.  Cao</span>, <span class="hlFld-ContribAuthor ">Min  Zhou</span>, <span class="hlFld-ContribAuthor ">John  Krupinski</span>, <span class="hlFld-ContribAuthor ">Jean M.  Whaley</span>, <span class="hlFld-ContribAuthor ">Jeffrey A.  Robl</span>, <span class="hlFld-ContribAuthor ">William R.  Ewing</span>, and <span class="hlFld-ContribAuthor ">Bruce Alan  Ellsworth</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (3)
                                     , 681-694. <a href="https://doi.org/10.1021/acs.jmedchem.7b00982" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00982</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00982&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00982%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BOrally%252BBioavailable%252BDihydropyrazole%252BGPR40%252BAgonists%26aulast%3DShi%26aufirst%3DJun%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D05072017%26date%3D27012018%26date%3D08022018%26date%3D09012018%26volume%3D61%26issue%3D3%26spage%3D681%26epage%3D694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Britton</span>, <span class="hlFld-ContribAuthor ">Veronique  Gouverneur</span>, <span class="hlFld-ContribAuthor ">Jin-Hong  Lin</span>, <span class="hlFld-ContribAuthor ">Michael  Meanwell</span>, <span class="hlFld-ContribAuthor ">Chuanfa  Ni</span>, <span class="hlFld-ContribAuthor ">Gabriele  Pupo</span>, <span class="hlFld-ContribAuthor ">Ji-Chang  Xiao</span>, <span class="hlFld-ContribAuthor ">Jinbo  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Contemporary synthetic strategies in organofluorine chemistry. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Methods Primers</span><span> <strong>2021,</strong> <em>1 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s43586-021-00042-1" title="DOI URL">https://doi.org/10.1038/s43586-021-00042-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s43586-021-00042-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs43586-021-00042-1%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Methods%2520Primers%26atitle%3DContemporary%252Bsynthetic%252Bstrategies%252Bin%252Borganofluorine%252Bchemistry%26aulast%3DBritton%26aufirst%3DRobert%26date%3D2021%26date%3D2021%26volume%3D1%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jie  He</span>, <span class="hlFld-ContribAuthor ">Yong  Chu</span>. </span><span class="cited-content_cbyCitation_article-title">Small-molecule GLP-1 secretagogs: challenges and recent advances. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (11)
                                     , 2023-2029. <a href="https://doi.org/10.1016/j.drudis.2020.08.003" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.08.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.08.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.08.003%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DSmall-molecule%252BGLP-1%252Bsecretagogs%25253A%252Bchallenges%252Band%252Brecent%252Badvances%26aulast%3DHe%26aufirst%3DJie%26date%3D2020%26volume%3D25%26issue%3D11%26spage%3D2023%26epage%3D2029" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rory T.  Gallagher</span>, <span class="hlFld-ContribAuthor ">Souradeep  Basu</span>, <span class="hlFld-ContribAuthor ">David R.  Stuart</span>. </span><span class="cited-content_cbyCitation_article-title">Trimethoxyphenyl (TMP) as a Useful Auxiliary for
              inâsitu
              Formation and Reaction of Aryl(TMP)iodonium Salts: Synthesis of Diaryl Ethers. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2020,</strong> <em>362 </em>
                                    (2)
                                     , 320-325. <a href="https://doi.org/10.1002/adsc.201901187" title="DOI URL">https://doi.org/10.1002/adsc.201901187</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201901187&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201901187%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DTrimethoxyphenyl%252B%252528TMP%252529%252Bas%252Ba%252BUseful%252BAuxiliary%252Bfor%252Bin%2525E2%252580%252585situ%252BFormation%252Band%252BReaction%252Bof%252BAryl%252528TMP%252529iodonium%252BSalts%25253A%252BSynthesis%252Bof%252BDiaryl%252BEthers%26aulast%3DGallagher%26aufirst%3DRory%2BT.%26date%3D2020%26date%3D2019%26volume%3D362%26issue%3D2%26spage%3D320%26epage%3D325" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Maria  Orfanoudaki</span>, <span class="hlFld-ContribAuthor ">Anja  Hartmann</span>, <span class="hlFld-ContribAuthor ">Mostafa  Alilou</span>, <span class="hlFld-ContribAuthor ">Thomas  Gelbrich</span>, <span class="hlFld-ContribAuthor ">Patricia  Planchenault</span>, <span class="hlFld-ContribAuthor ">SÃ©verine  DerbrÃ©</span>, <span class="hlFld-ContribAuthor ">Andreas  Schinkovitz</span>, <span class="hlFld-ContribAuthor ">Pascal  Richomme</span>, <span class="hlFld-ContribAuthor ">Andreas  Hensel</span>, <span class="hlFld-ContribAuthor ">Markus  Ganzera</span>. </span><span class="cited-content_cbyCitation_article-title">Absolute Configuration of Mycosporine-Like Amino Acids, Their Wound Healing Properties and In Vitro Anti-Aging Effects. </span><span class="cited-content_cbyCitation_journal-name">Marine Drugs</span><span> <strong>2020,</strong> <em>18 </em>
                                    (1)
                                     , 35. <a href="https://doi.org/10.3390/md18010035" title="DOI URL">https://doi.org/10.3390/md18010035</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/md18010035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmd18010035%26sid%3Dliteratum%253Aachs%26jtitle%3DMarine%2520Drugs%26atitle%3DAbsolute%252BConfiguration%252Bof%252BMycosporine-Like%252BAmino%252BAcids%25252C%252BTheir%252BWound%252BHealing%252BProperties%252Band%252BIn%252BVitro%252BAnti-Aging%252BEffects%26aulast%3DOrfanoudaki%26aufirst%3DMaria%26date%3D2020%26date%3D2019%26volume%3D18%26issue%3D1%26spage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vladimir  Kubyshkin</span>. </span><span class="cited-content_cbyCitation_article-title">Polarity effects in 4-fluoro- and 4-(trifluoromethyl)prolines. </span><span class="cited-content_cbyCitation_journal-name">Beilstein Journal of Organic Chemistry</span><span> <strong>2020,</strong> <em>16 </em>, 1837-1852. <a href="https://doi.org/10.3762/bjoc.16.151" title="DOI URL">https://doi.org/10.3762/bjoc.16.151</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3762/bjoc.16.151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3762%2Fbjoc.16.151%26sid%3Dliteratum%253Aachs%26jtitle%3DBeilstein%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DPolarity%252Beffects%252Bin%252B4-fluoro-%252Band%252B4-%252528trifluoromethyl%252529prolines%26aulast%3DKubyshkin%26aufirst%3DVladimir%26date%3D2020%26date%3D2020%26volume%3D16%26spage%3D1837%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Qiang  Ren</span>, <span class="hlFld-ContribAuthor ">Xuekun  Wang</span>, <span class="hlFld-ContribAuthor ">Zongtao  Zhou</span>, <span class="hlFld-ContribAuthor ">Lijun  Hu</span>, <span class="hlFld-ContribAuthor ">Liming  Deng</span>, <span class="hlFld-ContribAuthor ">Li  Guan</span>, <span class="hlFld-ContribAuthor ">Qianqian  Qiu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of HWL-088: A highly potent FFA1/GPR40 agonist bearing a phenoxyacetic acid scaffold. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2019,</strong> <em>92 </em>, 103209. <a href="https://doi.org/10.1016/j.bioorg.2019.103209" title="DOI URL">https://doi.org/10.1016/j.bioorg.2019.103209</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2019.103209&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2019.103209%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDiscovery%252Bof%252BHWL-088%25253A%252BA%252Bhighly%252Bpotent%252BFFA1%25252FGPR40%252Bagonist%252Bbearing%252Ba%252Bphenoxyacetic%252Bacid%252Bscaffold%26aulast%3DLi%26aufirst%3DZheng%26date%3D2019%26volume%3D92%26spage%3D103209" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zheng  Li</span>, <span class="hlFld-ContribAuthor ">Chunxia  Liu</span>, <span class="hlFld-ContribAuthor ">Jianyong  Yang</span>, <span class="hlFld-ContribAuthor ">Jiaqi  Zhou</span>, <span class="hlFld-ContribAuthor ">Zhiwen  Ye</span>, <span class="hlFld-ContribAuthor ">Dazhi  Feng</span>, <span class="hlFld-ContribAuthor ">Na  Yue</span>, <span class="hlFld-ContribAuthor ">Jiayi  Tong</span>, <span class="hlFld-ContribAuthor ">Wenlong  Huang</span>, <span class="hlFld-ContribAuthor ">Hai  Qian</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 608-622. <a href="https://doi.org/10.1016/j.ejmech.2019.06.087" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.087</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.087&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.087%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252BFFA1%25252FGPR40%252Bagonists%25253A%252BNew%252Bbreakthrough%252Bin%252Ban%252Bold%252Bscaffold%26aulast%3DLi%26aufirst%3DZheng%26date%3D2019%26volume%3D179%26spage%3D608%26epage%3D622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fernando  Rabasa-AlcaÃ±iz</span>, <span class="hlFld-ContribAuthor ">Daniel  Hammerl</span>, <span class="hlFld-ContribAuthor ">Anabel  SÃ¡nchez-Merino</span>, <span class="hlFld-ContribAuthor ">TomÃ¡s  Tejero</span>, <span class="hlFld-ContribAuthor ">Pedro  Merino</span>, <span class="hlFld-ContribAuthor ">Santos  Fustero</span>, <span class="hlFld-ContribAuthor ">Carlos  del Pozo</span>. </span><span class="cited-content_cbyCitation_article-title">Asymmetric synthesis of polycyclic 3-fluoroalkylproline derivatives by intramolecular azomethine ylide cycloaddition. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2019,</strong> <em>6 </em>
                                    (16)
                                     , 2916-2923. <a href="https://doi.org/10.1039/C9QO00525K" title="DOI URL">https://doi.org/10.1039/C9QO00525K</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9QO00525K&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9QO00525K%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DAsymmetric%252Bsynthesis%252Bof%252Bpolycyclic%252B3-fluoroalkylproline%252Bderivatives%252Bby%252Bintramolecular%252Bazomethine%252Bylide%252Bcycloaddition%26aulast%3DRabasa-Alca%25C3%25B1iz%26aufirst%3DFernando%26date%3D2019%26date%3D2019%26volume%3D6%26issue%3D16%26spage%3D2916%26epage%3D2923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hans  Renata</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient chemoenzymatic synthesis of (2S,3R)-3-hydroxy-3-methylproline, a key fragment in polyoxypeptin A and FR225659. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron</span><span> <strong>2019,</strong> <em>75 </em>
                                    (24)
                                     , 3253-3257. <a href="https://doi.org/10.1016/j.tet.2019.04.009" title="DOI URL">https://doi.org/10.1016/j.tet.2019.04.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tet.2019.04.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tet.2019.04.009%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%26atitle%3DEfficient%252Bchemoenzymatic%252Bsynthesis%252Bof%252B%2525282S%25252C3R%252529-3-hydroxy-3-methylproline%25252C%252Ba%252Bkey%252Bfragment%252Bin%252Bpolyoxypeptin%252BA%252Band%252BFR225659%26aulast%3DZhang%26aufirst%3DXiao%26date%3D2019%26volume%3D75%26issue%3D24%26spage%3D3253%26epage%3D3257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tingting  Chen</span>, <span class="hlFld-ContribAuthor ">Mengmeng  Ning</span>, <span class="hlFld-ContribAuthor ">Yangliang  Ye</span>, <span class="hlFld-ContribAuthor ">Kai  Wang</span>, <span class="hlFld-ContribAuthor ">Ying  Leng</span>, <span class="hlFld-ContribAuthor ">Jianhua  Shen</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and structureâactivity relationship studies of GPR40 agonists containing amide linker. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>152 </em>, 175-194. <a href="https://doi.org/10.1016/j.ejmech.2018.04.023" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.04.023</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.04.023&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.04.023%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bstructure%2525E2%252588%252592activity%252Brelationship%252Bstudies%252Bof%252BGPR40%252Bagonists%252Bcontaining%252Bamide%252Blinker%26aulast%3DChen%26aufirst%3DTingting%26date%3D2018%26volume%3D152%26spage%3D175%26epage%3D194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariateresa  Badolato</span>, <span class="hlFld-ContribAuthor ">Gabriele  Carullo</span>, <span class="hlFld-ContribAuthor ">Mariarita  Perri</span>, <span class="hlFld-ContribAuthor ">Erika  Cione</span>, <span class="hlFld-ContribAuthor ">Fabrizio  Manetti</span>, <span class="hlFld-ContribAuthor ">Maria Luisa  Di Gioia</span>, <span class="hlFld-ContribAuthor ">Antonella  Brizzi</span>, <span class="hlFld-ContribAuthor ">Maria Cristina  Caroleo</span>, <span class="hlFld-ContribAuthor ">Francesca  Aiello</span>. </span><span class="cited-content_cbyCitation_article-title">Quercetin/oleic acid-based G-protein-coupled receptor 40Â ligands as new insulin secretion modulators. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2017,</strong> <em>9 </em>
                                    (16)
                                     , 1873-1885. <a href="https://doi.org/10.4155/fmc-2017-0113" title="DOI URL">https://doi.org/10.4155/fmc-2017-0113</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc-2017-0113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc-2017-0113%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DQuercetin%25252Foleic%252Bacid-based%252BG-protein-coupled%252Breceptor%252B40%2525C2%2525A0ligands%252Bas%252Bnew%252Binsulin%252Bsecretion%252Bmodulators%26aulast%3DBadolato%26aufirst%3DMariateresa%26date%3D2017%26volume%3D9%26issue%3D16%26spage%3D1873%26epage%3D1885" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Graeme  Milligan</span>, <span class="hlFld-ContribAuthor ">Elisa  Alvarez-Curto</span>, <span class="hlFld-ContribAuthor ">Brian D.  Hudson</span>, <span class="hlFld-ContribAuthor ">Rudi  Prihandoko</span>, <span class="hlFld-ContribAuthor ">Andrew B.  Tobin</span>. </span><span class="cited-content_cbyCitation_article-title">FFA4/GPR120: Pharmacology and Therapeutic Opportunities. </span><span class="cited-content_cbyCitation_journal-name">Trends in Pharmacological Sciences</span><span> <strong>2017,</strong> <em>38 </em>
                                    (9)
                                     , 809-821. <a href="https://doi.org/10.1016/j.tips.2017.06.006" title="DOI URL">https://doi.org/10.1016/j.tips.2017.06.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tips.2017.06.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tips.2017.06.006%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Pharmacological%2520Sciences%26atitle%3DFFA4%25252FGPR120%25253A%252BPharmacology%252Band%252BTherapeutic%252BOpportunities%26aulast%3DMilligan%26aufirst%3DGraeme%26date%3D2017%26volume%3D38%26issue%3D9%26spage%3D809%26epage%3D821" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jing  Liu</span>, <span class="hlFld-ContribAuthor ">Jin  Xie</span>, <span class="hlFld-ContribAuthor ">Chengjian  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Photoredox organocatalytic Î±-amino C(sp
              3
              )âH functionalization for the synthesis of 5-membered heterocyclic Î³-amino acid derivatives. </span><span class="cited-content_cbyCitation_journal-name">Organic Chemistry Frontiers</span><span> <strong>2017,</strong> <em>4 </em>
                                    (12)
                                     , 2433-2436. <a href="https://doi.org/10.1039/C7QO00644F" title="DOI URL">https://doi.org/10.1039/C7QO00644F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7QO00644F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7QO00644F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Chemistry%2520Frontiers%26atitle%3DPhotoredox%252Borganocatalytic%252B%2525CE%2525B1-amino%252BC%252528sp%252B3%252B%252529%2525E2%252580%252593H%252Bfunctionalization%252Bfor%252Bthe%252Bsynthesis%252Bof%252B5-membered%252Bheterocyclic%252B%2525CE%2525B3-amino%252Bacid%252Bderivatives%26aulast%3DLiu%26aufirst%3DJing%26date%3D2017%26date%3D2017%26volume%3D4%26issue%3D12%26spage%3D2433%26epage%3D2436" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0023.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0001.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of GPR40 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0012.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Representative Synthesis of Pyrrolidine 2-Acetic Acid Analogues, As Depicted for Compound <b>(</b><i><b>S</b></i><b>)-7</b><sup>a</sup>,<sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions. (a) i. LHMDS, THF; ii. TsCl, 60%; (b) 130 Â°C, neat, 16%; (c) chiral separation; (d) Pd/C, H<sub>2</sub>, MeOH/EtOH, 88%; (e) K<sub>2</sub>CO<sub>3</sub>, DMF, 93%; (f) LiOH, THF/water, 44%.</p><p class="last"><span class="fn-label">Scheme b</span>See <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a> for other compounds that were synthesized via this general route.</p></p></figure><figure data-id="fig2" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0002.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Pyrrolidine series evolution.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0013.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Representative Synthesis of Chiral Pyrrolidine GPR40 Agonists, As Depicted for Compound <b>22</b><sup>a</sup>,<sup>b</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p><span class="fn-label">Scheme a</span>Reagents and conditions. (a) TsOH, NaNO<sub>2</sub>, KI, 74%; (b) <i>i</i>-BuO<sub>2</sub>CCl, NMM, THF; NaBH<sub>4</sub>, H<sub>2</sub>O, 95%; (c) HCl, dioxane, quant.; (d) CuI, NaOH, <i>i</i>-PrOH, 90 Â°C, 74%; (e) MsCl, NEt<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>; (f) NaCN, DMSO, 50 Â°C, 100% (2 steps); (g) KOH, EtOH/H<sub>2</sub>O, 120 Â°C, 43%.</p><p class="last"><span class="fn-label">Scheme b</span>Similar compounds made using an analogous method; see <a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0003.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Arbitrary nomenclature (AâC) for rings on the pyrrolidine chemotype of GPR40 agonists.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0004.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Overlay of low energy conformations of compounds <b>32</b> and <b>22</b> A and B rings only, demonstrating the influence of a 4-<i>cis</i>-CF<sub>3</sub> group on the pyrrolidine ring structure.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0005.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. (A) Inducible hGPR40 assay with high expression of GPR40. (B) Inducible hGPR40 assay with low expression of GPR40.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0014.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> and <b>68</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions. (a) PCC, CH<sub>2</sub>Cl<sub>2</sub>, 80%; (b) CF<sub>3</sub>TMS, TBAF, 79%; (c) SOCl<sub>2</sub>, pyridine, DIPEA, Boc<sub>2</sub>O, 62%; (d) H<sub>2</sub>, Pd/C, EtOH, 90%; (e) NMM, <i>i</i>-BuCOCl, NaBH<sub>4</sub>, THF/water, 84%; (f) HCl/dioxane, 93%; (g) 1-bromo-4-iodobenzene, CuI, NaOH, <i>i</i>-PrOH, 77%; (h) MsCl, TEA, CH<sub>2</sub>Cl<sub>2</sub>; NaCN, DMSO, 87% (2 steps); (i) TBAB, Pd(Ph<sub>3</sub>P)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, water, (92%); (j) LAH, THF, 89%; (k) LiBr, MsCl, TEA, THF, 89%; (l) Zn, TMS-Cl, ethylene dibromide; Pd(Ph<sub>3</sub>P)<sub>4</sub>, THF, 86%; (m) KOH, EtOH/water, 70%; (n) SFC chiral separation.</p></p></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0006.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Impact of pyrrolidine substituent stereoisomers on GPR40 binding potency and agonist efficacy.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0007.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Binding assay results with compounds <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> and <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> (negative slope indicates radiolabel displacement; positive slope indicates increase in radiolabel binding).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0008.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. (A) Potency of DHA versus DHA + 3 nM compound <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b>. (B) Potency of DHA versus DHA + 10 nM compound <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0009.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. In vitro insulin secretion from isolated primary mouse islets.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0010.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. GLP-1 secretion in STC-1 cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/medium/jm-2016-015597_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0011.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. In vivo evaluation of <b>(</b><i><b>R</b></i>,<i><b>R</b></i><b>)-68</b> and <b>(</b><i><b>S</b></i>,<i><b>S</b></i><b>)-68</b> efficacy in mice.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2017/jmcmar.2017.60.issue-4/acs.jmedchem.6b01559/20170216/images/large/jm-2016-015597_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.6b01559&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i41">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_10186" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_10186" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 37 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Bonow, R. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gheorghiade, M.</span><span> </span><span class="NLM_article-title">The Diabetes Epidemic: A National and Global Crisis</span> <span class="citation_source-journal">Am. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">â</span> <span class="NLM_lpage">10</span><span class="refDoi">Â DOI: 10.1016/j.amjmed.2003.10.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.amjmed.2003.10.014" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=2-10&author=R.+O.+Bonowauthor=M.+Gheorghiade&title=The+Diabetes+Epidemic%3A+A+National+and+Global+Crisis&doi=10.1016%2Fj.amjmed.2003.10.014"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.amjmed.2003.10.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.amjmed.2003.10.014%26sid%3Dliteratum%253Aachs%26aulast%3DBonow%26aufirst%3DR.%2BO.%26aulast%3DGheorghiade%26aufirst%3DM.%26atitle%3DThe%2520Diabetes%2520Epidemic%253A%2520A%2520National%2520and%2520Global%2520Crisis%26jtitle%3DAm.%2520J.%2520Med.%26date%3D2004%26volume%3D116%26spage%3D2%26epage%3D10%26doi%3D10.1016%2Fj.amjmed.2003.10.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span>Key Findings 2014 International Diabetes Foundation. <a href="http://www.idf.org/diabetesatlas/update-2014" class="extLink">http://www.idf.org/diabetesatlas/update-2014</a> (accessed Aug 17,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Key+Findings+2014+International+Diabetes+Foundation.+http%3A%2F%2Fwww.idf.org%2Fdiabetesatlas%2Fupdate-2014+%28accessed+Aug+17%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Nathan, D. M.</span><span> </span><span class="NLM_article-title">Long-Term Complications of Diabetes Mellitus</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1993</span><span class="NLM_x">, </span> <span class="NLM_volume">328</span><span class="NLM_x">, </span> <span class="NLM_fpage">1676</span><span class="NLM_x">â</span> <span class="NLM_lpage">1685</span><span class="refDoi">Â DOI: 10.1056/NEJM199306103282306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1056%2FNEJM199306103282306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=8487827" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=328&publication_year=1993&pages=1676-1685&author=D.+M.+Nathan&title=Long-Term+Complications+of+Diabetes+Mellitus&doi=10.1056%2FNEJM199306103282306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term complications of diabetes mellitus</span></div><div class="casAuthors">Nathan D M</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">328</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">1676-85</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQeI2Wva4wSrWlSCSgBhwJFfW6udTcc2eaHL9NGCLdY7rntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s3lsVGgsA%253D%253D&md5=2a29d58d4dec1bf483f668b439055709</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJM199306103282306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM199306103282306%26sid%3Dliteratum%253Aachs%26aulast%3DNathan%26aufirst%3DD.%2BM.%26atitle%3DLong-Term%2520Complications%2520of%2520Diabetes%2520Mellitus%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1993%26volume%3D328%26spage%3D1676%26epage%3D1685%26doi%3D10.1056%2FNEJM199306103282306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Briscoe, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tadayyon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andrews, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benson, W. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chambers, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eilert, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ellis, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elshourbagy, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goetz, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minnick, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murdock, P. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sauls, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shabon, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spinage, L. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strum, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szekeres, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Way, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ignar, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muir, A. I.</span><span> </span><span class="NLM_article-title">The Orphan G Protein-Coupled Receptor GPR40 is Activated by Medium and Long Chain Fatty Acids</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">278</span><span class="NLM_x">, </span> <span class="NLM_fpage">11303</span><span class="NLM_x">â</span> <span class="NLM_lpage">11311</span><span class="refDoi">Â DOI: 10.1074/jbc.M211495200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1074%2Fjbc.M211495200" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=278&publication_year=2003&pages=11303-11311&author=C.+P.+Briscoeauthor=M.+Tadayyonauthor=J.+L.+Andrewsauthor=W.+G.+Bensonauthor=J.+K.+Chambersauthor=M.+M.+Eilertauthor=C.+Ellisauthor=N.+A.+Elshourbagyauthor=A.+S.+Goetzauthor=D.+T.+Minnickauthor=P.+R.+Murdockauthor=H.+R.+Saulsauthor=U.+Shabonauthor=L.+D.+Spinageauthor=J.+C.+Strumauthor=P.+G.+Szekeresauthor=K.+B.+Tanauthor=J.+M.+Wayauthor=D.+M.+Ignarauthor=S.+Wilsonauthor=A.+I.+Muir&title=The+Orphan+G+Protein-Coupled+Receptor+GPR40+is+Activated+by+Medium+and+Long+Chain+Fatty+Acids&doi=10.1074%2Fjbc.M211495200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M211495200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M211495200%26sid%3Dliteratum%253Aachs%26aulast%3DBriscoe%26aufirst%3DC.%2BP.%26aulast%3DTadayyon%26aufirst%3DM.%26aulast%3DAndrews%26aufirst%3DJ.%2BL.%26aulast%3DBenson%26aufirst%3DW.%2BG.%26aulast%3DChambers%26aufirst%3DJ.%2BK.%26aulast%3DEilert%26aufirst%3DM.%2BM.%26aulast%3DEllis%26aufirst%3DC.%26aulast%3DElshourbagy%26aufirst%3DN.%2BA.%26aulast%3DGoetz%26aufirst%3DA.%2BS.%26aulast%3DMinnick%26aufirst%3DD.%2BT.%26aulast%3DMurdock%26aufirst%3DP.%2BR.%26aulast%3DSauls%26aufirst%3DH.%2BR.%26aulast%3DShabon%26aufirst%3DU.%26aulast%3DSpinage%26aufirst%3DL.%2BD.%26aulast%3DStrum%26aufirst%3DJ.%2BC.%26aulast%3DSzekeres%26aufirst%3DP.%2BG.%26aulast%3DTan%26aufirst%3DK.%2BB.%26aulast%3DWay%26aufirst%3DJ.%2BM.%26aulast%3DIgnar%26aufirst%3DD.%2BM.%26aulast%3DWilson%26aufirst%3DS.%26aulast%3DMuir%26aufirst%3DA.%2BI.%26atitle%3DThe%2520Orphan%2520G%2520Protein-Coupled%2520Receptor%2520GPR40%2520is%2520Activated%2520by%2520Medium%2520and%2520Long%2520Chain%2520Fatty%2520Acids%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2003%26volume%3D278%26spage%3D11303%26epage%3D11311%26doi%3D10.1074%2Fjbc.M211495200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Itoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawamata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujii, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukusumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hosoya, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uejima, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maruyama, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Satoh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okubo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsumura, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noguchi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shinohara, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinuma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujisawa, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujino, M.</span><span> </span><span class="NLM_article-title">Free Fatty Acids Regulate Insulin Secretion from Pancreatic Î² Cells through GPR40</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">422</span><span class="NLM_x">, </span> <span class="NLM_fpage">173</span><span class="NLM_x">â</span> <span class="NLM_lpage">176</span><span class="refDoi">Â DOI: 10.1038/nature01478</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1038%2Fnature01478" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=12629551" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=422&publication_year=2003&pages=173-176&author=Y.+Itohauthor=Y.+Kawamataauthor=M.+Haradaauthor=M.+Kobayashiauthor=R.+Fujiiauthor=S.+Fukusumiauthor=K.+Ogiauthor=M.+Hosoyaauthor=Y.+Tanakaauthor=H.+Uejimaauthor=H.+Tanakaauthor=M.+Maruyamaauthor=R.+Satohauthor=S.+Okuboauthor=H.+Kizawaauthor=H.+Komatsuauthor=F.+Matsumuraauthor=Y.+Noguchiauthor=T.+Shinoharaauthor=S.+Hinumaauthor=Y.+Fujisawaauthor=M.+Fujino&title=Free+Fatty+Acids+Regulate+Insulin+Secretion+from+Pancreatic+%CE%B2+Cells+through+GPR40&doi=10.1038%2Fnature01478"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Free fatty acids regulate insulin secretion from pancreatic Î² cells through GPR40</span></div><div class="casAuthors">Itoh, Yasuaki; Kawamata, Yuji; Harada, Masataka; Kobayashi, Makoto; Fujii, Ryo; Fukusumi, Shoji; Ogi, Kazuhiro; Hosoya, Masaki; Tanaka, Yasuhiro; Uejima, Hiroshi; Tanaka, Hideyuki; Maruyama, Minoru; Satoh, Rie; Okubo, Shoichi; Kizawa, Hideki; Komatsu, Hidetoshi; Matsumura, Fumika; Noguchi, Yuko; Shinohara, Tokuyuki; Hinuma, Shuji; Fujisawa, Yukio; Fujino, Masahiko</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">422</span>
        (<span class="NLM_cas:issue">6928</span>),
    <span class="NLM_cas:pages">173-176</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Diabetes, a disease in which carbohydrate and lipid metab. are regulated improperly by insulin, is a serious worldwide health issue.  Insulin is secreted from pancreatic Î² cells in response to elevated plasma glucose, with various factors modifying its secretion.  Free fatty acids (FFAs) provide an important energy source as nutrients, and they also act as signaling mols. in various cellular processes, including insulin secretion.  Although FFAs are thought to promote insulin secretion in an acute phase, this mechanism is not clearly understood.  A G-protein-coupled receptor, GPR40, which is abundantly expressed in the pancreas, functions as a receptor for long-chain FFAs.  Furthermore, the authors show that long-chain FFAs amplify glucose-stimulated insulin secretion from pancreatic Î² cells by activating GPR40.  The authors' results indicate that GPR40 agonists and/or antagonists show potential for the development of new anti-diabetic drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5Y9oes-9VG7Vg90H21EOLACvtfcHk0liCTdkrIVjdlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhvFKgs7w%253D&md5=96af869fb87b235a482ad6c0c42db5e3</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature01478&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature01478%26sid%3Dliteratum%253Aachs%26aulast%3DItoh%26aufirst%3DY.%26aulast%3DKawamata%26aufirst%3DY.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DKobayashi%26aufirst%3DM.%26aulast%3DFujii%26aufirst%3DR.%26aulast%3DFukusumi%26aufirst%3DS.%26aulast%3DOgi%26aufirst%3DK.%26aulast%3DHosoya%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DY.%26aulast%3DUejima%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DH.%26aulast%3DMaruyama%26aufirst%3DM.%26aulast%3DSatoh%26aufirst%3DR.%26aulast%3DOkubo%26aufirst%3DS.%26aulast%3DKizawa%26aufirst%3DH.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DMatsumura%26aufirst%3DF.%26aulast%3DNoguchi%26aufirst%3DY.%26aulast%3DShinohara%26aufirst%3DT.%26aulast%3DHinuma%26aufirst%3DS.%26aulast%3DFujisawa%26aufirst%3DY.%26aulast%3DFujino%26aufirst%3DM.%26atitle%3DFree%2520Fatty%2520Acids%2520Regulate%2520Insulin%2520Secretion%2520from%2520Pancreatic%2520%25CE%25B2%2520Cells%2520through%2520GPR40%26jtitle%3DNature%26date%3D2003%26volume%3D422%26spage%3D173%26epage%3D176%26doi%3D10.1038%2Fnature01478" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Burant, C. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marcinak, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakilynejad, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leifke, E.</span><span> </span><span class="NLM_article-title">TAK-875 Versus Placebo or Glimepiride in Type 2 Diabetes Mellitus: A Phase 2, Randomised, Double-Blind, Placebo-Controlled Tsrial</span> <span class="citation_source-journal">Lancet</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">379</span><span class="NLM_x">, </span> <span class="NLM_fpage">1403</span><span class="NLM_x">â</span> <span class="NLM_lpage">1411</span><span class="refDoi">Â DOI: 10.1016/S0140-6736(11)61879-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2FS0140-6736%2811%2961879-5" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=379&publication_year=2012&pages=1403-1411&author=C.+F.+Burantauthor=P.+Viswanathanauthor=J.+Marcinakauthor=C.+Caoauthor=M.+Vakilynejadauthor=B.+Xieauthor=E.+Leifke&title=TAK-875+Versus+Placebo+or+Glimepiride+in+Type+2+Diabetes+Mellitus%3A+A+Phase+2%2C+Randomised%2C+Double-Blind%2C+Placebo-Controlled+Tsrial&doi=10.1016%2FS0140-6736%2811%2961879-5"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2811%2961879-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252811%252961879-5%26sid%3Dliteratum%253Aachs%26aulast%3DBurant%26aufirst%3DC.%2BF.%26aulast%3DViswanathan%26aufirst%3DP.%26aulast%3DMarcinak%26aufirst%3DJ.%26aulast%3DCao%26aufirst%3DC.%26aulast%3DVakilynejad%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DB.%26aulast%3DLeifke%26aufirst%3DE.%26atitle%3DTAK-875%2520Versus%2520Placebo%2520or%2520Glimepiride%2520in%2520Type%25202%2520Diabetes%2520Mellitus%253A%2520A%2520Phase%25202%252C%2520Randomised%252C%2520Double-Blind%252C%2520Placebo-Controlled%2520Tsrial%26jtitle%3DLancet%26date%3D2012%26volume%3D379%26spage%3D1403%26epage%3D1411%26doi%3D10.1016%2FS0140-6736%2811%2961879-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Yabuki, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Komatsu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujihata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maeda, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsuda-Nagasumi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sakuma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyawaki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kikuchi, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, M.</span><span> </span><span class="NLM_article-title">A Novel Antidiabetic Drug, Fasiglifam/TAK-875, Acts as an Ago-Allosteric Modulator of FFAR1</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">e76280</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0076280</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1371%2Fjournal.pone.0076280" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=24130766" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Cjsr7J" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2013&pages=e76280&author=C.+Yabukiauthor=H.+Komatsuauthor=Y.+Tsujihataauthor=R.+Maedaauthor=R.+Itoauthor=K.+Matsuda-Nagasumiauthor=K.+Sakumaauthor=K.+Miyawakiauthor=N.+Kikuchiauthor=K.+Takeuchiauthor=Y.+Habataauthor=M.+Mori&title=A+Novel+Antidiabetic+Drug%2C+Fasiglifam%2FTAK-875%2C+Acts+as+an+Ago-Allosteric+Modulator+of+FFAR1&doi=10.1371%2Fjournal.pone.0076280"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1</span></div><div class="casAuthors">Yabuki, Chiori; Komatsu, Hidetoshi; Tsujihata, Yoshiyuki; Maeda, Risa; Ito, Ryo; Matsuda-Nagasumi, Kae; Sakuma, Kensuke; Miyawaki, Kazumasa; Kikuchi, Naoya; Takeuchi, Koji; Habata, Yugo; Mori, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e76280</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic Î² cells.  Although fasiglifam significantly improved glycemic control in type 2 diabetes patients with a min. risk of hypoglycemia in a phase 2 study, the precise mechanisms of its potent pharmacol. effects are not fully understood.  Here we demonstrate that fasiglifam acts as an ago-allosteric modulator with a partial agonistic activity for FFAR1.  In both Ca2+ influx and insulin secretion assays using cell lines and mouse islets, fasiglifam showed pos. cooperativity with the FFAR1 ligand Î³-linolenic acid (Î³-LA).  Augmentation of glucose-induced insulin secretion by fasiglifam, Î³-LA, or their combination was completely abolished in pancreatic islets of FFAR1-knockout mice.  In diabetic rats, the insulinotropic effect of fasiglifam was suppressed by pharmacol. redn. of plasma free fatty acid (FFA) levels using a lipolysis inhibitor, suggesting that fasiglifam potentiates insulin release in conjunction with plasma FFAs in vivo.  Point mutations of FFAR1 differentially affected Ca2+ influx activities of fasiglifam and Î³-LA, further indicating that these agonists may bind to distinct binding sites.  Our results strongly suggest that fasiglifam is an ago-allosteric modulator of FFAR1 that exerts its effects by acting cooperatively with endogenous plasma FFAs in human patients as well as diabetic animals.  These findings contribute to our understanding of fasiglifam as an attractive antidiabetic drug with a novel mechanism of action.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGZkQC0HrqVbVg90H21EOLACvtfcHk0liCTdkrIVjdlQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Cjsr7J&md5=788b16750f7de0ab4c7fcce79cd7c857</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0076280&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0076280%26sid%3Dliteratum%253Aachs%26aulast%3DYabuki%26aufirst%3DC.%26aulast%3DKomatsu%26aufirst%3DH.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DMaeda%26aufirst%3DR.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DMatsuda-Nagasumi%26aufirst%3DK.%26aulast%3DSakuma%26aufirst%3DK.%26aulast%3DMiyawaki%26aufirst%3DK.%26aulast%3DKikuchi%26aufirst%3DN.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DHabata%26aufirst%3DY.%26aulast%3DMori%26aufirst%3DM.%26atitle%3DA%2520Novel%2520Antidiabetic%2520Drug%252C%2520Fasiglifam%252FTAK-875%252C%2520Acts%2520as%2520an%2520Ago-Allosteric%2520Modulator%2520of%2520FFAR1%26jtitle%3DPLoS%2520One%26date%3D2013%26volume%3D8%26spage%3De76280%26doi%3D10.1371%2Fjournal.pone.0076280" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Negoro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mikami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujihata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takeuchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Odani, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kogame, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsunaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momose, Y.</span><span> </span><span class="NLM_article-title">Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">290</span><span class="NLM_x">â</span> <span class="NLM_lpage">294</span><span class="refDoi">Â DOI: 10.1021/ml1000855</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml1000855" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=290-294&author=N.+Negoroauthor=S.+Sasakiauthor=S.+Mikamiauthor=M.+Itoauthor=M.+Suzukiauthor=Y.+Tsujihataauthor=R.+Itoauthor=A.+Haradaauthor=K.+Takeuchiauthor=N.+Suzukiauthor=J.+Miyazakiauthor=T.+Santouauthor=T.+Odaniauthor=N.+Kanzakiauthor=M.+Funamiauthor=T.+Tanakaauthor=A.+Kogameauthor=S.+Matsunagaauthor=T.+Yasumaauthor=Y.+Momose&title=Discovery+of+TAK-875%3A+A+Potent%2C+Selective%2C+and+Orally+Bioavailable+GPR40+Agonist&doi=10.1021%2Fml1000855"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1021%2Fml1000855&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml1000855%26sid%3Dliteratum%253Aachs%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DIto%26aufirst%3DM.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DHarada%26aufirst%3DA.%26aulast%3DTakeuchi%26aufirst%3DK.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DJ.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DOdani%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DFunami%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DKogame%26aufirst%3DA.%26aulast%3DMatsunaga%26aufirst%3DS.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520TAK-875%253A%2520A%2520Potent%252C%2520Selective%252C%2520and%2520Orally%2520Bioavailable%2520GPR40%2520Agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D290%26epage%3D294%26doi%3D10.1021%2Fml1000855" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Leifke, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naik, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Viswanathan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeManno, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kipnes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vakilynejad, M.</span><span> </span><span class="NLM_article-title">A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects with Type 2 Diabetes</span> <span class="citation_source-journal">Clin. Pharmacol. Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">92</span><span class="NLM_x">, </span> <span class="NLM_fpage">29</span><span class="NLM_x">â</span> <span class="NLM_lpage">39</span><span class="refDoi">Â DOI: 10.1038/clpt.2012.43</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1038%2Fclpt.2012.43" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22669289" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XptVGmur4%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=92&publication_year=2012&pages=29-39&author=E.+Leifkeauthor=H.+Naikauthor=J.+Wuauthor=P.+Viswanathanauthor=D.+DeMannoauthor=M.+Kipnesauthor=M.+Vakilynejad&title=A+Multiple-Ascending-Dose+Study+to+Evaluate+Safety%2C+Pharmacokinetics%2C+and+Pharmacodynamics+of+a+Novel+GPR40+Agonist%2C+TAK-875%2C+in+Subjects+with+Type+2+Diabetes&doi=10.1038%2Fclpt.2012.43"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">A Multiple-Ascending-Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of a Novel GPR40 Agonist, TAK-875, in Subjects With Type 2 Diabetes</span></div><div class="casAuthors">Leifke, E.; Naik, H.; Wu, J.; Viswanathan, P.; DeManno, D.; Kipnes, M.; Vakilynejad, M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Pharmacology & Therapeutics (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">92</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">29-39</span>CODEN:
                <span class="NLM_cas:coden">CLPTAT</span>;
        ISSN:<span class="NLM_cas:issn">0009-9236</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">G-protein-coupled receptor 40 (GPR40), highly expressed in pancreatic Î²-cells, mediates free fatty acid (FFA)-induced insulin secretion.  This phase I, double-blind, randomized study investigated the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel, glucose-lowering GPR40 agonist, TAK-875 (q.d., orally Ã 14 days), in type 2 diabetics (placebo, n = 14; at 25, 50, 100, 200, or 400 mg, n = 45).  Approx. dose-proportional increases in AUC0-24 and Cmax occurred.  TAK-875 showed good tolerability with no dose-limiting side effects.  Two subjects (on TAK-875) had mild hypoglycemia, probably related to prolonged fasting after oral glucose tolerance tests (OGTTs).  TAK-875 showed redns. from baseline in fasting (2 to -93 mg/dL) and post-OGTT glucose (26 to -172 mg/dL), with an apparent dose-dependent increase in post-OGTT C-peptide over 14 days.  Consistent with preclin. data, TAK-875 apparently acts as a glucose-dependent insulinotropic agent with low hypoglycemic risk.  Its PK is suitable for once-daily oral administration.  Clin. Pharmacol. & Therapeutics (2012); 92 1, 29-39. doi:10.1038/clpt.2012.43.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJYd5s3KIC27Vg90H21EOLACvtfcHk0liGaFo3LGscZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XptVGmur4%253D&md5=ba8cb45d0ad71c894a6942731ec0f9bc</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fclpt.2012.43&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fclpt.2012.43%26sid%3Dliteratum%253Aachs%26aulast%3DLeifke%26aufirst%3DE.%26aulast%3DNaik%26aufirst%3DH.%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DViswanathan%26aufirst%3DP.%26aulast%3DDeManno%26aufirst%3DD.%26aulast%3DKipnes%26aufirst%3DM.%26aulast%3DVakilynejad%26aufirst%3DM.%26atitle%3DA%2520Multiple-Ascending-Dose%2520Study%2520to%2520Evaluate%2520Safety%252C%2520Pharmacokinetics%252C%2520and%2520Pharmacodynamics%2520of%2520a%2520Novel%2520GPR40%2520Agonist%252C%2520TAK-875%252C%2520in%2520Subjects%2520with%2520Type%25202%2520Diabetes%26jtitle%3DClin.%2520Pharmacol.%2520Ther.%26date%3D2012%26volume%3D92%26spage%3D29%26epage%3D39%26doi%3D10.1038%2Fclpt.2012.43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span>Takeda Announces Termination of Fasiglifam (TAK-875) Development. <a href="http://www.takeda.com/news/2013/20131227_6117.html" class="extLink">http://www.takeda.com/news/2013/20131227_6117.html</a> (accessed Dec 27,<span class="NLM_x"> </span><span class="NLM_year">2013</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Takeda+Announces+Termination+of+Fasiglifam+%28TAK-875%29+Development.+http%3A%2F%2Fwww.takeda.com%2Fnews%2F2013%2F20131227_6117.html+%28accessed+Dec+27%2C+2013%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Mancini, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poitout, V.</span><span> </span><span class="NLM_article-title">GPR40 Agonists for the Treatment of Type 2 Diabetes: Life After âTAKingâ a Hit</span> <span class="citation_source-journal">Diabetes, Obes. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">622</span><span class="NLM_x">â</span> <span class="NLM_lpage">629</span><span class="refDoi">Â DOI: 10.1111/dom.12442</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1111%2Fdom.12442" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=25604916" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVOnurzK" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2015&pages=622-629&author=A.+D.+Manciniauthor=V.+Poitout&title=GPR40+Agonists+for+the+Treatment+of+Type+2+Diabetes%3A+Life+After+%E2%80%98TAKing%E2%80%99+a+Hit&doi=10.1111%2Fdom.12442"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit</span></div><div class="casAuthors">Mancini, A. D.; Poitout, V.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes, Obesity and Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">622-629</span>CODEN:
                <span class="NLM_cas:coden">DOMEF6</span>;
        ISSN:<span class="NLM_cas:issn">1462-8902</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">The free fatty acid receptor GPR40 has been proposed as a potential target for type 2 diabetes (T2D) pharmacotherapy.  This idea has been validated in both preclin. and clin. studies, in which activation of GPR40 was shown to improve glycemic control by stimulating glucose-dependent insulin secretion; however, the recent termination of phase III clin. trials using the GPR40 agonist TAK-875 (fasiglifam) has raised important questions regarding the long-term safety and viability of targeting GPR40 and, more specifically, about our understanding of this receptor's basic biol.  In the present review, we provide a summary of established and novel concepts related to GPR40's pharmacobiol. and discuss the current status and future outlook for GPR40-based drug development for the treatment of T2D.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGroqi3di5RzzrVg90H21EOLACvtfcHk0liGaFo3LGscZg"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVOnurzK&md5=223c353aaa30bd0621fd1d5d50bf68df</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1111%2Fdom.12442&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fdom.12442%26sid%3Dliteratum%253Aachs%26aulast%3DMancini%26aufirst%3DA.%2BD.%26aulast%3DPoitout%26aufirst%3DV.%26atitle%3DGPR40%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%253A%2520Life%2520After%2520%25E2%2580%2598TAKing%25E2%2580%2599%2520a%2520Hit%26jtitle%3DDiabetes%252C%2520Obes.%2520Metab.%26date%3D2015%26volume%3D17%26spage%3D622%26epage%3D629%26doi%3D10.1111%2Fdom.12442" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Lin, D. C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, X. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Birdsall, N. J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span> </span><span class="NLM_article-title">Identification and Pharmacological Characterization of Multiple Allosteric Binding Sites on the Free Fatty Acid 1 Receptor</span> <span class="citation_source-journal">Mol. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">82</span><span class="NLM_x">, </span> <span class="NLM_fpage">843</span><span class="NLM_x">â</span> <span class="NLM_lpage">859</span><span class="refDoi">Â DOI: 10.1124/mol.112.079640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1124%2Fmol.112.079640" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22859723" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=82&publication_year=2012&pages=843-859&author=D.+C.-H.+Linauthor=Q.+Guoauthor=J.+Luoauthor=J.+Zhangauthor=K.+Nguyenauthor=M.+Chenauthor=T.+Tranauthor=P.+J.+Dransfieldauthor=S.+P.+Brownauthor=J.+Houzeauthor=M.+Vimolratanaauthor=X.+Y.+Jiaoauthor=Y.+Wangauthor=N.+J.+M.+Birdsallauthor=G.+Swaminath&title=Identification+and+Pharmacological+Characterization+of+Multiple+Allosteric+Binding+Sites+on+the+Free+Fatty+Acid+1+Receptor&doi=10.1124%2Fmol.112.079640"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor</span></div><div class="casAuthors">Lin, Daniel C.-H.; Guo, Qi; Luo, Jian; Zhang, Jane; Nguyen, Kathy; Chen, Michael; Tran, Thanh; Dransfield, Paul J.; Brown, Sean P.; Houze, Jonathan; Vimolratana, Marc; Jiao, Xian Yun; Wang, Yingcai; Birdsall, Nigel J. M.; Swaminath, Gayathri</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">82</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">843-859</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Activation of FFA1 (GPR40), a member of G protein-coupling receptor family A, is mediated by medium- and long-chain fatty acids and leads to amplification of glucose-stimulated insulin secretion, suggesting a potential role for free fatty acid 1 (FFA1) as a target for type 2 diabetes.  It was assumed previously that there is a single binding site for fatty acids and synthetic FFA1 agonists.  However, using members of two chem. series of partial and full agonists that have been identified, radioligand binding interaction studies revealed that the full agonists do not bind to the same site as the partial agonists but exhibit pos. heterotropic cooperativity.  Anal. of functional data reveals pos. functional cooperativity between the full agonists and partial agonists in various functional assays (in vitro and ex vivo) and also in vivo.  Furthermore, the endogenous fatty acid docosahexaenoic acid (DHA) shows neg. or neutral cooperativity with members of both series of agonists in binding assays but displays pos. cooperativity in functional assays.  Another synthetic agonist is allosteric with members of both agonist series, but apparently competitive with DHA.  Therefore, there appear to be three allosterically linked binding sites on FFA1 with agonists specific for each of these sites.  Activation of free fatty acid 1 receptor (FFAR1) by each of these agonists is differentially affected by mutations of two arginine residues, previously found to be important for FFAR1 binding and activation.  These ligands with their high potencies and strong pos. functional cooperativity with endogenous fatty acids, demonstrated in vitro and in vivo, have the potential to deliver therapeutic benefits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoH-mJkDwpnmbVg90H21EOLACvtfcHk0ljcMcz86XdckA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKktLvE&md5=2437a31476d8c7d7b4fb06972e1f43d6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1124%2Fmol.112.079640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.112.079640%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DD.%2BC.-H.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DHouze%26aufirst%3DJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%2BY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DBirdsall%26aufirst%3DN.%2BJ.%2BM.%26aulast%3DSwaminath%26aufirst%3DG.%26atitle%3DIdentification%2520and%2520Pharmacological%2520Characterization%2520of%2520Multiple%2520Allosteric%2520Binding%2520Sites%2520on%2520the%2520Free%2520Fatty%2520Acid%25201%2520Receptor%26jtitle%3DMol.%2520Pharmacol.%26date%3D2012%26volume%3D82%26spage%3D843%26epage%3D859%26doi%3D10.1124%2Fmol.112.079640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toteva, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shan, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span> </span><span class="NLM_article-title">A Potent Class of GPR40 Full Agonists Engages the EnteroInsular Axis to Promote Glucose Control in Rodents</span> <span class="citation_source-journal">PLoS One</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">e46300</span><span class="refDoi">Â DOI: 10.1371/journal.pone.0046300</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1371%2Fjournal.pone.0046300" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=23056280" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFKjtb%252FN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2012&pages=e46300&author=J.+Luoauthor=G.+Swaminathauthor=S.+P.+Brownauthor=J.+Zhangauthor=Q.+Guoauthor=M.+Chenauthor=K.+Nguyenauthor=T.+Tranauthor=L.+Miaoauthor=P.+J.+Dransfieldauthor=M.+Vimolratanaauthor=J.+B.+Houzeauthor=S.+Wongauthor=M.+Totevaauthor=B.+Shanauthor=F.+Liauthor=R.+Zhuangauthor=D.+C.+H.+Lin&title=A+Potent+Class+of+GPR40+Full+Agonists+Engages+the+EnteroInsular+Axis+to+Promote+Glucose+Control+in+Rodents&doi=10.1371%2Fjournal.pone.0046300"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents</span></div><div class="casAuthors">Luo, Jian; Swaminath, Gayathri; Brown, Sean P.; Zhang, Jane; Guo, Qi; Chen, Michael; Nguyen, Kathy; Tran, Thanhvien; Miao, Lynn; Dransfield, Paul J.; Vimolratana, Marc; Houze, Jonathan B.; Wong, Simon; Toteva, Maria; Shan, Bei; Li, Frank; Zhuang, Run; Lin, Daniel C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">PLoS One</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">e46300</span>CODEN:
                <span class="NLM_cas:coden">POLNCL</span>;
        ISSN:<span class="NLM_cas:issn">1932-6203</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Type 2 diabetes is characterized by impaired glucose homeostasis due to defects in insulin secretion, insulin resistance and the incretin response.  GPR40 (FFAR1 or FFA1) is a G-protein-coupled receptor (GPCR), primarily expressed in insulin-producing pancreatic Î²-cells and incretin-producing enteroendocrine cells of the small intestine.  Several GPR40 agonists, including AMG 837 and TAK-875, have been disclosed, but no GPR40 synthetic agonists have been reported that engage both the insulinogenic and incretinogenic axes.  In this report we provide a mol. explanation and describe the discovery of a unique and potent class of GPR40 full agonists that engages the enteroinsular axis to promote dramatic improvement in glucose control in rodents.  GPR40 full agonists AM-1638 and AM-6226 stimulate GLP-1 and GIP secretion from intestinal enteroendocrine cells and increase GSIS from pancreatic islets, leading to enhanced glucose control in the high fat fed, streptozotocin treated and NONcNZO10/LtJ mouse models of type 2 diabetes.  The improvement in hyperglycemia by AM-1638 was reduced in the presence of the GLP-1 receptor antagonist Ex(9-39)NH2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtvpODI2wMLVg90H21EOLACvtfcHk0ljcMcz86XdckA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFKjtb%252FN&md5=7f500c96809b644b3f3ba440564f90da</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pone.0046300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pone.0046300%26sid%3Dliteratum%253Aachs%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DToteva%26aufirst%3DM.%26aulast%3DShan%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26atitle%3DA%2520Potent%2520Class%2520of%2520GPR40%2520Full%2520Agonists%2520Engages%2520the%2520EnteroInsular%2520Axis%2520to%2520Promote%2520Glucose%2520Control%2520in%2520Rodents%26jtitle%3DPLoS%2520One%26date%3D2012%26volume%3D7%26spage%3De46300%26doi%3D10.1371%2Fjournal.pone.0046300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Bodmer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">KrÃ¤henbÃ¼hl, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jick, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meier, C. R.</span><span> </span><span class="NLM_article-title">Metformin, Sulfonylureas, or Other Antidiabetes Drugs and the Risk of Lactic Acidosis or Hypoglycemia: A Nested Case-Control Analysis</span> <span class="citation_source-journal">Diabetes Care</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">2086</span><span class="NLM_x">â</span> <span class="NLM_lpage">2091</span><span class="refDoi">Â DOI: 10.2337/dc08-1171</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.2337%2Fdc08-1171" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=18782901" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLzL" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2008&pages=2086-2091&author=M.+Bodmerauthor=C.+Meierauthor=S.+Kr%C3%A4henb%C3%BChlauthor=S.+S.+Jickauthor=C.+R.+Meier&title=Metformin%2C+Sulfonylureas%2C+or+Other+Antidiabetes+Drugs+and+the+Risk+of+Lactic+Acidosis+or+Hypoglycemia%3A+A+Nested+Case-Control+Analysis&doi=10.2337%2Fdc08-1171"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis</span></div><div class="casAuthors">Bodmer, Michael; Meier, Christian; Krahenbuhl, Stephan; Jick, Susan S.; Meier, Christoph R.</div><div class="citationInfo"><span class="NLM_cas:title">Diabetes Care</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2086-2091</span>CODEN:
                <span class="NLM_cas:coden">DICAD2</span>;
        ISSN:<span class="NLM_cas:issn">0149-5992</span>.
    
            (<span class="NLM_cas:orgname">American Diabetes Association, Inc.</span>)
        </div><div class="casAbstract">Lactic acidosis has been assocd. with use of metformin.  Hypoglycemia is a major concern using sulfonylureas.  The aim of this study was to compare the risk of lactic acidosis and hypoglycemia among patients with type 2 diabetes using oral antidiabetes drugs.  This study is a nested case-control anal. using the U.K.-based General Practice Research Database to identify patients with type 2 diabetes who used oral antidiabetes drugs.  Within the study population, all incident cases of lactic acidosis and hypoglycemia were identified, and hypoglycemia case subjects were matched to up to four control patients based on age, sex, practice, and calendar time.  - Among the study population of 50,048 type 2 diabetic subjects, six cases of lactic acidosis during current use of oral antidiabetes drugs were identified, yielding a crude incidence rate of 3.3 cases per 100,000 person-years among metformin users and 4.8 cases per 100,000 person-years among users of sulfonylureas.  Relevant comorbidities known as risk factors for lactic acidosis could be identified in all case subjects.  A total of 2025 case subjects with hypoglycemia and 7278 matched control subjects were identified.  Use of sulfonylureas was assocd. with a materially elevated risk of hypoglycemia.  The adjusted odds ratio for current use of sulfonylureas was 2.79 (95% CI 2.23-3.50) compared with current metformin use.  Lactic acidosis during current use of oral antidiabetes drugs was very rare and was assocd. with concurrent comorbidity.  Hypoglycemic episodes were substantially more common among sulfonylurea users than among users of metformin.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpuiCyJ59PPibVg90H21EOLACvtfcHk0ljcMcz86XdckA"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsVeqsLzL&md5=dfe11decd59a50c0b021380fd77e8941</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.2337%2Fdc08-1171&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdc08-1171%26sid%3Dliteratum%253Aachs%26aulast%3DBodmer%26aufirst%3DM.%26aulast%3DMeier%26aufirst%3DC.%26aulast%3DKr%25C3%25A4henb%25C3%25BChl%26aufirst%3DS.%26aulast%3DJick%26aufirst%3DS.%2BS.%26aulast%3DMeier%26aufirst%3DC.%2BR.%26atitle%3DMetformin%252C%2520Sulfonylureas%252C%2520or%2520Other%2520Antidiabetes%2520Drugs%2520and%2520the%2520Risk%2520of%2520Lactic%2520Acidosis%2520or%2520Hypoglycemia%253A%2520A%2520Nested%2520Case-Control%2520Analysis%26jtitle%3DDiabetes%2520Care%26date%3D2008%26volume%3D31%26spage%3D2086%26epage%3D2091%26doi%3D10.2337%2Fdc08-1171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">AhrÃ©n, B.</span><span> </span><span class="NLM_article-title">GLP-1-Based Therapy of Type 2 Diabetes: GLP-1 Mimetics and DPP-IV Inhibitors</span> <span class="citation_source-journal">Curr. Diabetes Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">340</span><span class="NLM_x">â</span> <span class="NLM_lpage">347</span><span class="refDoi">Â DOI: 10.1007/s11892-007-0056-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1007%2Fs11892-007-0056-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=18173966" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhvFShtw%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=340-347&author=B.+Ahr%C3%A9n&title=GLP-1-Based+Therapy+of+Type+2+Diabetes%3A+GLP-1+Mimetics+and+DPP-IV+Inhibitors&doi=10.1007%2Fs11892-007-0056-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">GLP-1-based therapy of type 2 diabetes: GLP-1 mimetics and DPP-IV inhibitors</span></div><div class="casAuthors">Ahren, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Current Diabetes Reports</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">340-347</span>CODEN:
                <span class="NLM_cas:coden">CDRUAK</span>;
        ISSN:<span class="NLM_cas:issn">1534-4827</span>.
    
            (<span class="NLM_cas:orgname">Current Medicine Group LLC</span>)
        </div><div class="casAbstract">A review.  Glucagon-like peptide-1 (GLP-1)-based therapy is a novel treatment for type 2 diabetes.  It is executed either by GLP-1 mimetics or by dipeptidyl peptidase-IV inhibitors.  In type 2 diabetes, the two strategies reduce Hb A1c by 0.6% to 1.1% from baseline levels of 7.7% to 8.5%.  They are efficient both in monotherapy and in combination with metformin or thiazolidinediones.  Both treatments are well tolerated with low risk of hypoglycemia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsNMAnSNTTvLVg90H21EOLACvtfcHk0ljhnQ2Huefl5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhvFShtw%253D%253D&md5=bf777156385d9785e46b4afc0dafe993</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11892-007-0056-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11892-007-0056-9%26sid%3Dliteratum%253Aachs%26aulast%3DAhr%25C3%25A9n%26aufirst%3DB.%26atitle%3DGLP-1-Based%2520Therapy%2520of%2520Type%25202%2520Diabetes%253A%2520GLP-1%2520Mimetics%2520and%2520DPP-IV%2520Inhibitors%26jtitle%3DCurr.%2520Diabetes%2520Rep.%26date%3D2007%26volume%3D7%26spage%3D340%26epage%3D347%26doi%3D10.1007%2Fs11892-007-0056-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Pais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gribble, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reimann, F.</span><span> </span><span class="NLM_article-title">Stimulation of Incretin Secreting Cells</span> <span class="citation_source-journal">Ther. Adv. Endocrinol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2016</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">24</span><span class="NLM_x">â</span> <span class="NLM_lpage">42</span><span class="refDoi">Â DOI: 10.1177/2042018815618177</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1177%2F2042018815618177" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=26885360" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A280%3ADC%252BC28jhslaltg%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=24-42&author=R.+Paisauthor=F.+M.+Gribbleauthor=F.+Reimann&title=Stimulation+of+Incretin+Secreting+Cells&doi=10.1177%2F2042018815618177"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of incretin secreting cells</span></div><div class="casAuthors">Pais Ramona; Gribble Fiona M; Reimann Frank</div><div class="citationInfo"><span class="NLM_cas:title">Therapeutic advances in endocrinology and metabolism</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">24-42</span>
        ISSN:<span class="NLM_cas:issn">2042-0188</span>.
    </div><div class="casAbstract">The incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon like peptide-1 (GLP-1) are secreted from enteroendocrine cells in the gut and regulate physiological and homeostatic functions related to glucose control, metabolism and food intake.  This review provides a systematic summary of the molecular mechanisms underlying secretion from incretin cells, and an understanding of how they sense and interact with lumen and vascular factors and the enteric nervous system through transporters and G-protein coupled receptors (GPCRs) present on their surface to ultimately culminate in hormone release.  Some of the molecules described below such as sodium coupled glucose transporter 1 (SGLT1), G-protein coupled receptor (GPR) 119 and GPR40 are targets of novel therapeutics designed to enhance endogenous gut hormone release.  Synthetic ligands at these receptors aimed at treating obesity and type 2 diabetes are currently under investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRdC2ThtY1Qy86Js-BCLiifW6udTcc2eY1TzTkq4E2Mrntkvexoksv"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28jhslaltg%253D%253D&md5=80f26d4b71d3d6bfedf2c03ab4df9050</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1177%2F2042018815618177&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2042018815618177%26sid%3Dliteratum%253Aachs%26aulast%3DPais%26aufirst%3DR.%26aulast%3DGribble%26aufirst%3DF.%2BM.%26aulast%3DReimann%26aufirst%3DF.%26atitle%3DStimulation%2520of%2520Incretin%2520Secreting%2520Cells%26jtitle%3DTher.%2520Adv.%2520Endocrinol.%2520Metab.%26date%3D2016%26volume%3D7%26spage%3D24%26epage%3D42%26doi%3D10.1177%2F2042018815618177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J. B.</span><span> </span><span class="NLM_article-title">Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">726</span><span class="NLM_x">â</span> <span class="NLM_lpage">730</span><span class="refDoi">Â DOI: 10.1021/ml300133f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300133f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=726-730&author=S.+P.+Brownauthor=P.+J.+Dransfieldauthor=M.+Vimolratanaauthor=X.+Jiaoauthor=L.+Zhuauthor=V.+Pattaropongauthor=Y.+Sunauthor=J.+Liuauthor=J.+Luoauthor=J.+Zhangauthor=S.+Wongauthor=R.+Zhuangauthor=Q.+Guoauthor=F.+Liauthor=J.+C.+Medinaauthor=G.+Swaminathauthor=D.+C.+H.+Linauthor=J.+B.+Houze&title=Discovery+of+AM-1638%3A+A+Potent+and+Orally+Bioavailable+GPR40%2FFFA1+Full+Agonist&doi=10.1021%2Fml300133f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist</span></div><div class="casAuthors">Brown, Sean P.; Dransfield, Paul J.; Vimolratana, Marc; Jiao, XianYun; Zhu, Liusheng; Pattaropong, Vatee; Sun, Ying; Liu, Jinqian; Luo, Jian; Zhang, Jane; Wong, Simon; Zhuang, Run; Guo, Qi; Li, Frank; Medina, Julio C.; Swaminath, Gayathri; Lin, Daniel C.-H.; Houze, Jonathan B.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">726-730</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">GPR40 (FFA1) is a G-protein-coupled receptor, primarily expressed in pancreatic islets, the activation of which elicits increased insulin secretion only in the presence of elevated glucose levels.  A potent, orally bioavailable small mol. GPR40 agonist is hypothesized to be an effective antidiabetic posing little or no risk of hypoglycemia.  The authors recently reported the discovery of AMG 837 (I), a potent partial agonist of GPR40.  Herein, they present the optimization from the GPR40 partial agonist I to the structurally and pharmacol. distinct GPR40 full agonist AM-1638 (II).  Moreover, they demonstrate the improved in vivo efficacy that GPR40 full agonist II exhibits in BDF/DIO mice as compared to partial agonist I.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGooInVzD6ZYdrVg90H21EOLACvtfcHk0ljhnQ2Huefl5A"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Slsr%252FI&md5=d2abd60e8e86d96b0d0683b0401b62c8</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fml300133f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300133f%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26atitle%3DDiscovery%2520of%2520AM-1638%253A%2520A%2520Potent%2520and%2520Orally%2520Bioavailable%2520GPR40%252FFFA1%2520Full%2520Agonist%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D726%26epage%3D730%26doi%3D10.1021%2Fml300133f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Walsh, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Severino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">He, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, G.-B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">3-Substituted 3-(4-Aryloxyaryl)-Propanoic Acids as GPR40 Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">3390</span><span class="NLM_x">â</span> <span class="NLM_lpage">3394</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.03.114</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.bmcl.2011.03.114" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=3390-3394&author=S.+P.+Walshauthor=A.+Severinoauthor=C.+Zhouauthor=J.+Heauthor=G.-B.+Liangauthor=C.+P.+Tanauthor=J.+Caoauthor=G.+J.+Eiermannauthor=L.+Xuauthor=G.+Salituroauthor=A.+D.+Howardauthor=S.+G.+Millsauthor=L.+Yang&title=3-Substituted+3-%284-Aryloxyaryl%29-Propanoic+Acids+as+GPR40+Agonists&doi=10.1016%2Fj.bmcl.2011.03.114"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.03.114&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.03.114%26sid%3Dliteratum%253Aachs%26aulast%3DWalsh%26aufirst%3DS.%2BP.%26aulast%3DSeverino%26aufirst%3DA.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DHe%26aufirst%3DJ.%26aulast%3DLiang%26aufirst%3DG.-B.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DXu%26aufirst%3DL.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3D3-Substituted%25203-%25284-Aryloxyaryl%2529-Propanoic%2520Acids%2520as%2520GPR40%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D3390%26epage%3D3394%26doi%3D10.1016%2Fj.bmcl.2011.03.114" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Houze, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akerman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qiu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmitt, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reagan, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tonn, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, J. Y.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lopez, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shuttleworth, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span> </span><span class="NLM_article-title">AMG 837: A Potent, Orally Bioavailable GPR40 Agonist</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1267</span><span class="NLM_x">â</span> <span class="NLM_lpage">1270</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2011.10.118</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.bmcl.2011.10.118" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22217876" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1267-1270&author=J.+B.+Houzeauthor=L.+Zhuauthor=Y.+Sunauthor=M.+Akermanauthor=W.+Qiuauthor=A.+J.+Zhangauthor=R.+Sharmaauthor=M.+Schmittauthor=Y.+Wangauthor=J.+Liuauthor=J.+Liuauthor=J.+C.+Medinaauthor=J.+D.+Reaganauthor=J.+Luoauthor=G.+Tonnauthor=J.+Zhangauthor=J.+Y.-L.+Luauthor=M.+Chenauthor=E.+Lopezauthor=K.+Nguyenauthor=L.+Yangauthor=L.+Tangauthor=H.+Tianauthor=S.+J.+Shuttleworthauthor=D.+C.+H.+Lin&title=AMG+837%3A+A+Potent%2C+Orally+Bioavailable+GPR40+Agonist&doi=10.1016%2Fj.bmcl.2011.10.118"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">AMG 837: A potent, orally bioavailable GPR40 agonist</span></div><div class="casAuthors">Houze, Jonathan B.; Zhu, Liusheng; Sun, Ying; Akerman, Michelle; Qiu, Wei; Zhang, Alex J.; Sharma, Rajiv; Schmitt, Michael; Wang, Yingcai; Liu, Jiwen; Liu, Jinqian; Medina, Julio C.; Reagan, Jeff D.; Luo, Jian; Tonn, George; Zhang, Jane; Lu, Jenny Ying-Lin; Chen, Michael; Lopez, Edwin; Nguyen, Kathy; Yang, Li; Tang, Liang; Tian, Hui; Shuttleworth, Steven J.; Lin, Daniel C.-H.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">1267-1270</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The discovery that certain long chain fatty acids potentiate glucose stimulated insulin secretion through the previously orphan receptor GPR40 sparked interest in GPR40 agonists as potential antidiabetic agents.  Optimization of a series of Î²-substituted phenylpropanoic acids led to the identification of (S)-3-(4-((4'-(trifluoromethyl)biphenyl-3-yl)methoxy)phenyl)hex-4-ynoic acid (AMG 837) as a potent GPR40 agonist with a superior pharmacokinetic profile and robust glucose-dependent stimulation of insulin secretion in rodents.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMJp4-u_YDyLVg90H21EOLACvtfcHk0liFr85U3_u7zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFarug%253D%253D&md5=7e7d38679794abb7244d5a64d6f5ecd7</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2011.10.118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2011.10.118%26sid%3Dliteratum%253Aachs%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DAkerman%26aufirst%3DM.%26aulast%3DQiu%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DA.%2BJ.%26aulast%3DSharma%26aufirst%3DR.%26aulast%3DSchmitt%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26aulast%3DReagan%26aufirst%3DJ.%2BD.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DTonn%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DJ.%2BY.-L.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLopez%26aufirst%3DE.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DH.%26aulast%3DShuttleworth%26aufirst%3DS.%2BJ.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26atitle%3DAMG%2520837%253A%2520A%2520Potent%252C%2520Orally%2520Bioavailable%2520GPR40%2520Agonist%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1267%26epage%3D1270%26doi%3D10.1016%2Fj.bmcl.2011.10.118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cline, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiermann, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petrov, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salituro, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meinke, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mosley, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akiyama, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Einstein, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thornberry, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, L.</span><span> </span><span class="NLM_article-title">Discovery of 5-Aryloxy-2,4-Thiazolidinediones as Potent GPR40 Agonists</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">â</span> <span class="NLM_lpage">1301</span><span class="refDoi">Â DOI: 10.1016/j.bmcl.2009.10.052</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.bmcl.2009.10.052" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=1298-1301&author=C.+Zhouauthor=C.+Tangauthor=E.+Changauthor=M.+Geauthor=S.+Linauthor=E.+Clineauthor=C.+P.+Tanauthor=Y.+Fengauthor=Y.-P.+Zhouauthor=G.+J.+Eiermannauthor=A.+Petrovauthor=G.+Salituroauthor=P.+Meinkeauthor=R.+Mosleyauthor=T.+E.+Akiyamaauthor=M.+Einsteinauthor=S.+Kumarauthor=J.+Bergerauthor=A.+D.+Howardauthor=N.+Thornberryauthor=S.+G.+Millsauthor=L.+Yang&title=Discovery+of+5-Aryloxy-2%2C4-Thiazolidinediones+as+Potent+GPR40+Agonists&doi=10.1016%2Fj.bmcl.2009.10.052"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.10.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.10.052%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DC.%26aulast%3DChang%26aufirst%3DE.%26aulast%3DGe%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DS.%26aulast%3DCline%26aufirst%3DE.%26aulast%3DTan%26aufirst%3DC.%2BP.%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.-P.%26aulast%3DEiermann%26aufirst%3DG.%2BJ.%26aulast%3DPetrov%26aufirst%3DA.%26aulast%3DSalituro%26aufirst%3DG.%26aulast%3DMeinke%26aufirst%3DP.%26aulast%3DMosley%26aufirst%3DR.%26aulast%3DAkiyama%26aufirst%3DT.%2BE.%26aulast%3DEinstein%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DS.%26aulast%3DBerger%26aufirst%3DJ.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DThornberry%26aufirst%3DN.%26aulast%3DMills%26aufirst%3DS.%2BG.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DDiscovery%2520of%25205-Aryloxy-2%252C4-Thiazolidinediones%2520as%2520Potent%2520GPR40%2520Agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D1298%26epage%3D1301%26doi%3D10.1016%2Fj.bmcl.2009.10.052" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">U.S. Department of Health and Human Services, Food and Drug Administration</span><span class="NLM_x">, </span> <span class="citation_source-book">Guidance for Industry, Diabetes Mellitus: Developing Drugs and Therapeutic Biologics for Treatment and Prevention</span>; <span class="NLM_publisher-name">Center for Drug Evaluation and Research (CDER)</span>: <span class="NLM_publisher-loc">Rockville, MD</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=U.S.+Department+of+Health+and+Human+Services%2C+Food+and+Drug+Administration&title=Guidance+for+Industry%2C+Diabetes+Mellitus%3A+Developing+Drugs+and+Therapeutic+Biologics+for+Treatment+and+Prevention"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3D%26btitle%3DGuidance%2520for%2520Industry%252C%2520Diabetes%2520Mellitus%253A%2520Developing%2520Drugs%2520and%2520Therapeutic%2520Biologics%2520for%2520Treatment%2520and%2520Prevention%26pub%3DCenter%2520for%2520Drug%2520Evaluation%2520and%2520Research%2520%2528CDER%2529%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Jiang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Job, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klapars, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchwald, S. L.</span><span> </span><span class="NLM_article-title">Copper-Catalyzed Coupling of Amides and Carbamates with Vinyl Halides</span> <span class="citation_source-journal">Org. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">3667</span><span class="NLM_x">â</span> <span class="NLM_lpage">3669</span><span class="refDoi">Â DOI: 10.1021/ol035355c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol035355c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1OnsLo%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2003&pages=3667-3669&author=L.+Jiangauthor=G.+E.+Jobauthor=A.+Klaparsauthor=S.+L.+Buchwald&title=Copper-Catalyzed+Coupling+of+Amides+and+Carbamates+with+Vinyl+Halides&doi=10.1021%2Fol035355c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-catalyzed coupling of amides and carbamates with vinyl halides</span></div><div class="casAuthors">Jiang, Lei; Job, Gabriel E.; Klapars, Artis; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3667-3669</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A general and efficient copper-catalyzed method for the amidation of vinyl bromides and iodides was developed.  This protocol uses a combination of 5 mol % copper iodide and 20 mol % N,N'-dimethyl ethylenediamine.  Substrates bearing ester, silyl ether, and amino groups were successfully coupled under the reaction conditions.  The double bond geometry of the vinyl halides was retained under the reaction conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkzwHM3lXNL7Vg90H21EOLACvtfcHk0liFr85U3_u7zw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1OnsLo%253D&md5=83985d31d5e9e4ab995932566a4ed9da</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fol035355c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol035355c%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DJob%26aufirst%3DG.%2BE.%26aulast%3DKlapars%26aufirst%3DA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DCopper-Catalyzed%2520Coupling%2520of%2520Amides%2520and%2520Carbamates%2520with%2520Vinyl%2520Halides%26jtitle%3DOrg.%2520Lett.%26date%3D2003%26volume%3D5%26spage%3D3667%26epage%3D3669%26doi%3D10.1021%2Fol035355c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Kenakin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span> </span><span class="NLM_article-title">Signalling Bias in New Drug Discovery: Detection, Quantification and Therapeutic Impact</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">205</span><span class="NLM_x">â</span> <span class="NLM_lpage">216</span><span class="refDoi">Â DOI: 10.1038/nrd3954</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1038%2Fnrd3954" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=23411724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=205-216&author=T.+Kenakinauthor=A.+Christopoulos&title=Signalling+Bias+in+New+Drug+Discovery%3A+Detection%2C+Quantification+and+Therapeutic+Impact&doi=10.1038%2Fnrd3954"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Signalling bias in new drug discovery: detection, quantification and therapeutic impact</span></div><div class="casAuthors">Kenakin, Terry; Christopoulos, Arthur</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">205-216</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Agonists of seven-transmembrane receptors, also known as G protein-coupled receptors (GPCRs), do not uniformly activate all cellular signalling pathways linked to a given seven-transmembrane receptor (a phenomenon termed ligand or agonist bias); this discovery has changed how high-throughput screens are designed and how lead compds. are optimized for therapeutic activity.  The ability to exptl. detect ligand bias has necessitated the development of methods for quantifying agonist bias in a way that can be used to guide structure-activity studies and the selection of drug candidates.  Here, we provide a viewpoint on which methods are appropriate for quantifying bias, based on knowledge of how cellular and intracellular signalling proteins control the conformation of seven-transmembrane receptors.  We also discuss possible predictions of how biased mols. may perform in vivo, and what potential therapeutic advantages they may provide.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkDNsO17tty7Vg90H21EOLACvtfcHk0lg3Si_7nghfbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wrt7c%253D&md5=712258b9158f753689e35fa31f1b67f0</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fnrd3954&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3954%26sid%3Dliteratum%253Aachs%26aulast%3DKenakin%26aufirst%3DT.%26aulast%3DChristopoulos%26aufirst%3DA.%26atitle%3DSignalling%2520Bias%2520in%2520New%2520Drug%2520Discovery%253A%2520Detection%252C%2520Quantification%2520and%2520Therapeutic%2520Impact%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D205%26epage%3D216%26doi%3D10.1038%2Fnrd3954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Christiansen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Due-Hansen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grundmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">SchrÃ¶der, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milligan, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cawthorne, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostenis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassack, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulven, T.</span><span> </span><span class="NLM_article-title">Free Fatty Acid Receptor 1 (FFA1/GPR40) Agonists: Mesylpropoxy Appendage Lowers Lipophilicity and Improves ADME Properties</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6624</span><span class="NLM_x">â</span> <span class="NLM_lpage">6628</span><span class="refDoi">Â DOI: 10.1021/jm3002026</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3002026" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6624-6628&author=E.+Christiansenauthor=M.+E.+Due-Hansenauthor=C.+Urbanauthor=M.+Grundmannauthor=R.+Schr%C3%B6derauthor=B.+D.+Hudsonauthor=G.+Milliganauthor=M.+A.+Cawthorneauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=T.+Ulven&title=Free+Fatty+Acid+Receptor+1+%28FFA1%2FGPR40%29+Agonists%3A+Mesylpropoxy+Appendage+Lowers+Lipophilicity+and+Improves+ADME+Properties&doi=10.1021%2Fjm3002026"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm3002026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3002026%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DGrundmann%26aufirst%3DM.%26aulast%3DSchr%25C3%25B6der%26aufirst%3DR.%26aulast%3DHudson%26aufirst%3DB.%2BD.%26aulast%3DMilligan%26aufirst%3DG.%26aulast%3DCawthorne%26aufirst%3DM.%2BA.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DFree%2520Fatty%2520Acid%2520Receptor%25201%2520%2528FFA1%252FGPR40%2529%2520Agonists%253A%2520Mesylpropoxy%2520Appendage%2520Lowers%2520Lipophilicity%2520and%2520Improves%2520ADME%2520Properties%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6624%26epage%3D6628%26doi%3D10.1021%2Fjm3002026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Christiansen, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Due-Hansen, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Urban, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merten, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pfleiderer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karlsen, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steensgaard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamacher, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Drewke, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petersen, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kristiansen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostenis, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kassack, M. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulven, T.</span><span> </span><span class="NLM_article-title">StructureâActivity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">345</span><span class="NLM_x">â</span> <span class="NLM_lpage">349</span><span class="refDoi">Â DOI: 10.1021/ml100106c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml100106c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=345-349&author=E.+Christiansenauthor=M.+E.+Due-Hansenauthor=C.+Urbanauthor=N.+Mertenauthor=M.+Pfleidererauthor=K.+K.+Karlsenauthor=S.+S.+Rasmussenauthor=M.+Steensgaardauthor=A.+Hamacherauthor=J.+Schmidtauthor=C.+Drewkeauthor=R.+K.+Petersenauthor=K.+Kristiansenauthor=S.+Ullrichauthor=E.+Kostenisauthor=M.+U.+Kassackauthor=T.+Ulven&title=Structure%E2%80%93Activity+Study+of+Dihydrocinnamic+Acids+and+Discovery+of+the+Potent+FFA1+%28GPR40%29+Agonist+TUG-469&doi=10.1021%2Fml100106c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469</span></div><div class="casAuthors">Christiansen, Elisabeth; Due-Hansen, Maria E.; Urban, Christian; Merten, Nicole; Pfleiderer, Michael; Karlsen, Kasper K.; Rasmussen, Sanne S.; Steensgaard, Mette; Hamacher, Alexandra; Schmidt, Johannes; Drewke, Christel; Petersen, Rasmus Koefoed; Kristiansen, Karsten; Ullrich, Susanne; Kostenis, Evi; Kassack, Matthias U.; Ulven, Trond</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">345-349</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The free fatty acid 1 receptor (FFA1 or GPR40), which is highly expressed on pancreatic Î²-cells and amplifies glucose-stimulated insulin secretion, has emerged as an attractive target for the treatment of type 2 diabetes.  Several FFA1 agonists contg. the para-substituted dihydrocinnamic acid moiety are known.  We here present a structure-activity relationship study of this compd. family suggesting that the central methyleneoxy linker is preferable for the smaller compds., whereas the central methyleneamine linker gives higher potency to the larger compds.  The study resulted in the discovery of the potent and selective full FFA1 agonist TUG-469 (I).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2Ue5bdjcoY7Vg90H21EOLACvtfcHk0lg3Si_7nghfbw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXosVWitb8%253D&md5=e3a7642f2fd42b1bc932fa9470cfb75c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fml100106c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml100106c%26sid%3Dliteratum%253Aachs%26aulast%3DChristiansen%26aufirst%3DE.%26aulast%3DDue-Hansen%26aufirst%3DM.%2BE.%26aulast%3DUrban%26aufirst%3DC.%26aulast%3DMerten%26aufirst%3DN.%26aulast%3DPfleiderer%26aufirst%3DM.%26aulast%3DKarlsen%26aufirst%3DK.%2BK.%26aulast%3DRasmussen%26aufirst%3DS.%2BS.%26aulast%3DSteensgaard%26aufirst%3DM.%26aulast%3DHamacher%26aufirst%3DA.%26aulast%3DSchmidt%26aufirst%3DJ.%26aulast%3DDrewke%26aufirst%3DC.%26aulast%3DPetersen%26aufirst%3DR.%2BK.%26aulast%3DKristiansen%26aufirst%3DK.%26aulast%3DUllrich%26aufirst%3DS.%26aulast%3DKostenis%26aufirst%3DE.%26aulast%3DKassack%26aufirst%3DM.%2BU.%26aulast%3DUlven%26aufirst%3DT.%26atitle%3DStructure%25E2%2580%2593Activity%2520Study%2520of%2520Dihydrocinnamic%2520Acids%2520and%2520Discovery%2520of%2520the%2520Potent%2520FFA1%2520%2528GPR40%2529%2520Agonist%2520TUG-469%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D1%26spage%3D345%26epage%3D349%26doi%3D10.1021%2Fml100106c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Mikami, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitamura, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Negoro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sasaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsujihata, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suzuki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazaki, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funami, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasuma, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Momose, Y.</span><span> </span><span class="NLM_article-title">Discovery of Phenylpropanoic Acid Derivatives Containing Polar Functionalities as Potent and Orally Bioavailable G Protein-Coupled Receptor 40 Agonists for the Treatment of Type 2 Diabetes</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">3756</span><span class="NLM_x">â</span> <span class="NLM_lpage">3776</span><span class="refDoi">Â DOI: 10.1021/jm2016123</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2016123" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=3756-3776&author=S.+Mikamiauthor=S.+Kitamuraauthor=N.+Negoroauthor=S.+Sasakiauthor=M.+Suzukiauthor=Y.+Tsujihataauthor=T.+Miyazakiauthor=R.+Itoauthor=N.+Suzukiauthor=J.+Miyazakiauthor=T.+Santouauthor=N.+Kanzakiauthor=M.+Funamiauthor=T.+Tanakaauthor=T.+Yasumaauthor=Y.+Momose&title=Discovery+of+Phenylpropanoic+Acid+Derivatives+Containing+Polar+Functionalities+as+Potent+and+Orally+Bioavailable+G+Protein-Coupled+Receptor+40+Agonists+for+the+Treatment+of+Type+2+Diabetes&doi=10.1021%2Fjm2016123"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm2016123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2016123%26sid%3Dliteratum%253Aachs%26aulast%3DMikami%26aufirst%3DS.%26aulast%3DKitamura%26aufirst%3DS.%26aulast%3DNegoro%26aufirst%3DN.%26aulast%3DSasaki%26aufirst%3DS.%26aulast%3DSuzuki%26aufirst%3DM.%26aulast%3DTsujihata%26aufirst%3DY.%26aulast%3DMiyazaki%26aufirst%3DT.%26aulast%3DIto%26aufirst%3DR.%26aulast%3DSuzuki%26aufirst%3DN.%26aulast%3DMiyazaki%26aufirst%3DJ.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DFunami%26aufirst%3DM.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DYasuma%26aufirst%3DT.%26aulast%3DMomose%26aufirst%3DY.%26atitle%3DDiscovery%2520of%2520Phenylpropanoic%2520Acid%2520Derivatives%2520Containing%2520Polar%2520Functionalities%2520as%2520Potent%2520and%2520Orally%2520Bioavailable%2520G%2520Protein-Coupled%2520Receptor%252040%2520Agonists%2520for%2520the%2520Treatment%2520of%2520Type%25202%2520Diabetes%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D3756%26epage%3D3776%26doi%3D10.1021%2Fjm2016123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dransfield, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Du, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiao, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, A.-r.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kasparian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vimolratana, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pattaropong, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houze, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swaminath, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhuang, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bartberger, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Correll, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chow, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medina, J. C.</span><span> </span><span class="NLM_article-title">Discovery and Optimization of Potent GPR40 Full Agonists Containing Tricyclic Spirocycles</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">551</span><span class="NLM_x">â</span> <span class="NLM_lpage">555</span><span class="refDoi">Â DOI: 10.1021/ml300427u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml300427u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=551-555&author=Y.+Wangauthor=J.+Liuauthor=P.+J.+Dransfieldauthor=L.+Zhuauthor=Z.+Wangauthor=X.+Duauthor=X.+Jiaoauthor=Y.+Suauthor=A.-r.+Liauthor=S.+P.+Brownauthor=A.+Kasparianauthor=M.+Vimolratanaauthor=M.+Yuauthor=V.+Pattaropongauthor=J.+B.+Houzeauthor=G.+Swaminathauthor=T.+Tranauthor=K.+Nguyenauthor=Q.+Guoauthor=J.+Zhangauthor=R.+Zhuangauthor=F.+Liauthor=L.+Miaoauthor=M.+D.+Bartbergerauthor=T.+L.+Correllauthor=D.+Chowauthor=S.+Wongauthor=J.+Luoauthor=D.+C.+H.+Linauthor=J.+C.+Medina&title=Discovery+and+Optimization+of+Potent+GPR40+Full+Agonists+Containing+Tricyclic+Spirocycles&doi=10.1021%2Fml300427u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Fml300427u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300427u%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DDransfield%26aufirst%3DP.%2BJ.%26aulast%3DZhu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DDu%26aufirst%3DX.%26aulast%3DJiao%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DA.-r.%26aulast%3DBrown%26aufirst%3DS.%2BP.%26aulast%3DKasparian%26aufirst%3DA.%26aulast%3DVimolratana%26aufirst%3DM.%26aulast%3DYu%26aufirst%3DM.%26aulast%3DPattaropong%26aufirst%3DV.%26aulast%3DHouze%26aufirst%3DJ.%2BB.%26aulast%3DSwaminath%26aufirst%3DG.%26aulast%3DTran%26aufirst%3DT.%26aulast%3DNguyen%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DQ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhuang%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DF.%26aulast%3DMiao%26aufirst%3DL.%26aulast%3DBartberger%26aufirst%3DM.%2BD.%26aulast%3DCorrell%26aufirst%3DT.%2BL.%26aulast%3DChow%26aufirst%3DD.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DD.%2BC.%2BH.%26aulast%3DMedina%26aufirst%3DJ.%2BC.%26atitle%3DDiscovery%2520and%2520Optimization%2520of%2520Potent%2520GPR40%2520Full%2520Agonists%2520Containing%2520Tricyclic%2520Spirocycles%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2013%26volume%3D4%26spage%3D551%26epage%3D555%26doi%3D10.1021%2Fml300427u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Qiu, X.-l.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qing, F.</span><span> </span><span class="NLM_article-title">-l. Practical Synthesis of Boc-Protected <i>cis</i>-4-Trifluoromethyl and <i>cis</i>-4-Difluoromethyl-<i>L</i>-Prolines</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">7162</span><span class="NLM_x">â</span> <span class="NLM_lpage">7164</span><span class="refDoi">Â DOI: 10.1021/jo0257400</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo0257400" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=7162-7164&author=X.-l.+Qiuauthor=F.+Qing&title=-l.+Practical+Synthesis+of+Boc-Protected+cis-4-Trifluoromethyl+and+cis-4-Difluoromethyl-L-Prolines&doi=10.1021%2Fjo0257400"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1021%2Fjo0257400&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo0257400%26sid%3Dliteratum%253Aachs%26aulast%3DQiu%26aufirst%3DX.-l.%26aulast%3DQing%26aufirst%3DF.%26atitle%3D-l.%2520Practical%2520Synthesis%2520of%2520Boc-Protected%2520cis-4-Trifluoromethyl%2520and%2520cis-4-Difluoromethyl-L-Prolines%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2002%26volume%3D67%26spage%3D7162%26epage%3D7164%26doi%3D10.1021%2Fjo0257400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Del Valle, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goodman, M.</span><span> </span><span class="NLM_article-title">Stereoselective Synthesis of Boc-Protected <i>cis</i> and <i>trans</i>-4-Trifluoromethylprolines by Asymmetric Hydrogenation Reactions</span> <span class="citation_source-journal">Angew. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">114</span><span class="NLM_x">, </span> <span class="NLM_fpage">1670</span><span class="NLM_x">â</span> <span class="NLM_lpage">1672</span><span class="refDoi">Â DOI: 10.1002/1521-3757(20020503)114:9<1670::AID-ANGE1670>3.0.CO;2-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=114&publication_year=2002&pages=1670-1672&author=J.+R.+Del+Valleauthor=M.+Goodman&title=Stereoselective+Synthesis+of+Boc-Protected+cis+and+trans-4-Trifluoromethylprolines+by+Asymmetric+Hydrogenation+Reactions&doi=10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F1521-3757%252820020503%2529114%253A9%253C1670%253A%253AAID-ANGE1670%253E3.0.CO%253B2-1%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BValle%26aufirst%3DJ.%2BR.%26aulast%3DGoodman%26aufirst%3DM.%26atitle%3DStereoselective%2520Synthesis%2520of%2520Boc-Protected%2520cis%2520and%2520trans-4-Trifluoromethylprolines%2520by%2520Asymmetric%2520Hydrogenation%2520Reactions%26jtitle%3DAngew.%2520Chem.%26date%3D2002%26volume%3D114%26spage%3D1670%26epage%3D1672%26doi%3D10.1002%2F1521-3757%2820020503%29114%3A9%3C1670%3A%3AAID-ANGE1670%3E3.0.CO%3B2-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Grant, S. G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seidman, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanahan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bautch, V. L.</span><span> </span><span class="NLM_article-title">Early Invasiveness Characterizes Metastatic Carcinoid Tumors in Transgenic Mice</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4917</span><span class="NLM_x">â</span> <span class="NLM_lpage">4923</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1991&pages=4917-4923&author=S.+G.+N.+Grantauthor=I.+Seidmanauthor=D.+Hanahanauthor=V.+L.+Bautch&title=Early+Invasiveness+Characterizes+Metastatic+Carcinoid+Tumors+in+Transgenic+Mice"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGrant%26aufirst%3DS.%2BG.%2BN.%26aulast%3DSeidman%26aufirst%3DI.%26aulast%3DHanahan%26aufirst%3DD.%26aulast%3DBautch%26aufirst%3DV.%2BL.%26atitle%3DEarly%2520Invasiveness%2520Characterizes%2520Metastatic%2520Carcinoid%2520Tumors%2520in%2520Transgenic%2520Mice%26jtitle%3DCancer%2520Res.%26date%3D1991%26volume%3D51%26spage%3D4917%26epage%3D4923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Rindi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grant, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yiangou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghatei, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bloom, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bautch, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solcia, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polak, J. M.</span><span> </span><span class="NLM_article-title">Development of Neuroendocrine Tumors in the Gastrointestinal Tract of Transgenic Mice. Heterogeneity of Hormone Expression</span> <span class="citation_source-journal">Am. J. Pathol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1990</span><span class="NLM_x">, </span> <span class="NLM_volume">136</span><span class="NLM_x">, </span> <span class="NLM_fpage">1349</span><span class="NLM_x">â</span> <span class="NLM_lpage">1363</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=2162628" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADyaK3MXktV2h" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=136&publication_year=1990&pages=1349-1363&author=G.+Rindiauthor=S.+G.+Grantauthor=Y.+Yiangouauthor=M.+A.+Ghateiauthor=S.+R.+Bloomauthor=V.+L.+Bautchauthor=E.+Solciaauthor=J.+M.+Polak&title=Development+of+Neuroendocrine+Tumors+in+the+Gastrointestinal+Tract+of+Transgenic+Mice.+Heterogeneity+of+Hormone+Expression"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Development of neuroendocrine tumors in the gastrointestinal tract of transgenic mice.  Heterogeneity of hormone expression</span></div><div class="casAuthors">Rindi, Guido; Grant, Seth G. N.; Yiangou, Yiangos; Ghatei, Mohammed A.; Bloom, Stephen R.; Bautch, Victoria L.; Solcia, Enrico; Polak, Julia M.</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">136</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1349-63</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    </div><div class="casAbstract">Expression of hormones in endocrine tumors and derived cell lines of transgenic mice carrying insulin-promoted oncogenes has been investigated by histochem., immunohistochem., ultrastructural, and radioimmunol. means.  Tumors of the pancreas, small intestine, mesentery, and liver were examd.  Insulin-immunoreactive cells were prevalent in pancreatic tumors, with a significant subpopulation of pancreatic polypeptide-immunoreactive elements.  Conventional ultrastructural and immunogold anal. identified insulin-storing Î²-granules in pancreatic tumor cells.  In contrast, the largest immunoreactive subpopulation of intestinal tumors expressed secretin (53% of total cells), followed by proglucagon-related peptides (15%), glucose-dependent insulinotropic polypeptide (7%), gastrin (7%), pancreatic polypeptide (2%), neurotensin (2%), and somatostatin (1%).  No detectable immunoreactivity for either insulin or serotonin was obsd.  Electron microscopy and immunogold labeling showed that intestinal tumor cells contained secretin-storing S-type granules.  Lymph node and liver tumors contained secretin-immunoreactive cells with ultrastructural features similar to those of intestinal tumors.  In addn., high levels of circulating insulinlike and secretinlike immnoreactants were detectable.  Analogous hormone profiles were identified in tumor cell lines and culture media.  Large T-antigen immunoreactivity was detected in all the nuclei of neoplastic cells, as well as in insulin-immunoreactive elements of non-neoplastic islets and pancreatic ducts and in some secretin-immunoreactive cells of small intestinal mucosa.  These data indicate that neuroendocrine tumors arise both in Î²-cell and S-cell subpopulations of transgenic mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp_sj64TWYwNrVg90H21EOLACvtfcHk0lhU5uvk3gaYxw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXktV2h&md5=097c4ad56e31d546c13b803dabe113c6</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRindi%26aufirst%3DG.%26aulast%3DGrant%26aufirst%3DS.%2BG.%26aulast%3DYiangou%26aufirst%3DY.%26aulast%3DGhatei%26aufirst%3DM.%2BA.%26aulast%3DBloom%26aufirst%3DS.%2BR.%26aulast%3DBautch%26aufirst%3DV.%2BL.%26aulast%3DSolcia%26aufirst%3DE.%26aulast%3DPolak%26aufirst%3DJ.%2BM.%26atitle%3DDevelopment%2520of%2520Neuroendocrine%2520Tumors%2520in%2520the%2520Gastrointestinal%2520Tract%2520of%2520Transgenic%2520Mice.%2520Heterogeneity%2520of%2520Hormone%2520Expression%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D1990%26volume%3D136%26spage%3D1349%26epage%3D1363" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Hauge, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vestmar, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Husted, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ekberg, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wright, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Salvo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinglass, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelstoft, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madsen, A. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LÃ¼ckmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trujillo, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frimurer, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holst, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Howard, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, T. W.</span><span> </span><span class="NLM_article-title">GPR40 (FFAR1) â Combined Gs and Gq Signaling in vitro is Associated with Robust Incretin Secretagogue Action ex vivo and in vivo</span> <span class="citation_source-journal">Mol. Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">3</span><span class="NLM_x">â</span> <span class="NLM_lpage">14</span><span class="refDoi">Â DOI: 10.1016/j.molmet.2014.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1016%2Fj.molmet.2014.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=25685685" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=3-14&author=M.+Haugeauthor=M.+A.+Vestmarauthor=A.+S.+Hustedauthor=J.+P.+Ekbergauthor=M.+J.+Wrightauthor=J.+Di+Salvoauthor=A.+B.+Weinglassauthor=M.+S.+Engelstoftauthor=A.+N.+Madsenauthor=M.+L%C3%BCckmannauthor=M.+W.+Millerauthor=M.+E.+Trujilloauthor=T.+M.+Frimurerauthor=B.+Holstauthor=A.+D.+Howardauthor=T.+W.+Schwartz&title=GPR40+%28FFAR1%29+%E2%80%93+Combined+Gs+and+Gq+Signaling+in+vitro+is+Associated+with+Robust+Incretin+Secretagogue+Action+ex+vivo+and+in+vivo&doi=10.1016%2Fj.molmet.2014.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">GPR40 (FFAR1) - Combined Gs and Gq signaling in vitro is associated with robust incretin secretagogue action ex vivo and in vivo</span></div><div class="casAuthors">Hauge, Maria; Vestmar, Marie A.; Husted, Anna S.; Ekberg, Jeppe P.; Wright, Michael J.; Di Salvo, Jerry; Weinglass, Adam B.; Engelstoft, Maja S.; Madsen, Andreas N.; Luckmann, Michael; Miller, Michael W.; Trujillo, Maria E.; Frimurer, Thomas M.; Holst, Birgitte; Howard, Andrew D.; Schwartz, Thue W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Metabolism</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">3-14</span>CODEN:
                <span class="NLM_cas:coden">MMOEAS</span>;
        ISSN:<span class="NLM_cas:issn">2212-8778</span>.
    
            (<span class="NLM_cas:orgname">Elsevier GmbH</span>)
        </div><div class="casAbstract">GPR40 (FFAR1), a clin. proven anti-diabetes target, is a Gq-coupled receptor for long chain fatty acids (LCFA) stimulating insulin secretion directly and mediating a major part of the dietary triglyceride-induced secretion of the incretins GLP-1 and GIP.  In phase-II studies the GPR40 agonist TAK-875 decreased blood glucose but surprisingly without stimulating incretins.  Here we find that GPR40 can signal through not only Gq and IP3 but also Gs and cAMP when stimulated with certain agonists such as AM-1638 and AM-5262 in contrast to the endogenous LCFA ligands and agonists such as TAK-875 and AM-837, which only signal through Gq.  In competition binding against [3H]AM-1638 and [3H]L358 the Gq + Gs and the Gq-only agonists either competed for or showed pos. cooperativity by increasing the binding of the two different radio-ligands, in opposite ways.  Nevertheless, both the Gq-only and the Gq + Gs agonists all docked surprisingly well into the binding site for TAK-875 in the X-ray structure of GPR40.  In murine intestinal primary cell-cultures the endogenous LCFAs and the Gq-only agonists stimulated GLP-1 secretion with rather poor efficacy as compared with the high efficacy Gq + Gs GPR40 agonists and a prototype GPR119 agonist.  Similarly, in fasting both male and female mice the Gq + Gs agonists showed significantly higher efficacy than the Gq-only agonists in respect of increasing plasma GLP-1 and plasma GIP in a GPR40-dependent manner.  It is concluded that stimulation of GPR40 by endogenous LCFAs or by Gq-only synthetic agonists result in a rather limited incretin response, whereas Gq + Gs GPR40 agonists stimulate incretin secretion robustly.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZyjcjTNd0QbVg90H21EOLACvtfcHk0ljw1KbXcILpYQ"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVCku7bN&md5=895136bef8c9542711e6daf5fa57219c</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.molmet.2014.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molmet.2014.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DHauge%26aufirst%3DM.%26aulast%3DVestmar%26aufirst%3DM.%2BA.%26aulast%3DHusted%26aufirst%3DA.%2BS.%26aulast%3DEkberg%26aufirst%3DJ.%2BP.%26aulast%3DWright%26aufirst%3DM.%2BJ.%26aulast%3DDi%2BSalvo%26aufirst%3DJ.%26aulast%3DWeinglass%26aufirst%3DA.%2BB.%26aulast%3DEngelstoft%26aufirst%3DM.%2BS.%26aulast%3DMadsen%26aufirst%3DA.%2BN.%26aulast%3DL%25C3%25BCckmann%26aufirst%3DM.%26aulast%3DMiller%26aufirst%3DM.%2BW.%26aulast%3DTrujillo%26aufirst%3DM.%2BE.%26aulast%3DFrimurer%26aufirst%3DT.%2BM.%26aulast%3DHolst%26aufirst%3DB.%26aulast%3DHoward%26aufirst%3DA.%2BD.%26aulast%3DSchwartz%26aufirst%3DT.%2BW.%26atitle%3DGPR40%2520%2528FFAR1%2529%2520%25E2%2580%2593%2520Combined%2520Gs%2520and%2520Gq%2520Signaling%2520in%2520vitro%2520is%2520Associated%2520with%2520Robust%2520Incretin%2520Secretagogue%2520Action%2520ex%2520vivo%2520and%2520in%2520vivo%26jtitle%3DMol.%2520Metab.%26date%3D2015%26volume%3D4%26spage%3D3%26epage%3D14%26doi%3D10.1016%2Fj.molmet.2014.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Staels, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fruchart, J.-C.</span><span> </span><span class="NLM_article-title">Therapeutic Roles of Peroxisome ProliferatorâActivated Receptor Agonists</span> <span class="citation_source-journal">Diabetes</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">2460</span><span class="NLM_x">â</span> <span class="NLM_lpage">2470</span><span class="refDoi">Â DOI: 10.2337/diabetes.54.8.2460</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.2337%2Fdiabetes.54.8.2460" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2005&pages=2460-2470&author=B.+Staelsauthor=J.-C.+Fruchart&title=Therapeutic+Roles+of+Peroxisome+Proliferator%E2%80%93Activated+Receptor+Agonists&doi=10.2337%2Fdiabetes.54.8.2460"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.2337%2Fdiabetes.54.8.2460&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2337%252Fdiabetes.54.8.2460%26sid%3Dliteratum%253Aachs%26aulast%3DStaels%26aufirst%3DB.%26aulast%3DFruchart%26aufirst%3DJ.-C.%26atitle%3DTherapeutic%2520Roles%2520of%2520Peroxisome%2520Proliferator%25E2%2580%2593Activated%2520Receptor%2520Agonists%26jtitle%3DDiabetes%26date%3D2005%26volume%3D54%26spage%3D2460%26epage%3D2470%26doi%3D10.2337%2Fdiabetes.54.8.2460" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Azoulay, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Filion, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Assayag, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Majdan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pollak, M. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suissa, S.</span><span> </span><span class="NLM_article-title">The Use of Pioglitazone and the Risk of Bladder Cancer in People with Type 2 Diabetes: Nested Case-Control Study</span> <span class="citation_source-journal">BMJ</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">344</span><span class="NLM_x">, </span> <span class="NLM_fpage">e3645</span><span class="refDoi">Â DOI: 10.1136/bmj.e3645</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1136%2Fbmj.e3645" title="">Crossref</a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=344&publication_year=2012&pages=e3645&author=L.+Azoulayauthor=H.+Yinauthor=K.+B.+Filionauthor=J.+Assayagauthor=A.+Majdanauthor=M.+N.+Pollakauthor=S.+Suissa&title=The+Use+of+Pioglitazone+and+the+Risk+of+Bladder+Cancer+in+People+with+Type+2+Diabetes%3A+Nested+Case-Control+Study&doi=10.1136%2Fbmj.e3645"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1136%2Fbmj.e3645&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fbmj.e3645%26sid%3Dliteratum%253Aachs%26aulast%3DAzoulay%26aufirst%3DL.%26aulast%3DYin%26aufirst%3DH.%26aulast%3DFilion%26aufirst%3DK.%2BB.%26aulast%3DAssayag%26aufirst%3DJ.%26aulast%3DMajdan%26aufirst%3DA.%26aulast%3DPollak%26aufirst%3DM.%2BN.%26aulast%3DSuissa%26aufirst%3DS.%26atitle%3DThe%2520Use%2520of%2520Pioglitazone%2520and%2520the%2520Risk%2520of%2520Bladder%2520Cancer%2520in%2520People%2520with%2520Type%25202%2520Diabetes%253A%2520Nested%2520Case-Control%2520Study%26jtitle%3DBMJ%26date%3D2012%26volume%3D344%26spage%3De3645%26doi%3D10.1136%2Fbmj.e3645" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Mamtani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haynes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bilker, W. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaughn, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strom, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glanz, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lewis, J. D.</span><span> </span><span class="NLM_article-title">Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study</span> <span class="citation_source-journal">J. Natl. Cancer Inst.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">104</span><span class="NLM_x">, </span> <span class="NLM_fpage">1411</span><span class="NLM_x">â</span> <span class="NLM_lpage">1421</span><span class="refDoi">Â DOI: 10.1093/jnci/djs328</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1093%2Fjnci%2Fdjs328" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=22878886" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsVWgtb%252FJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2012&pages=1411-1421&author=R.+Mamtaniauthor=K.+Haynesauthor=W.+B.+Bilkerauthor=D.+J.+Vaughnauthor=B.+L.+Stromauthor=K.+Glanzauthor=J.+D.+Lewis&title=Association+Between+Longer+Therapy+With+Thiazolidinediones+and+Risk+of+Bladder+Cancer%3A+A+Cohort+Study&doi=10.1093%2Fjnci%2Fdjs328"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Association Between Longer Therapy With Thiazolidinediones and Risk of Bladder Cancer: A Cohort Study</span></div><div class="casAuthors">Mamtani, Ronac; Haynes, Kevin; Bilker, Warren B.; Vaughn, David J.; Strom, Brian L.; Glanz, Karen; Lewis, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the National Cancer Institute</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1411-1421</span>CODEN:
                <span class="NLM_cas:coden">JNCIEQ</span>;
        ISSN:<span class="NLM_cas:issn">0027-8874</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Background: The use of pioglitazone, a thiazolidinedione (TZD), may increase the risk of bladder cancer in patients with type 2 diabetes.  In this study, we assessed the risk of bladder cancer assocd. with the use of TZDs and between pioglitazone and rosiglitazone, an alternative TZD.  Methods: We conducted a retrospective cohort study of patients with type 2 diabetes mellitus who initiated treatment with a TZD (n = 18 459 patients) or a sulfonylurea (SU) (n = 41 396 patients) between July 1, 2000, and August 31, 2010, using The Health Improvement Network database in the United Kingdom.  Incident cancers were identified for 196 708 person-years of follow-up.  Cox proportional hazards regression models were used to est. hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of bladder cancer in the TZD cohort compared with the SU cohort (referent), adjusted for potential confounders.  Risk assocd. with increasing duration of drug exposure was also examd.  All statistical tests were two-sided.  Results: We identified 60 incident bladder cancers in the TZD cohort and 137 cancers in the SU cohort.  No difference in bladder cancer risk was found between the two cohorts (TZD vs SU, HR = 0.93, 95% CI = 0.68 to 1.29) in analyses that did not account for duration of exposure.  However, the risk of bladder cancer was increased among patients with the longest duration of TZD vs SU therapy (â¥5 years of use, HR = 3.25, 95% CI = 1.08 to 9.71) and among those with the longest time since initiation of therapy (â¥5 years since first use, HR = 2.53, 95% CI = 1.12 to 5.77).  Risk of bladder cancer also increased with increasing time since initiation of pioglitazone (Ptrend < .001) and rosiglitazone (Ptrend = .006).  Comparison of pioglitazone to rosiglitazone use did not demonstrate difference in cancer risk (P = .49).  Conclusion: Long-term TZD therapy (â¥5 years) in patients with type 2 diabetes may be assocd. with an increased risk of bladder cancer, which may be common to all TZDs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrsEIfUELvjMbVg90H21EOLACvtfcHk0lisgG9v_7Jwqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsVWgtb%252FJ&md5=c0ed848df5d55c6a57ca326135a84ee2</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjs328&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjs328%26sid%3Dliteratum%253Aachs%26aulast%3DMamtani%26aufirst%3DR.%26aulast%3DHaynes%26aufirst%3DK.%26aulast%3DBilker%26aufirst%3DW.%2BB.%26aulast%3DVaughn%26aufirst%3DD.%2BJ.%26aulast%3DStrom%26aufirst%3DB.%2BL.%26aulast%3DGlanz%26aufirst%3DK.%26aulast%3DLewis%26aufirst%3DJ.%2BD.%26atitle%3DAssociation%2520Between%2520Longer%2520Therapy%2520With%2520Thiazolidinediones%2520and%2520Risk%2520of%2520Bladder%2520Cancer%253A%2520A%2520Cohort%2520Study%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2012%26volume%3D104%26spage%3D1411%26epage%3D1421%26doi%3D10.1093%2Fjnci%2Fdjs328" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Nissen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolski, K.</span><span> </span><span class="NLM_article-title">Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">356</span><span class="NLM_x">, </span> <span class="NLM_fpage">2457</span><span class="NLM_x">â</span> <span class="NLM_lpage">2471</span><span class="refDoi">Â DOI: 10.1056/NEJMoa072761</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1056%2FNEJMoa072761" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=17517853" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD2sXms1SisrY%253D" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=356&publication_year=2007&pages=2457-2471&author=S.+E.+Nissenauthor=K.+Wolski&title=Effect+of+Rosiglitazone+on+the+Risk+of+Myocardial+Infarction+and+Death+from+Cardiovascular+Causes&doi=10.1056%2FNEJMoa072761"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes</span></div><div class="casAuthors">Nissen, Steven E.; Woslki, Kathy</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">356</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">2457-2471</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Rosiglitazone is widely used to treat patients with type 2 diabetes mellitus, but its effect on cardiovascular morbidity and mortality has not been detd.  We conducted searches of the published literature, the Web site of the Food and Drug Administration, and a clin.-trials registry maintained by the drug manufacturer (GlaxoSmithKline).  Criteria for inclusion in our meta-anal. included a study duration of more than 24 wk, the use of a randomized control group not receiving rosiglitazone, and the availability of outcome data for myocardial infarction and death from cardiovascular causes.  Of 116 potentially relevant studies, 42 trials met the inclusion criteria.  We tabulated all occurrences of myocardial infarction and death from cardiovascular causes.  Data were combined by means of a fixed-effects model.  In the 42 trials, the mean age of the subjects was approx. 56 years, and the mean baseline glycated Hb level was approx. 8.2%.  In the rosiglitazone group, as compared with the control group, the odds ratio for myocardial infarction was 1.43 (95% confidence interval [CI], 1.03 to 1.98; P = 0.03), and the odds ratio for death from cardiovascular causes was 1.64 (95% CI, 0.98 to 2.74; P = 0.06).  Rosiglitazone was assocd. with a significant increase in the risk of myocardial infarction and with an increase in the risk of death from cardiovascular causes that had borderline significance.  Our study was limited by a lack of access to original source data, which would have enabled time-to-event anal.  Despite these limitations, patients and providers should consider the potential for serious adverse cardiovascular effects of treatment with rosiglitazone for type 2 diabetes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnruxfTnPBe7Vg90H21EOLACvtfcHk0lisgG9v_7Jwqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXms1SisrY%253D&md5=0cf21e448c286873e88c3e2eec6106a8</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa072761&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa072761%26sid%3Dliteratum%253Aachs%26aulast%3DNissen%26aufirst%3DS.%2BE.%26aulast%3DWolski%26aufirst%3DK.%26atitle%3DEffect%2520of%2520Rosiglitazone%2520on%2520the%2520Risk%2520of%2520Myocardial%2520Infarction%2520and%2520Death%2520from%2520Cardiovascular%2520Causes%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2007%26volume%3D356%26spage%3D2457%26epage%3D2471%26doi%3D10.1056%2FNEJMoa072761" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Nissen, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Topol, E. J.</span><span> </span><span class="NLM_article-title">Effect of Muraglitazar on Death and Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus</span> <span class="citation_source-journal">JAMA</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">294</span><span class="NLM_x">, </span> <span class="NLM_fpage">2581</span><span class="NLM_x">â</span> <span class="NLM_lpage">2586</span><span class="refDoi">Â DOI: 10.1001/jama.294.20.joc50147</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=10.1001%2Fjama.294.20.joc50147" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=16239637" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1KisLjJ" title="">CAS</a></a>],Â <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=294&publication_year=2005&pages=2581-2586&author=S.+E.+Nissenauthor=K.+Wolskiauthor=E.+J.+Topol&title=Effect+of+Muraglitazar+on+Death+and+Major+Adverse+Cardiovascular+Events+in+Patients+with+Type+2+Diabetes+Mellitus&doi=10.1001%2Fjama.294.20.joc50147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 Diabetes Mellitus</span></div><div class="casAuthors">Nissen, Steven E.; Wolski, Kathy; Topol, Eric J.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">294</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2581-2586</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    
            (<span class="NLM_cas:orgname">American Medical Association</span>)
        </div><div class="casAbstract">Context: Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that modulate gene expression.  Therapeutic agents targeting 2 distinct families of PPARs (Î± and Î³) have been introduced in the United States.  The first dual-PPAR agonist, muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory committee on Sept. 9, 2005, resulting in a vote of 8:1 recommending approval for its use in controlling blood glucose levels in patients with type 2 diabetes.  Objective: To evaluate the incidence of death, myocardial infarction (MI), stroke, congestive heart failure (CHF), and transient ischemic attack (TIA) in diabetic patients treated with muraglitazar compared with controls.  Design, Setting, and Participants: The source material for this anal. consisted of documents about phase 2 and 3 clin. trials released under public disclosure laws for the FDA advisory committee meeting.  All reviewed trials were prospective, randomized, double-blind, multicenter studies enrolling patients with type 2 diabetes and Hb Arc levels between 7% and 10%.  Patients (N = 3725) were randomized to receive differing doses of muraglitazar, pioglitazone, or placebo as monotherapy or in combination with metformin or glyburide in trials ranging from 24 to 104 wk.  Main Outcome Measures: The primary outcome was the incidence of death, non-fatal MI, or nonfatal stroke.  A more comprehensive composite outcome included these events plus the incidence of CHF and TIA.  Results In the muraglitazar-treated patients, death, MI, or stroke occurred in 35 of 2374 (1.47%) patients compared with 9 of 1351 (0.67%) patients in the combined placebo and pioglitazone treatment groups (controls) (relative risk [RR], 2.23; 95% confidence interval [CI], 1.07 - 4.66; P = .03).  For the more comprehensive outcome measure that included TIA and CHF, the incidence was 50 of 2374 (2.11%) for muraglitazar compared with 11 of 1351 (0.81%) for controls (RR, 2.62; 95% CI, 1.36 - 5.05; P = .004).  Relative risks for each of the individual components of the composite end point exceeded 2.1 but were not statistically significant.  Incidence of adjudicated CHF was 13 of 2374 (0.55%) muraglitazar-treated patients and 1 of 1351 controls (0.07%) (RR, 7.43; 95% CI, 0.97 - 56.8; P = .053).  Conclusions: Compared with placebo or pioglitazone, muraglitazar was assocd. with an excess incidence of the composite end point of death, major adverse cardiovascular events (MI, stroke, TIA), and CHF.  This agent should not be approved to treat diabetes based on lab. end points until safety is documented in a dedicated cardiovascular events trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHR4RoUDPpmrVg90H21EOLACvtfcHk0lisgG9v_7Jwqw"> >> More from SciFinder <sup>Â®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1KisLjJ&md5=f35a6103fdab2ab9303f5bd37f2475bc</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1001%2Fjama.294.20.joc50147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.294.20.joc50147%26sid%3Dliteratum%253Aachs%26aulast%3DNissen%26aufirst%3DS.%2BE.%26aulast%3DWolski%26aufirst%3DK.%26aulast%3DTopol%26aufirst%3DE.%2BJ.%26atitle%3DEffect%2520of%2520Muraglitazar%2520on%2520Death%2520and%2520Major%2520Adverse%2520Cardiovascular%2520Events%2520in%2520Patients%2520with%2520Type%25202%2520Diabetes%2520Mellitus%26jtitle%3DJAMA%26date%3D2005%26volume%3D294%26spage%3D2581%26epage%3D2586%26doi%3D10.1001%2Fjama.294.20.joc50147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i37"><a href="/doi/suppl/10.1021/acs.jmedchem.6b01559">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_51013"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.6b01559">10.1021/acs.jmedchem.6b01559</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Experimental procedures for the synthesis of compounds <b>5</b>â<b>85</b> and methods for in vitro and in vivo biological studies (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_002.csv">CSV</a>)</p></li><li><p class="inline">Compound <b>22</b> A and B rings only (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_003.pdb">PDB</a>)</p></li><li><p class="inline">Compound <b>32</b> A and B rings only (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_004.pdb">PDB</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_001.pdf">jm6b01559_si_001.pdf (2.59 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_002.csv">jm6b01559_si_002.csv (5.37 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_003.pdb">jm6b01559_si_003.pdb (3.55 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.6b01559/suppl_file/jm6b01559_si_004.pdb">jm6b01559_si_004.pdb (3.25 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.6b01559&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.6b01559%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2017.60.issue-4%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.6b01559" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                2MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright Â© 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">Youâve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799491aef103ce2","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
